var title_f20_59_21424="Balance walk video";
var content_f20_59_21424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/59269/Balance_walk_video.mp4?title=Balance+walk+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balance exercise video: Balance walk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Good balance helps you walk safely and avoid tripping and falling over objects in your way.",
"    <br>",
"     <ol>",
"      <li>",
"       Raise arms to sides, shoulder height.",
"      </li>",
"      <li>",
"       Choose a spot ahead of you and focus on it to keep you steady as you walk.",
"      </li>",
"      <li>",
"       Walk in a straight line with one foot in front of the other.",
"      </li>",
"      <li>",
"       As you walk, lift your back leg. Pause for one second before stepping forward.",
"      </li>",
"      <li>",
"       Repeat for 20 steps, alternating legs.",
"      </li>",
"     </ol>",
"     As you progress, try looking from side to side as you walk, but skip this step if you have inner ear problems.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21424=[""].join("\n");
var outline_f20_59_21424=null;
var title_f20_59_21425="Metronidazole: Pediatric drug information";
var content_f20_59_21425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Metronidazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=see_link\">",
"       Metronidazole (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23252?source=see_link\">",
"       Metronidazole (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12606 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21425=[""].join("\n");
var outline_f20_59_21425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=related_link\">",
"      Metronidazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23252?source=related_link\">",
"      Metronidazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_59_21426="Patient information: Constipation in adults (The Basics)";
var content_f20_59_21426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15385\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29661\">",
"           Amount of fiber in different foods",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/15/41202\">",
"         Patient information: Hemorrhoids (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/51/35634\">",
"         Patient information: High-fiber diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/55/23411\">",
"         Patient information: Pregnancy symptoms (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/10/34977\">",
"         Patient information: Constipation in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Constipation in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/constipation-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H33678058\">",
"      <span class=\"h1\">",
"       What is constipation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Constipation is a common problem that makes it hard to have bowel movements. Your bowel movements might be:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Too hard",
"       </li>",
"       <li>",
"        Too small",
"       </li>",
"       <li>",
"        Hard to get out",
"       </li>",
"       <li>",
"        Happening fewer than 3 times a week",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33678065\">",
"      <span class=\"h1\">",
"       What causes constipation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Constipation can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Side effects of some medicines",
"       </li>",
"       <li>",
"        Poor diet",
"       </li>",
"       <li>",
"        Diseases of the digestive system (",
"        <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33678072\">",
"      <span class=\"h1\">",
"       What other symptoms should I watch for?",
"      </span>",
"      &nbsp;&mdash;&nbsp;These symptoms could signal a more serious problem:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood in the toilet or on the toilet paper after having a bowel movement",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Feeling weak",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33678079\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to get rid of constipation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Try these steps:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat foods that have a lot of fiber. Good choices are fruits, vegetables, prune juice, and cereal (",
"        <a class=\"graphic graphic_table graphicRef52349 \" href=\"UTD.htm?28/61/29661\">",
"         table 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        In the morning, drink coffee, tea, or another drink that has caffeine.",
"       </li>",
"       <li>",
"        Drink plenty of water and other fluids.",
"       </li>",
"       <li>",
"        When you feel the need to go to the bathroom, go to the bathroom. Don&rsquo;t hold it.",
"       </li>",
"       <li>",
"        Take laxatives. These are medicines that help make bowel movements easier to get out. Some are pills that you swallow. Others go into the rectum. These are called &ldquo;suppositories.&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33678086\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your symptoms are new or not normal for you",
"       </li>",
"       <li>",
"        You do not have a bowel movement for a few days",
"       </li>",
"       <li>",
"        The problem comes and goes, but lasts for longer than 3 weeks",
"       </li>",
"       <li>",
"        You are in a lot of pain",
"       </li>",
"       <li>",
"        You have other symptoms that also worry you",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33678093\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, other symptoms, and individual situation. There are lots of tests, but you may not need any.",
"     </p>",
"     <p>",
"      Here are the most common tests doctors use to find the cause of constipation:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rectal exam &ndash; Your doctor will look at the outside of your anus. He or she will also use a finger to feel inside the opening.",
"       </li>",
"       <li>",
"        Sigmoidoscopy or colonoscopy &ndash; For these tests, the doctor puts a thin tube into your anus. Then, he or she threads the tube into your large intestine. The large intestine is also called the colon. The tube has a camera attached to it, so the doctor can look inside your intestines. During these tests, the doctor can also take samples of tissue to look at under a microscope (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        X-rays",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33678100\">",
"      <span class=\"h1\">",
"       How is constipation treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your constipation. First, your doctor will want you to try eating more fiber and drinking more water. If that doesn&rsquo;t help, your doctor might suggest:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines that you swallow or put in your rectum",
"       </li>",
"       <li>",
"        Changing the medicines you are taking for other conditions",
"       </li>",
"       <li>",
"        A treatment called an &ldquo;enema.&rdquo; For this treatment, a doctor or nurse will squirt water into your rectum. He or she might also use a thin tool to help break up bowel movements that are still inside you.",
"       </li>",
"       <li>",
"        Biofeedback. This is a technique that teaches you to relax your muscles so you can let go and push bowel movements out.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33678107\">",
"      <span class=\"h1\">",
"       Can constipation be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting constipation again by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eating a diet that is full of fiber (",
"        <a class=\"graphic graphic_table graphicRef52349 \" href=\"UTD.htm?28/61/29661\">",
"         table 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Drinking caffeine in the morning",
"       </li>",
"       <li>",
"        Drinking water and other fluids during the day",
"       </li>",
"       <li>",
"        Going to the bathroom at regular times every day",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H33678114\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=see_link\">",
"       Patient information: Hemorrhoids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"       Patient information: High-fiber diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/55/23411?source=see_link\">",
"       Patient information: Pregnancy symptoms (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"       Patient information: Constipation in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/59/21426?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15385 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21426=[""].join("\n");
var outline_f20_59_21426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678058\">",
"      What is constipation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678065\">",
"      What causes constipation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678072\">",
"      What other symptoms should I watch for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678079\">",
"      Is there anything I can do on my own to get rid of constipation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678086\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678093\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678100\">",
"      How is constipation treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678107\">",
"      Can constipation be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33678114\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15385\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_table\" href=\"UTD.htm?28/61/29661\">",
"        Amount of fiber in different foods",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=related_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/15/41202?source=related_link\">",
"      Patient information: Hemorrhoids (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/55/23411?source=related_link\">",
"      Patient information: Pregnancy symptoms (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_59_21427="Oblique uncomplicated fracture of the lateral malleolus";
var content_f20_59_21427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Oblique uncomplicated fracture of the lateral malleolus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fracture is best seen on the lateral view (blue arrow). The&nbsp;anteroposterior (AP)&nbsp;x-ray demonstrates the symmetry of the joint: the distance between the superior aspect of the medial malleolus and the talus is equal to the distance between the tibial plafond and the talus (black arrows). This relationship must be confirmed on the mortise view. This is a stable injury; surgical intervention is not needed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jari Salo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21427=[""].join("\n");
var outline_f20_59_21427=null;
var title_f20_59_21428="Porokeratosis multiple lesions";
var content_f20_59_21428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCCFsBkyDxkDuPr61ZRsIF2BnAJIHUe4qByUKn5Rk5U4/SrMTdDt25GGOcbR/hXlH0aYqyhhtZ1KhQwJ457g+lW4ZmMiuUYLgsuR+XFV5F+dAkaggYViMnjtViI7zGWywHTBwcY5+lBRp200mMkqMrktj7w9D7mrwnTMUYQocdVfg+me3HvzWZCwVY40LKc8qeMfjVp5HCKGXIDZwF5HrTQNC3RLJskjcMQdw3ZGPU0ot0DCVVClRkc9TU0GJOCgVcFjzgFfX2qO480B2WNQG+Y/T1A/rSYR3KssKyptO5ZB8xJP86rGOMCSQsrbudo+nanz3DlArKRIuQx/v8A/wBaqskjBlaVVPHC46D1qDRMZIv+jv5eBuGee2eKU2w8ncGVyoypHGfaq32kpIPM2oh+6cjaatb0KqqglRzkd/pTsJliGwEqDacJgA+me+eM1NpcL7mEbNG8Y2g7sZ/2h7U+zvFkmXcAUUgjBx+Jq+yML0sE3iXEhXIyW9B2q0ZMqSM25YZXQK/yq/lksRjkeh+pqLVpQlsrMjxBBkE/OTj17Z96nn8ldSCFRtY/Jhsg5xyP5Uy+ERjYSPGYgdxLsBuGemPUVZizkdUuWuISUEZhYZLcg59Pw/WueUzeQpPQ8RseMn+ldPO0aXUjQhPLbLksTgDPbiuVvXKiVgRtck4B9e/tQRLRmXqkv2sSGT/WKPmUc7SK4LWSTdsWPJ7f3fau9uF3I2NqAjBArhtQjZpZNq5zJtBPsOea3obnJiNjoItPik+HBkbcJt7zIeg+Vuh/DNZ2gOf3ZzznH09jXYeHLRLvwHDFIfNjdXGxOSfnP5da4nQCCXiZsEHGcZ79DXZio+5F+RyYaXvtHaW02VYhGYnqcYxV6PakqksMEYBA6Cs2wJb73Uc8HoO1aUeHbAABPJNeS0exB6FxWSOFgowSOR/eqXeysiLI67VIPPX2qrHtkkTyycZwewq0MvPuJUqB8xPp26daRoWLKcL8mJAyHGwjkD69wa3IGkym8EM5yoU8Ee9c/sMZ3RkurYL7ieCOB0rUs52MgjaQCTOWB+Ykf0qhJ2Nl9xkDRkZY7gyoRz2B65p6Tu6PKVMYPylflJ69u9UlkaPA87cqnABfn+fFPkncsu5hwem3P4f/AF6RSQtwFKyOHbdnO4nHNRRlTGCmWz2J5HufSoXkKmRpAp7RhTgge4+tVbeQpCzLIA44x2/GpZaNJYVkjaJV+QDIIPDfShZJUgBiAYLhW9/rWdDcuzwxspLLkkcBcdutaulo5BNztc4yE7L7Hv8AjTRL1NbTpnKeYjfMflI4LbfT2NasTNAkWxd/zHcxwMjHTn0/WsdbdYwrgjYr85bkHvzV+CWYXsQSSEAgPlcnGOintmnYT0Lkyzyu/mW+VK7cMwAU9fxpq2TeYd7RqJGBIT7pbHTFWjOryxtOFj25JJ+Q4z+PNVpZZPtUL7AE+ZlwPlwMktn8RzTSuJysUpFebh1GICPM2ngt2wOvTtVFQkUkiSHedpZAOSCexqxHK7xmQ5dWY7nJ2llzyR/npUN2jXFtGtvGwdHAUn5TgHgYPapNEUJZRHbSLlwRlBnjJNY06uoCGP5z1Vv4R61sAGZPMb947N1YYDMOuPSql6sceCxJbeBuHH+R7U0RPY5HxWoXS52kUhgu3p+WaPAco3R7yOmOal8ZsV0W+XBJZAcn0zWH4YufLjRgw455q5fCZUmlU1Ox8e7IbBYf4pMcfU1yGtkJpV1kcbMfrWhr+oNqmq2ce7cIhvb0wP8A69ZfiTP9jXJHYAn869LBw5aUn3PNx9TnrRS6D/BTklUT7xPU969IXT2KggdR/dryvwXcCKdT1Ir1yLUE8pPmHQd68moveZ7uGacDDMhKKR8wUgq1WlI+XDDLEcYyAe//ANaqqgxxllACd/Uf/Wp1pG8m8tkAkgLnAz603oYxdy/E4cAj5CD0PapbR/LwHAwSflJ7+tVxE3moX5weS3ORVqUhRu2AowqTQlSRxcRqyA4VuDyQf8+ta9k4ZXDEliMHJ5FYceAQSzKQOuelPjuGCNkjAO4BV7/zpgzdnaGBVmnWRmXPQEZJ6Ej+lVATNsibIYnDMecc9KrWV0Hy04Y7v45CT9M+tW5JHiRfLZFRvlwPXPpQ0CZnXVv514FXepAy55+VfWmFdwYL90f6tjzn8Ks3C/6SVZmWTAx7n6Uy6b5Nqckck4xg/wCFTYtNFAQxFSzyk5O0Iw4PvSRkqNudwTheegptxG+ASo8tT06Z/wDrU6VSnRlV2YHcvJI9KaRMnYLeVlumUgB2IKj371fN3LFIkjZlC5IJ9Dwee1UJYHndSP3eR/rD1Y/h2q4sEjqA3qFO4g5H17mrSMXILuVpV8+P92AAwwu7kH8uagN4WUi4Ci3B3Ehfvn0qcS/ZpEJXCDgHqAD2+oqj9ojaUxqscuPlEhHUA8YHf8K06GWxUuZo23clFIJ2k7WHPA+lcy5UXEg8sAuhCk8+/H610c9kNqtCyeaScgj5Qax5N39psjIjNtzuzgcCo2B67nOagDEw3fLgFQM46dM1xGsSFptnAQEtgDGT616Hq0I2u79c4I7YrzrUzuuiAMn1rfDvU5MStD1DwTKqeC7Ir/rV3duxY1wd3AbLxJcxnaFkIkG08EMM16D4PtVm8J6X5bvE6xZOD1OTXL+PbQ22q2MzdXj2k/qK9WvC9JHmUZWqE9swlC+Udq/xN+FaFusbZYZ3jhR/e9eKw7EOYAqKCrjj3rUt4WQgKXHbJTr+NeHJHt02bMHlH5UIAIwSams8MGypwT8hU9T0zWe7iOPAjG4javuDUsWUj2Mh+7y27qfapsa8xqJKyb23bcYLKenHoKtR3DSRqkTKIfvZcDnPXisGaRkMbSAZGAW68fj37VYVTNKQ7EIVySvb0HNUJyubUUgdmMckatjgfzpJZn84ATZYrlQn3R2rHjidpo16Jn7/AE49Kv2UEqR7nxiPOFxg0milIdDLMwLMzMM8564H8qRVkMgEgUAtkL02jPBqygkaZAwVA67gMf16CldA3mbj8wUYI7VLRotRVVVkZnwM8ZAzzV+xG2NRuwSSOEAz6+9RqCPKXIyTuJKjjirsUgXlwEJ5UHnHvQFjStQEiQSA7MYfpnn29ahEkTSvDG2IkbO9RjceOPr6moftjZeOHa/y71GeN3uau2OFtichjgM2fvBhycegNUiWiVDG86uHllhC5XdggnuQBxkUy7djdBrmVxbmPy/LBwCg5Ix7+lWTCHkBRQGB3bWxlM+9NucFolwsjYYMccj1ouPl0HyOZSEjUMz4CL0AQYPI9PYVHOis7guwlKnL9t3fH4VBASXd42dWBztB5YY45Pb2qK5jaO5MCqGlf94fMbOMdh6VJa2IyEDg5ygbaF/u9/8AJrMvNjPC7ksdxIz269q0CD+7wuJGYHbuyDjmsLU90F9tXGzazcc85xj86cdzOekTD19Be20scjP5cilQq4457VxX9matYv5duizxno4bHHvXd3wWOwYk/N53JPQAnpVFicHHTODXp4WjCpB8x4+JrShNWM/SbJ7SBmuGDXMnLkdAOyipr23W6tJoG6SKVz6GrbdMZHNRnjivTjBRjyrY89yblzPc4W0mn0e98m6Qow6Ejhh6g11i+I22jDnGPWrFzDFcJtmjSRc52sMiovslv/zwj/KuCpgFJ3TO2lmEoKzOut518tSgyFPPp04zVlAqrCo3BiuevNZ9qWRmBx5T/MT6+4q+shZcDkDn3ryZHtwZZEg8pRlS44IB5P096VZvMwQMHoV989qrqwbEigEtjA+nenuWTKgld3IA9ag0ENw7SYChRnnA6VehUMdw+cOMAk1Sg3hpC+VLAfN1H4+1WbVk58s4JYty/TPX8KYy2qbIw0fJ4XIH3fWke4SKRY4y77DgoVI8xscDPQAc02C48pyNikdS/TH0pJGSVuMlhyDn1/lTTsJxuTSSs6AuFeUjKlemfT1qlclmk3K+1lI+RV+9mpBuIXYdi52cDrk8n2+tMkYJIDjeu4qVY8YqW7jSKUqs8mxmzgHr2J9aaS8MSpPJgKuVOOfbNTlk3sSW8snJBH+TSeWhPy7sdQeopomSNKyUPENrDaMNnp/kVZd9mPLkIZsEo+Nhx/EMdPpVC0mK71K5QrxuGAvuKsSzNcW0kaBRGVxkgZOOmKpGbELIJXBYoThTsXj6c9KqXVrE/neVIsYU5wRtIPtmnS3e6VndgyMR8pGPmxwc0XUsclsoQyBShJGQSV//AF/jVXIMGSWQyhy/lxcgsTnB9/Wqa26S3HmqSJDlyTwWU9au3UUM8sa72CZJYHo3ovPfjn0qK5SUypnKiJcK44GOOh9amQ4ruc7rRjXcsS7ifXtXn+s4SRkGMlss2Ocegr0bVYlXzlxyvPy15/r0OxiffOa2oOzOXEq6PT/h8m/wnp5Vj8qkbScc5OTWP8SYw9q8mwr5LIyjH+0QxP51qfDSQS+FLZSuSjuvHP8AF3/OpfGdqbjR7woGQCMo2xc7s84/MCvdtzUreR4idp3ON0FsoC3boB/OtuLYu478uehz/KuW0WdhEpVgGYcZ9fSt6O43pGI0VnUZyeteBUjaTPepSXKXx85LsF2A7R3570IAkwyNhJ5PY/X0FQxSvyoXeTy3GQPpVi1UMjM7BoByQw+97moNdy5Gq7gWI+78pAyPSrECRLbbGU4LfMvTB+vrVWMhmLKqBV7A8fWpxN5pRPP/AHf0/rQMs5RJ2DbvK24z159avw7Eto9vO9tx83qKxLmQRbxGRtC/fHP4CpFumDxrLv8Au5CnkD2NA0b32hIkA4MhB46fpVA3HnSF2jCLn+HoapiRDt/5ZnjcKcr5RnUqq8jaKllo0oZPN8obmUFjnJzjj9auRRQ3cscrAgqNuDzkDv7Vi20cpyGIKKNyqvYnsa0YblmUQxFlRFwR756A96Q077mpDgBQnKZ2PjsDWrYxx26qis0Z5BAPf/8AVWRE6qu5QSzIDt6dOtLa3LswDqWYMcsTjP8An1FMLo0YdpunEgICjYCTU93JxIqhkUpgMp6epyao2VwU3NIrEb+McA+3vV44WRQ6mTau5gB1psa1QxrtY5En2jyjhQynuOxqlqt4u5WjYLKzllYHJA9qsqI/JDIwjK/OoCZP09OlUp4muFZpTkYyjEAbvbI+vSpG2yOKXMsaycosfzMV4DHk81h3DC6BkjXjLFCT1IPStH7A5PkyAusbBSN+CQefxpmoxR4B2BBlsIOqYHWqRlK70OVv5g0cjPznDFM5+YdRUcL4JPXIyT71c1S3AhOwEHAJB657VXRAFC46V7GBXuM8PG/GgJPXvTDUhHJ96YV79q9A4xp6UmaVvam4NAjoLEOypyQVYgfQ1Yj+ZmbgLkrj17ZP41Tsm+eRSTj74b0zwR+lXYV/0dTuyuM+ma+XZ9VDUfuAww3CNGI9eo6VLJLvZWAGAuMHkfWoA/lpt+XKnzM9iKjilXymIxgEkZ71BrcsLIyKdzgMD35GKlQAq3BHOR2H1qkH2lcdCTkdSBjpj0qwZAqn5QAOQQf0oC5cUktsBXbjG7vjHapXt9qKETLKOinJb3z7VRDGPpKPMHzYA657Cr9nqDEFGCrkgkjjI9DTBMRlZppzE+AigOqr0J+tMeI+b5Af5tuS3b65qWVonWaSNvmPV+hBqOPZHDiUmRgCwI4IH9aQEYjcjaTtlbnrjdVZ5TEwC7lB4GBkc9hS/aJDMA7p5e3AO00QOy+YdykyNkMeoHp7VSJloXrdnYgk4AOBuXoPT3qUxr5SgkNDncyKTu/+tVdbwGQMh3n7vXt9as+dKFZYBGi7cHPYeo96oy3IrRBtltbiLJXg9sDqvH5VFHGPOaN3iDICwkPIkPtnpViSBtqyoVaZVy7BvmZfoP5irLyxzW6qUYKAFYbfuE+9JsaRzN5dRws1v5sUe1i0iBtxY44IPoP61EytNaCPJYSjJAHEfc5Pc1oXdhGJUSRWYxP8zkEcH1Pf6VXk8wFssGLA4AG3j6USdyYpq5z+pRMtz5bOGBHzL3rh/EkJ2k9Sc16FqUDeW3kkncSxJ6n6VxviGALGWzuBqqTtIyrLSxtfCl2l0SeMPjyLljt9mUGusvYzJaGFtwD53AnHX3/KuI+EpKjVo2ztPluBnGeSK76cCRQdp4yRjrn+v0r6Ki700eBVVpM8dsImt7iW3YbTHIy9Pu4NbtqjKC6qrMQSOeRxVTVYhbeIrqL5gsxEgB65/wD11dspd8Sr9xxkMfavFrx5ZNHr4d3ii5aS5gCBWjbGSSOfwqwjRF0+8yj5vmHQ02FSkZPL9MDGQP8A61T24UOTx0ydxyT9K5jrsOMqRAPgK5OIweufX6VPbSYX54gznjBPyj/69VkRZG3KRnO0Kx5qWWOQIVB2OecAdKAHuqhgZJVCkfNz0/8Ar0WqM7bt43Z7nJx/+qqQEg25KsSM8noPWrVqy+WEYLuOdqk9frQxJ6k5cguojDIp5Yn5j60jfcWVzg5wBjtSFx5zIr8Y5bGB9MVHPcRtKm7/AFa/Lx27UjS5fbc7lA5RSAMp16fyqWEGP7p46FcYI561n2dwgllC7uQSHI6/StS3ZACp+8Oefukf41Jad0a8doqZLbnx75I96dbzC3IhkIAU5zjhsn17VQguBtjba4f7pHXg9DVndBJPsCu0u0MrMclfUcVSESTO4hZo+VDd24xn9a0bS4ijXbJ5rOV4Ve/4+lZkEyNLJsXzT6OMAfSrKgTRAtOIzkYKnJXH+f1pSGmasZUx5YIpDcqeARiktsnCyuCoG5E24zVIzeX5ZZE2Ak88BR6moHvMsGi57p83P5GpLRcun3OGBUuzbeT/AJ4rHu7fzUkmckkAqD04HT9atXZ86MKx2vvGCPTr+VQ3qvJGyEZmAO7Jxj1H5VSIkc7qrHBBZvlA4B/lWfGTuJOc4/SrF66oHQsdynDO/f0qFQAvy9Ox9a9vAfwzwcb/ABAJHekNOI+X3pvrXccZG1Jx6U9sYpvFAjWsYysYG/czAk4/iPP9TV5FCZOd2Vzg/wA6y7NpHhiYoMncOvOTzir5mBjQhTzznHT2r5dn1ENgRiqb9pVcA888ZpSTGxDgYByMDj60xpCVMahlBBx6/hTDK2ASobsM/wBamxrfuWG2fM2csuMbelV2LBVZ2ClTkgelQpKV+8AMD+dCFt4BIBXgE8YzQJs0ITna+CRjtnv2pk8+SGSE/LktuOB+NRoxZnJzlepwMGm+aRKJPulsjB6cGgfQti+bhngYHjnGcCrTSrOvmMpL8HA6n3z6VkLOfOPmMWkYDt1Hv7VIbhWcgbg56le3sfagSZeeU5Ctg9QccbvrVE3ADMSxy5ABHO0D+lQTSvnOfmHykA4Jz6e1V4pQJQgJU9S2eapIicjR+3BYt4Xc+eAv61rWd0lxzh9gG3Y3U561zmx7S5D+Wxhk+8CM4PqK6m1tkURtuij/ANo85+vf8qZnF6izIsSukBUFBnG79MjqKnhgmIPlTokrHAQenbmpEIBjSOJdoOcnt64NTzwO8imBV8tuFUcgenIpXNbGFqr+RA4eRpZy4yCc8/Wm3Fustu8COqkjJYD5mI7E/WrPkv5rRPJvkCNuCgAAA8n8elJfQrs2QlFGCSFyVX396lgYsiGXazHoFUDuDjoa4zxHb7ScE9STjpXe3luLMEKPmcBmYtnkdya5HxCpKO2MAnaPfHU04b3M6nwmd8K5sa5qcLgEyQBufZv/AK9ekzHoNu5j0GcfrXlXgBxF4y2M23zYHUHGfQ/0r1RAwj2sN2R1Dda+iwsr00fPYhWmzzzxrA0OtW8inDSIec55B/xJqjEXgdApVia6Dx7bnyrObYFMcoX5TwAQc/0rBkI2xlcH5gp9a8/Gq1Q7sJK9M07GV3YKG2h+oxwavkoEG9VJzuI6fjmsW0WZEQEqoOSNwzz/AErahddildpbGSpGfyzXny0Z6UHdWERSpJQfuycqTjP5VZjbhwT8pXlc/wBfWq+2NWbzAAxOOBgZ7GovMXAR2CHOOtNCbsNVsyAFc7FOc9TUcXmiQtGoK7cfMenpT3L+e2yLzBxjHb8acGkYKCpyTuZRyBQ0RfUY+8uyZAOc46Y96cV+Zty8vyA3pTl+Z/lUMp4OfX6VIIyFjIQ7ugHWgodZEvclYyvyr/FWtudolwECDADEdW9qz7e0I5Zyjjk8Zq7CpEe4nkd/Q1LLjexbtEcQyIzqWPTZ2H+NasYhhCqDtlHVs4P/AOqsuziMqs427D0YnuPSr8Mrz7i5RlKhcFT79PQ+9BSHTOMgsmMcFup5quiLHKzIdgIwAOmastHlNzE7eB/9bNKLeJVLP8hI+UZ6n6UMpFSV2x5bOGI5J9OelTi7aOWISKQwXCgdh6D1FQ+VtjxtVnYhs+3vSTSJ5kbBuSNnA6E9D/KpK8y9djy4DKBuYOMfTNE7lY5Mu2dvXrn1NVmBljiVCU+boD6cmo5JE2NnC7lYhT16cfzpomTRzmrCN7iTzGyVwoHYDv8AjUQcnLKv5ntVzVUKzz5T5BtO0jJz65qmgITaQFGe1e1gPgZ4WM+NDs8fWmEk5pxpDj1rvOIb3pvHqKVsEHJpOf8AJpgaNpGxjVcgqw64+7jrVmORTHh2OQABg9qq6fJwVX7rEkA9qeoAVlU/n+lfMS3PpobFi4YbQV5YDjFV5CEJY8knGMetPkkVkUIVY9cVC0pMPOHUDJx6g1Bo2DSAM24HHQkdqB8h2rksR65qN5GVmOMRgYB9zQjZAOCXbB+YcU7CuW0dD/fMnoe9ICBGULYYMelRKU2bimVH3cEjB9aFAL7trBmXIYH/ADmkNDnhZJ8biy9A3c/SiTIXaflZeQF7e5NJKrmNIyzfewu7qfU1KtvlEeQFpFGB2GB60Il+RFbqQPMlAO4dV9KkngVnjbaAwPOF4qcI0Z2kg4HG49fYiqm/MhbzCc8EHsatEMuQuWQhRzzngnPt9KfAGgkUKzStngHkZ/8A1UyIABCpVpBwRjp+PerSRMw8s7gn3+eefrSbKSua8c4lWN5JcgvuII6EDoK1baciBRIQoQZ57DtWFbwR7QrsSTyBuxj35p9w/kq4TfIoXC9Tx6+/pUs1StuW7vJuJ51UEBSp789c57dOlV2ADo6ocMcAepxxk/rTbK2+0eW0jb1T5gCNoz71YBAZhEAVUHg9W9/qPWkKxTlt3mjkabEjMuNqjhT6+5rjPEMSiLDNlgTkDoPSvQ7hGDhWAGW4GOvHeuJ8UWzMokRAFQ5IBxmqpvWzMqytE4nw3GU8bafjgkuPx2mvWFbB5/Md68n0yQQeLNLkPB84DP1yP/rV6wPu4PGBXvYL+GeDiviMbxbCs2hXaupyieahH94HPP61xdmoeA8jLHINeiajEs1nJGw5eNlH5V5rp25QNxwVO36exrDMI7M2wL3RrKhRdwI68DvVmF12qG/UcgjtUEbqsAZ23FiSBjv/AIUx5GCISAATk5715J6y0LUzJL8xRnAH97ANCbiod1G7pn0HbFSR3EJVjCAx9M9zSSkmMOrL5uOB0FCHLuNRJJI0JBXIwT6VJtYfKFLKqE5PTNVoz8xDZYqNoUN8pP8A9akmuZUhCoTvcdv51a1M2PXCNEqsOC31q3uRHUId3AAYrgg1mW8xBxOBk8epAqRJF3ja4Az0JyaTQJmpDISqlgSx4yemc1ZimMfzsAw3ZPuPSs1WYEfK5VSctu7/AEq3F8u4B41VjnOelQzWLNS1jZWJVsHduB9PoKtBR5i5dQ4OPXK/41QSSHeqhifMX7xJAqcDayu8auB1I+bH09qY2y+zgbtzFkGQccbqp3k22WPc5MgGBz2zxSSSFmy7Nx0xwMVUmeIyrtKtjkKO/Pf1pWG5FyeRg8Y4CnJJbrjHeo7mVJ7aWTy1Ulfl7ZbscVnSuZWCh96sfXJAzyKtKWKhWAYAYRc5OfT2pWsNSbLNowEAEjcrgE5/T8afdGR4ZTGuMk9u/wBfpUMA2QHcoJPygA9TmrKlhEY5GIdFw2Txg/5xTQpbGLKG8h/NO+QLzt5xgdaojBII9K1r4qrzGMjkA4XnAxjishchto//AFV7GXv3ZHi41Wkhxz3pjDJqTnn2prfrXoHCRkYptP74pM+1MCxZv+9TewK424AqSWRmZQq5YEL0qt5nlWykkfK29fr3FTH51VpAA2c4zwR/jXzMtz6Km9BwICNu2gMdo/xpu4YCkEccDHGKj/eMjcqpPKgLkU1nJKg/KFyGPfmoNbj4gWmJLAjoPQ1K5Hl8Fu4wPaowyRXDbTuBHO0c49afCgkILNz/AAjOMfWmCEGRF85OWHYYoEuyMtvIYf6sH+lPYFId5+bnDNnp9RSEjknJ8sHbtHQev+NFgbHW8mzMjgSNyADnHP8AKtVZ40jZQu2RF69ifTFY5lCwIY1DyYxnPeoZJG8tElLEE5O0nI+poSuHNY0pbn7WjFoiAo53ZzmqsfltCxnYOSN3qcfWlE+YxFgkAbuOOPWoxbyMu4fMo9ODj2FO5O5pwzIersqgDHc1owyeYCp3HnKc4xWPbt5Tgnlc9CB0rTtp1LIfvgDJwcbRUM1ijUgkQEiQOG7HqQfYU+UgSs0cb/u+/qfU59vSorYqATHkZy3P9KnmZgqrIVd3IBY8fiKSZo9iG2WVkaNPughQoPXueanE0pby5x+8Q7QUGOP8mrdlCrvJ5iYXvntj1qWS3YsQoJYAEbf0pslJjHjWVNqKQ5UDGfbk1x3iFQ2+KQnd0weOK7mL/Vo7srNu3Ek9Dnpj+dctr2LgzBYyArMScdT1/KpWjFNXR5Lc5h1qykLfKk6Yb1+YV7Ccbz7HFeUaxCJNVtIuNrTxj/x4V6uw5bPPNe9gHeDPn8arTSK8y7kZHVmQ8YBx+ftXnM0Yt7u5jVV3rIQBnI/OvTJFyMnHHb1rgdfhMGv3C/Jhwr5HAGarGq9O/YnCO1SxUj8xVV0wQSMjrj61oRpjIUbnbk8cD8fpVZV8tFIUsBg4x3rQUYj3RAeSBjHcV4j3PbiRRJDlfl2KORjt3pk8jQ7vM3c8qw9Km+URleOemeQKSUKoyoBA59v8mkmNor4cOFXAZuSxGQPx9ajYKHKDDD0bkn8elTyOHHylcAdAMYqgXbZ90gZ4JODiriYvQk8tVYeb8q+g6mpFeHcdoYgd8Z596rrJlgRnngeo9qahlO8qhwDyScEZqmiU7Go06rgr82OcYwKnt5EKq0sYJbqAcZHYVjkhomKsCSNpA7ip7CVkjAIIAGATjg1DiWpWZvxTBUCoMOORzkYPFStO7OGUjKtjbnoDWTHM4YBAEdeRVm3kuDIXeMhAAS4I/wD11Ni+Y1oXZGJGB2OeQPb3qcxpIpLwg5JyoAIAz6Cs+GZTIBCvTk/Nyfxq4spjjJDb+CcAnp6n3FFiiokQW6mKFkHBI2/w+59athipJyBE5+X1Geaq7w25olGCqhhuzn157VI7qs6Nj5Mg4I6e3vSaKiyeLlxubEZOQf8AP0q6WAQBgUzkE98VmlGnLKjHbtyBnjk5yKlRJGLiWRn+TBbPqf06U0EmZt5ICLuL5dyYBU9x1BqnE6iNSD8xGTx3q1qyxpd3GEyXQAAdfqarFAoA644JFetl/wALPHx3xIQkn+Gk79Kccj72PqKZ16GvROAQ0nHrS5GKZmmAyE7hCCMj0PbFWxHlM7yxbOP8KzrEyFSMBgv8XcVoMxAVhkegAr5yorHv0noDOiQsQW+6cD8Kp+eGSBWXDdWJ6jFSuxZVCgHILH/CogitiQr0XkN6+tZGrfYem1ssCcnqasxZLBCeD+v1qG2jwilOWPTd29qf5g3MwAYdAF6H6UDRLccqVZSATj5TSD5SpEm4YzycYqMlmdd2OfeplAG0kDAB+Yc0AMd2VXlkw5B+UVBKCwwgXnknJwPapQ4fywWBCgllI5HvQqCPakmzaR9880IlshRZEQBwTjkHFaNi7yLjgbTgA5zVVAoJYqdq9GZeD9avxIh2s6NgcgjqKTLgOtY5CG2gIcnr0q9bx3MSqm5YweSSc7vTrVdHWKZXVmAHUFuOf5Gr+9m2bkyM9N2cj1qTVDoXkVCzHBbhvT8KseZIqKzw8ZHU8/hVZJ1THk7mbHAVf5mrKzGOMsyksMEleg9qRaNeznmTm5I8rOSQu489B2z6VbmuNwJiXkuQQT82MelU4r6IpGJgscQYHcykg+3FW7eJDJDLHGc84djlhn09vrRcTK11HNIyh/lVsllyBzjv7Vh+JpAqqoUlyMAe3+FdXKjssp2qCwCsSvU56fpXMa4qiFtq5ZuMnnoOlNaieiPLr8MNXsSRj/SEz7fMK9OOd55715veRM+qWW7IBuE5/GvRyTnr+PrXuZf8DPnsd8aCQAjpk+xrh/FaCPWYzgASRYAB6kHHNduOa4/xjbhtTtGICrtONp5PNb4pXpMywztURWgyigbcyYxknp70vmlWJRvlJxu9faoE3FiBj7uM5PP1qR2Ji6qEUc59fWvAZ7iemg5rhWwF4JPf2p2+Tbzt3Ht/hVaJnZMqFBIw2RnPHWnj5VCkfLnqe9IE2I4j2BRyVPQnH61XuIzyyjbjnPQVamYeXwoOeMnqPpVQsEJ3AZYcBfWriTIAMSYBCjGTk/1pkr7UAUjk4yM07cuSSCBjjpVVJWc4TpncCODVozexZcksSTtGMDB6mrse0KNynPfpx+FUYN/nIWyo6eo/OrgIKlsAH1z1qWNFqBlkwU+cfdG4f0q5EVJAeLkDgjv+lULVEUbkDbm5x0q0py8aqokQj94pYrg/5/ClYtOxbRmlc7sLsGMEAD9KnSVkkKq4XA4b/wCv61SQGNcwjlzkgE9B706SRnUHK4HXOQRRYLloCRs+VJuVssy+/r0prwkIUUDccOc/r+FRwzAKgWMD3zk5zVsk8bo89QTnt6UmXFoltS8ilg0iogyDgA/ifT2q3aockb0aQ5JyMDJ46VX08h7dGwcx/e3Nt69vwqcny/KZdrR4+cjoGz61KLexj6s21WUqS+CH2/Xp+dVBkhVkGGx+lX9ac+ROoXowJXP6/Ss2EdXJOcevavXy/wCFnj474kStjPFRnrzTzimdhmvROEa3Wm5FObk03b7UCIrdGiupVAIO4jbmrEhOSgyGJLL+FPu0aC/nx8wzkDr1qNuvcBcAZ7ZHNeDXjabR7dCV4JiBWJ+8PmGAfT1pAPnGRgdCPSkRsIWYdM/n61EGDFcHLNknPfFc1joRoKd2eowBiqsDKh552g+3OaHmCW5bjKDIXrk1GD5SHeoJP3h70rFNksbfvCrLg56ZqYyqsYCnJPBPpVNbiMZCrnPVwPu+1PhJuJlPH7sYBPr607WFccpEYYvvLnue1SB1kdZXOFAzsxytMOfMHUqTzgjmpVy0YXgwpliCQCfSgWhJ8rR7X3MB0x2zVmIMkSiM8BemMn8qojdJEixfeU52E/KaekoJ+VmVwMFQ1ItM0YwSygkAHkgrjNM+0fZzkLujXnjtVWa7KJlVXcONxBFLBBJcSK8h68hB6UrF83Yu2N24Qr5aq/JGc5Aratbg7F3kkAdDjAJ7+9Yu0blUYSTjtW3bqyKmXjZQcHjjHc1DNIItQXSpMF8vAcgHB+77itszfOrI0hJJ9OuOo9axXCFDt2gnphcZ/H0qfzVSOQBSzZAXd29T+AoWpT0NHzvlVGVi+cNgYAwOp981g68VjKLGS3y5PHVs1orIiWp5ZMrgDPLZPX61hatcmV1jddjhSwx064/lTS1M5vQ4nURjU7dlHyG4Vwfx5/Wu4BHArh9VdfOgwBkSLjB967jHP04Fe5lzvB/10PCx3xoX/JrmvGQBnsGI4+cfjwa6U9CRXOeMFIWwYg4EjD9K6cT/AApHNQ/iIxFQhCYxkudo+lTqsbgHeFyOh7UsWdgQ7ckkj3HpUqQIu7fgsfl9sV86z34ojHy5K5x0Axg/WoJVKn92QQ3UtU6hgznIYE4B7mmThMANIq55w3J/AUIOhVLAudgJI49vwqrcuVIIYgryMLxUpwGO1iF9z/KjduVDjJ681S3M2VgvnsqI21WGWLevpVqLOBGq5HfnqfeneXGV3EL+OanSSJYsFFwB6/rV3JIkhZAeRuBxyCavRwqEVmkYMBuG1Qcn3qtDIsshK4EQH3mPX8KslljIMbnb1ALHj8BQFkJtUwKpVN2d2SOfWnyOgAILhz26kU9mLjAEjAnOMtgE9eRSzEuW3rkoeiDOM/rSARctyQfkPDMQMijzA7lAhzt2kAHOKlD5ERcBlz3UcVPERJNujXkE4Izg+3FAyGJgXQAYAIIx0HFalgrkM0vB/iUj5h/n1qGVhEgXYQo+6WBIqWCSaWYTDCfwsACalq5cS9DGMMiKqhgRzwWAHX61LdqsLFMYGcdMDpU8IhECgtuJB3knJI7UssbyQNkMFU9McYPPSpNbnPasg+wO7gg4A4PT1FZVrkxK6sTv6ewroNTDHTXyv3sgr6Cucs1f7PGQQQBjnj8a9TL38SPKx61TLJ6UwnilA655xz1pAK9RHnCEUzAp7UzHvQBb1eNkvyBgqYx7c81AUX7MkgbJfGWHOPrWhrw/4mNswXPG0/nVIxqYCqjlWwcH07V42Mjaqz1sG700V0TBbLZA5I9TVcKfkZhgDnIqw7kyFt6gk8gVEz+W3znKiuLc6ySQKylyynABHsTUc7oWG0k54B96ZGuHYZ+U84HoaaxyxQKwIHzEjqaLDvcYcqTlcg989D61ato1GFZiD/eAyaiXBUBTj0DEAVI0bR8xLtz1O7g0gFRFZ23OQo6NnA+pFWkRQWaVyCoG1cg5+lMjC8hIyxA4xnj296JUXzFYLtP90nj86aQth7l92F3BFG4Bv4qf5xeLHlszHksAOPYk0tvASyq4OACcen/1qmEIJbBbaOwINSyoojS2/eBgpRc9AQfz/wDrVpwwqER2YgZJBGOaoYVWZmID9sE1ciZgNzIxGcYDDBqWawtsS229Jx825TxlRnPPY1rR5AO4YAHJAIrMikUuwdSi9MDtVsztEQu5pFJAJxUt3N4mmkQOdh+QDDbh0psqPGpZnZjjgf3R+NMtpQm0NuHZlHb396VnLuDICI4xuUE53UhtXEQTcQSSL5fLAg7iPbJrO1AgONykY+dgD17AVfMJ8xZclE25C56/WqVxvaYoSJCTuZm96ZnJHKahbhr+1+TB85cj8a68nk8cZrAu1P8AaNmBzmYdR3rocfSvby3+G/X9Dwcx/iIbgVz/AIxANnbEDIE2D+INdAaxfFo/4laHP3Z1/rXbXV6cvQ5KP8RGIi7sDHsPYVJAN4I+9tPK9PxqO3OQo6k8deasoE3qGX5lHO0feGa+bZ9FDYZNEgXzMYUNnb0yKqXKh5F2LxkNjtV+baMo3X7vzDpTZY97ptQnjPJxu/GhMckZcSJ5rArtbt2zTJsIc/MCe2ev41eP7srIvB6DFM3ALu2jc46bTx+dUmrmLRluzjA3c9eTniopHaMElX5IUknoPrVqcBWO05JNRzRlgCQuAMkHviruZtDLdnklBRnHy5Pbp6etWLeZmZmEhIxzhep9jmqkkSFsbSiqMlQMflV2GEhFKIQoGR8nb39qYrMuQsC6o0RTb0GMnPtVkL8wLHkkA/J69M1TXqdytyQMhT17Zq/bheAcccjC9D780hosxW/zAtgdh1wtXYnhUSEMoweH6nPp9KSOByofzEfjn5SCPxzV+3VJDhgCidTvTn0A3DtSLsUTCZCJJBk9SBxj0qeJfJkC85zzjt6A1ZulVT8nyvnkLtb9KLWynWZiTGzHjaCFOfakUia2G1Q8fPIOZBxu9vpV5t8iK7uoI52/ToahRP32NrRttJy3T68ZFWCwP7pW27Tt3e/rUGsTLu1DLMobIKg89vauQsJV8koSf3ZIx6jJxXY3YWKJZFGVAJkB6gd81xtugjup1VydsjcgcEZz/WvRy9++zzcwVkmWsYGT1PJppOOacWBzio2HFeueUITnJpMn1pTScUDNbXHUFVGA6PuzjmsxnEaZfad/IA7H6Vp+I+JoZIxlslWH06f1rOlUeakigbl55HXPUV4+N/is9TBL92QLHv4IK88sRVeRCgXIOfXPWtUKzRsQFXGeM/eqjOql8bTt2/eH8q4Fud7VkV1IVgQfqB/LNTiOVjkps7lQc/marK6/aFTBIOOnNaK2jKMqSzdSBkirZESoInIIXGMjjHBqW3VREW2hQ5xnGT9RUrQZVgxwoHTkZqSG2jEfQqOzY6moLSZEXRCQrnn2zmpIysir+5zg/e2YINWbdkWFgFIdOpPDL/WrEJGxn3MN3BDHINFx8rZWstwDYD/KeQ4OR9PStIWsgkVniVWPRxg/rVaSePczKEJUYOVxkUtvdKyt0I6BgoyfzpMpK2gsgCSFfMVXJyd0fOfqDS7F2qPM2kngdQf8KhmJaUsRtA6Ajn9OKh85HDoZHSQHOOOfpxSsWmkacSjZsEgPoD6Vcg42sHCjHbJrMguIwu1n+bplTgj1rQCo5V4F6Hncf51nI3iXIXdgigKTg/MRjPtirUaPG6u4R/T1z6+wqijOVPnKGLcBu4q3mSNNp+cEZDZ5+lAxtxKJV81l+Yj7qnIOPU1lsRtY9A2QcjHbNWppyqo67CcAFun6e1ZrTlgzscnkHjoB1P40zKT1KzZk1eyyTnfuPPsa3FVeABwOgrFs13aup28Rqx/pmtte1e9ly/dX8z5/MHeqOIAHFYviyMPo0jEco6tx9cVtcgc1l+I1LaJeBR/Bn8iDXZUV4M5IO0kzl7X5o13gEnkc9PerIYiRZfukZAK8Z9qo2kgKYGS2OPzq6G3BvXHIr5mW59HDYcXVZMPnfjg9vamyFm4BOQuOOn5UK5wA3yjGeO9MRxvJdVPfhRyf8KChyRhNueg5PNQ3ckauDtOemFGaa87Bs24xzyw4FQkySqqxlgc5Zm6n8PSmiHpoRiIyyZaQKBzg/wAqRoWckgg4GSanUhImQqM92HrRGyGIkIC3GQD271SM2NjVFAAA3D+8CD9DmrEEexiNxZSPmAOcH8qWNgr52AnGMkn9PWrQidv3piYuACNoxkfj0qiRLe2ikJUly68hef5VoR2q5UruBHvVWAMVBCyDHRSQfxNaVtsdiq5Lg527u3tSLVmLFaouChGSOdzYGfpWtDEQoZixOMH5Q2P/AB2oLa38sFsshzkcgmr0MQlfawLMeTwD/hUtlJEAti7uJICV6K7xDp68cVo2tsNzAOAVGAB8ue/FPtIkCYCsOoGOB/OmXvkxoT50TZ4AI59+CMYpgV3uTCWDktk8MOR9fb6UxGzGFAyBjcQMcmqc0ygyYVFB6MpxgZ9DTPNlWRXSfbH99jjI/wAKllxYl1KMTbFVhjp0zXOTROl7Ozcb8OBnoCBxW3MQGYAhRjgdc1iXpLXSoSSQoOQeo5/rXZgZWqW7nFjlemN7UhpQeKQ9ea9s8cafXpTM09gO1NxQB0GuKFji2rySWY+h96x50byt+7c+c4J71ra4nyAsWJcg57Lx0rLYKYQ+ckDIrx8fpVPWwGtMC5lG0Lt+X5mYdP8AGoJFXcN3zqO3QVaLlo3OVKnoR1qqF65bGO3rn3rgW53T2IguxPuFFXpVm1lwm1W2565OMfSoVOG5G36/406PCkqOAcEFRVszirFzYJY2LkndwAB0IpudxAIdXY8Dsf6U6JSzA/KzE55zzTntzIvzDK5yo7fjU2sa3Ks6AOGzlQNu7j+dSWxbAycgj7rMMn8KuxQwMAC4RwOeOD+FK9lC+G2sp7MoOKTC3UqqfMUAll3dFz0FKYOSgTYT3LY/I1dEcP3dkchHAKJ81TmFQduw/wB44jHapuPluUI/OjUCRm3Y9WGfoelRyFbjBBBK9T5vI+uRWh5ZjQKsq4Y5KyRkAfQjvWdKpMkgZoGTORk5H544p3C1i/E+1c3EZZh3YAj86ngmDPmEsWH8AXmo7WXZF5ZDKSPl5+Vf51IA20hmR93o2dtZPc6loi35pmbAU7j0IFK6gHGw+YBncM9qqxkAKv8AD0OOCakaYxp5cYwo7Nz+NA+hVvZGmh8tAq4IyFHIqmWO0cE7eDU7ygjZny9xzx6e9Vg4PmqfmweoqkYS3LOhoWlmkIxtxHz371sAYOao6LGEsVYZy7Fsn9Kv4J6V9JhY8lKKPmsRPnqyYvWoLyHzrO4i/vxsv6VORyKOhyemea6DFHmtk5VFwSMcZHarZk2jcMkk84PH41XuY/s97cwjqkrAD8c08yHKgjgDFfNVYtSaPoKEuaKZYM+RjIAHXdx+VLFEDExkAQ5yccZFREHapw2AOR1//VT4ifNUug4PUHJNZmtwCEjj5UPCheg9zUboQMswc46en0FW9+5dv8RJPrx71Cw8xeAcZxu6Y+pPGKpESKJcEbMAMOpwBj61cigPBjC7TnJYgc1GIvL9FTPGMnP6VYSLfgHcG7DeRii5NiwIPlcvOqFgOY+5+pxViGwC7XYOzg4JklXB+uKS2YxqEmHl7v4xyCP6GtSzgVw/lZmdOjbQBj05NF7FKNyC2t3DDaARnJG7j9KvRWSlQACD1TAwR64qeOFQ253CHPJVTnH51bjSIkFU3kfxyDnHtRctQsLYQbZFkDMwHDAqOfxxW1FaEL8itjkrufjJ+gqlZZRVVw/l9AMkY961oiUwwWQKclWIwD9KkrlRM1riEKpcBV3DMmMce55rn9TlnI4YjPOGK4Az71vXCxtFGsyFskZWPKsD9R2Nc3q00cZJSIj5ieRkAfic1dyGjL8x3LDftwc/eUnr6VKpZFkaRh5cvGTnr7gdj/OqFxM00hAIjZhw2APp2qWCSXy1+YEDgDcMjPpxUyZUCOdUVwdvGc5U5Cisa/OzVAF25aM49BzmtieVyyFmRoxn5B1PasPURtvo2UFmOQc/SujBu1VHNjFekwTqc59M+tKxHTFNyWbJ2+wFByRz1r3keGJng4pmTTzTaYHRa7LsijTZ95wBk/j+lYgldcgpkj0/nXRa7Ei2iSEDKyjBx61ztw27oMbeeOoNePmH8X5HrYD+F8yMMCzkgb1OCcYzT/OUDlsnofWoHII2zjIIznPNTQ26uf3TKqnue34VwxVzrlIlAjH3Qo+ozzS7Q8gIww77ucfSmpFCoDtIMVKiRAkbQEHAGSCD71RSJQ6Ko2MXl6FCPlX3zViNHcgyKHXb8vBJPNVFaa3c3FqEUDnAJOaemoFf3hZ0c8/KcAe1Ia8y/FaPsYvI8G5s7W4p4fjDFnwcllY5I/CqKXTSuRJJIRnKgnP61Zt7hRuaTd14ZZO34CoNNDRt5kIx5XUZ3E4/pTtqSPgBF46jPP0qK3VpNphB2dvepXjzJnK8DI28YP8AKkUhlxFCikMh2YA/vfjWZdeQvEOY2YkYBBX8QafcvKCyKzY6cHj8zWPezOo2NgHjluRj6CmlcmTNKF1gjwFcZ7DjHvxUsd3Du2KX25yyPjP61l2twyq2JAoPBU5/mKuIUZQM7l79w39azaNoyTReVw0bPGdpxkDH6+1VTPcXEipNHBt6hwAX/E/0pI48uWhLRP1yrcUyR9mQ/B7lhtbPqPWknbcJq+osnyy4LbsD+LsaovxJ8hAOMFc9+2KkYBwcHK549B706xi8/UIIz8w3bsj0HNa0o881FHPVnyQcmdHbxeVBFH/dUCpwKO+TS19QtFY+Ybu7h0ppXg5HFOzTGNMRxHiqDyNbZ+izIrge+MH+VZpO1Rljzzxzmum8ZW5eyhukGWhbDf7p/wDr1yYkyjfxcV4uMpuNRvuevg6nNCxY35kR1DhR94A8Af41bDLjemAcY4FZsMgXaoBwv3R0yask8ZC8k55Pf2rhtY7C1ExICltwHG0rj/P1NJLtwcknn7zEkj2AqCN5N275WY8ZPOPb0qaaVlU8v6Ek/wBaaBjYwZJsuBjGPm6nFX4cMSIwXIIGQBgVkx3Akm8tGAXODxyT6DFaVnvGRs6Hhf8AGlIcTYtt0Q/dhXdiBuPOPpWl54KlXDcNnaoyOlZtt8xwTtwRjkVbaaOJmDh1IIBOcbh60jQmkmKLuIb5hxgenYVLFJPJE77VjTaOWI6Vnz6jEg2SO6wDgbTjP0plxrdgsYRLSdnIwy5OV/DvTS6ilJGrHfCEZffhQTgcZ/Ac1p6XNJc+SYTt80kFXbLJ7j2PvXIPeym13W0bQyRkliBnKkY+YCnaRqN5G5RWWIkHA6Y9wB3qmkjNTbZ6Hqsl0FbZHcbdmBvbaC3c464+tcTfzzCf5jHITyTmn6hr19JA0XmMFXgqVAJ+vcmsZftFyx8wk55/H6UrDbJTHcYLRSJGjHncc5qxaRXAkyYQ27jch4P9fxpn2XEahCgG7BJyx/KtO10+5RSWEagnjLcn/gPX8qXKC3M11aVmSPzFMOck/d/+vWfqgZo1dAdquASffuPetuWObZIPmEi8AhMA8+9Z+oAfZZQfkZSpC9wAa0oO1SJNdXpyMzAUY7CmljilY9qZzX0R88BbjBpMe1IWpuaYzrvEL501ht5DKcde9c3N82Tj52GBiun1w4s7hAN58vd1xyDmuTc7gCSa8nMV+8Xoepl79x+pXjkLu4aPhBnd0P0HrVtDGSG3gc9e4qixVbhQQ2AdwGepNSSpHjJHPYEVx2sjpbu9S1uiRV2SJIwbGF64pUdWc7rnZj0GcntWexTy/khDHd977tKZpg5Cou1ecY5FS0VzG1HbQyHO+SRGGTt4IPrile2iVQq2gfnIMjcn3rKjNwcna+Cei54qYyXMDEmRxjowB4+vNTqaJp7mghLcbEjA42hsD657VYaaZmAWSCMMMYVd5zWI95Kz7o1ZmHoeG/OpPtUxKZVon7YwaTGmjoMFConuGeEjIdSAOPVcZqRlDRkw3EJyOFyWb8qxoJl3I+SCc8E5H41auJ4WhZ8qhOCecj8Kkq9kSSmUCRFifcBzuwVP49qqQQzSx5ngcL3OMkfX2qb7WsshdSptNgVCh7jGd3vz0p13HJkSRW4aNRnOcH8ec4qmrCUubUri2WFT5cvmLjn5Tx+IpkIaMkBUYN6HBH8qehUSOyDbnBaPcOnsak+VyNm4NngNw355qGaRWg5MMFVhgdEyc5NJO7SYy4IHHPI/WmRsyu24qme7Dmo7iViCqoirnjngfSlYHJjnEQhYZKn/AGavaBFmaaU4wo2Kf51itIWDMcj29K6XR4vJ06INxIw3t7E135dS5qvN2PPzCrany9y83WjrSE803PNe6eJccevU01jSZOelNYmgCO6hW6t5YJPuSKVPt6V5rPvtpZIWG1oyVIPrXpZNcV43tDHdR3cYO2QYf/e9fxFcmMpc8ObsdOFnyys+pjxuWfhgoHUN3q4rqvIyM/z9vSsmF2EgGBtPStBGIYMCrFewPH1rxZI9eDuW1f5s7OWH5CoL6Yxx4UKcLgt6f/X9qC4B+RxI/XAHGfSo8NIRnlievYVK3KexNpVusSK2CX/oe1bULfNnb+RzWRCSJCN3T7xx0H0qV5JhgxZ2ngZNEtxxdkak18kb7csW74GcfhVOe9nlSQxxkRngbup+n/1qktLRixMsauev3sbv8cVeto4fvbJDLg5LH8sDtSQ3cqaagiWQXTQyz5UgNltox2A4zWnJFJI6CNPKU4BwgAFV7SWSxmZprNJIWbDTLhGTJ6kng1ZdfNklVSXaNuiyFh9ckAfzq2iYvoweBYrgBGYKpzuUkkn6Dv8AWo/KkV3QSuVDEAbScj1q5GXjA+zEGTBGGUouT0xjr61JbWzC3BY5dR+8cnJLZ5OaOgre9oVykhXjaikZODtJ/Mdau2Vn5gCRtiRhkhSMqPU/Wnc5EbR7mYbifvEjt9BWrpiBnCCMpHkkrgIppF2uS2FmLfZsTc6k/efOGx6dquTygRxuFaWRVb5x8pJ+tSRJiJ03EMc8+3rWdOk4d1RAWwCG/u+4pJlcpi31y8rMqj+6Nw/hPfism6bdbyhsY2kD860LtvLWRiSzkkPg9azNRmAtnCrxgEkVdL+IvUit/DZnE0hpAwJHPWivoT54aw5zTMU8nNMzTA7zVLUz6dcJEP3jAsD6mvP0LyLtkJEZIyB1r0t8shA6dK8+mT7PdTRMeY5cD8+v5VwZhH4ZHdgZayiRCLdcvwyq8m1d55H41chiYqBuUnGMEZ4qNSguCXUt+8yNx9fU1YWXCEHrnrjP4V5reh6EdyIWzIhxzlhyF6Ur28nmlwG+7jheDTWudoLFNxHXOeaswXgUBkXkd/apLSK0MaySHzFJUDnA5FaFrY2g+cTqRjcp2Hn2qJLqXeFjU5B64HFW7cTswEcTjHz4AA/pSZQRWMU3Md0eMnbgn9BUz6Zsi4nV1B5Hkkj9ev4UsUDMSWdhIoLbWwAR6EVND5ZwyKuSOBgt+AqWyopCWek2DqY5n3Z5+SLBP4ipB4VilZ/srOVPKq64x79eauWYdZMBFHIKHBUZ9hWzFCJELOSW3bgNp59eM0rl8mhyFz4fFo6OGXI5ZTna3vwP51LJIZI2UFvNXgg8DHoQBmuqns4xB5qquezHj+VZ95Zed8u/a2OC4yH9s+n1ptkqFjhbiZ4Z/wB9EEjPR4+9W1cG3JLB4m5552/1FdGdGwjJJDltvMYIKn3BPFZNzprW6O9jG2w/8s2YMo+h6ipZaVitGFMYCNxjqWJH5VSlhfLPsznp8wGf5VamdI1ZLqz2kr95eCPoR2qlMkY+ZZJVZhkEtxipQ5bEdtB513HCqnLtg85+tdqihFCqCABXM+GozLf+bkELGWB9zxXU/Xmvdy+FqfN3PBx871EuxG2aTp1qQ4pr464rvOAYDimsc0MaYSaYCEnPHSqGrWy3dhLAy7i/K/7w6VeJJqJycjHrQ1dWZS01PL543id0k+QxnawI7iplZtnlsAiEda2PFtoIb9LrGFmGDj+8PWsWOUH/AFigknr614OIp8kmj2KFRTimX4hHkJGcjHXFSMuFIK8e/FR243/LnBI7dBj1NX7WEtcbmIaMAEEngn+ZrmWh0aspwqygbxnPzHsFX3rThyzLuVTgcbv6AdKsMgiR2Z1V2Ppkk+2e1NBwHK/ePOTxUy7lpdC1FtMY80cYOCowAfpUyjhkRiUCjcwX8uapxyBmAK8fwjGc/wBKmgw2+Te/l52jJ+XjrxSKZIyefE6O28EFQTzj3xmiC4mQrFcWj3WB8pgyCf8AeHSkExd12bsgYJjYAY+gqYFkAGwNjnc5PA9K0uZuPUlgdhIjG2Ea7iQCyhj/AL3XH9avRFSQzn3JUbjiqNuSm7kiQgEBV2g8/nWjCzMMyjPPLe1JjSJ4oAHX5fkJPGeD9TWpZiGVP3Zbzc4C9Mj2HrVeKRpmWIlREOcjsD/LnFaVrsjt5VKEzZG1+vvQWgZzG7L9oyv3Cu7II68e1U7gpuP2YuI1XlT1Pr+PpWhHDLDcBAAH3A5PTp0+tVJSmGVWOevPrU7FbnN6lGphDKCTkiTA/lWDMxNo5bDYbb9feuovS8UpRFDK+eD6/wCTXL3jFVZGxh3BAH61th1erH1OfEu1NlI4G3jkGhjyaCOp9eKZ0GDX0B4Ip603FLSZoA9IPCnP5Yrh/FEbW+rhyuVuVDceo4Nd4T0561zfjS2EtlBOA2beUM2P7p4OPxxWWKp89N+Rph58s15mDIyyPG+MyNhcY7gYzT1LBWDAjtkVFa4k6gBj0B6VPEA25WUbUPUHmvCke1EFJjba6hnPPTIp4YwP8yjYfShbaOQAjerdyKUwRrgmbAb5WHep3NNi1EA4O5Mq3A4Oan2EwKAjkKcc549u1RG1VHwtzvTHy8c4pyCAvIXkkZQOijHPuaTKWpJHAAMySR7h06ZGe3XmpS/lsqruk54GwL/n8KgjeDK7YWbaOQwIq/DP8vyqijGcbqRSRZs2aRciKRVzjO0Hn8a17OUM4UfuyRgliu78hWJAoEKZkGOSQeTz71esZdi71Pz5xknkD6CpZrE2JphDGUMjSYGSBEQT+OKpxajDvWNnKMBxlD681OJycKrHv17/AIVn3V6jFlmSN0xjaT+ppIb0ZoCSKUujxQkjvkdapXlr982kkqeqH51NY80ltCxNu0scmfl2gsAaeb+Zflkc7yOXU4oHdFK/VpYtjKsmM/Mw27vw9awp4VTkwsp6gE5H0rWur1pnYA5wcAjAB96ybuUA4bJJH1oSM5vQ2PC6AW8020KGYKMewrayM9c1T0aIRaZbpx93ccepq2VGeOK+lw8OSnGJ8xXnz1HId2zTSMigAjvSmtzMiZcGmN1qYioyKBEJGPamn0p7VE3T3oGZ+t2QvrJ4TkFvukdm7V57HG8ZdZTsaMkMG4we9ekyuQhDnJHQDp/9euT8WWBhuxeIBtmIDnHAYDr+NcWMpc0eZdDrwtTldmVLJQ6gu2UHOOg/AVsRSoEO3bkHglegrCt2whO7DE8D29auQ5kIY5O37p6YrxXE9aM9DQlZcbizbh3zkgVWSXedvzFf7xzSb26FFJ9e1SRM5IaU5HtjFKw76liIERF1Unrxnr+NXLRJDbDBZIzwMjkj8TVfdyNpzk4LY4H096tB3LBUGQOilulIofHIxdYomdn6HAxxU6JjDB2bB4GeM/Sq8K/K8xXaAMHBz9DVqNgu3aVfB6iqBFmIszrJJl8HBJ5JH9KuQhSrJFg7j37is9XP7wkllPBx0q3bS5URbSJG44bA20FI1AB5isMKvA298Y71s2bLcXJVxubblABkEAcZFY0LO7opPCcAn+tXgJUgZLfAUDzOB0P+FAzWnPkvEpBEj8HCgZ57D6iqF6eDJsAZxkEdOvT8P609RNdySRzvGCyksffHOMVJeShbdQNjLGVJIHtSY0c3qkUg3yKGLjbhQfauN1Zts1vtOQZMAkdjXb6ic4yWA3Eqx7fWuG18NDHHJuUlJeoHQHof51rh9KiObFfw2VznkZ5oIxj3pgkY9wff2+lOBHfk176PDFJ4pMj0oLDsMUm+mI9NA4qpq1oL3T54CBl0IUnse1XP4QRTHy8bbhz2xVNX0EnZ3PPIWMTRl/4kGfY5wR+dWgMMrgcEYYehpnBVw2TLHIynP90ninFyhKnIcEHp96vnJrU96k9ESoy87eR0wPWnC0H+tlbCsTtHoKWN8IREoB3AD0561aAYRqCcdcDrms9joSvuQG2RGXcCMdvSnRjaWK5GTnA4yfrUrsjNhizIBuwvOfao5zCRhHGG/SqRLLFuMqxzliN25uTz2qcQhDtHAPOM4xVQCQpEi8KoAI/vH29qtCMuQ5blT6ZH5VBaLEUMUeNuXJH3sgFfqK0YV3Oi5JJ9R2qjHJjCDaVPPHFXLdsK3PzYyd3f6VLNIlqQeXGiZY5Izznj+lZ92uXIh3FRx2zj8K05CkseR98DdtIA+uayJQyJhGRWDZ2k4GKRUihIscTtud1Y8bTiqM7oVkVM7V9CefrmtSe4eFZZtqFCMEA7Rn2HWsCeRWy2WBzwefmNMzbsJNL5qlc4A6L7VVP72aNUJJZgntStt5YrhiMdc1JpkZbUYsZ+U7to74rWjHmqJeZhXnywbOyjDiP58HHoMZp+AR7Uy1xsJMrMGJOCvI9qnwO1fSo+cZFjikNPZaTFMQztUZqZhULDmgZEaibg1YYY6VE4p3AqyoCrAYyRnJGay9WthdWZjDhDIePr24+ta8mMj19arXCBlKgYBPJqZJSVmUnZ3PPombcQx2t0+lX7ZwcA8e4p+uWv2XURKSdsueT6+hqtZ/N8zHJPb0rwa9Nwk4nr0Z86TNFZAyEAj6dB/wDWpqSbdpPLA9emBTEGz+IEemOSfSo+rEjhR26iue10dBprIJDzhh14qdWGGVBhh/Fk1mxzBGTI47gf4VYheZpMlcKTkc0krFcxpxSIFDkkkjOAMA1at5A8QES/KRzxWaxkAQkgBs/KecfSriKqxKB8jKueaYJlhMq25izKrAkegq9Zok7F++47QvpVG1DycoGAJPBOBitC2BQM2AEfj/69BaL0fyuxllAQjBPUcevpV+yuTLdhpmYxqpwqkAv6H2rMtZBIqKyrkP1xxjtWhHIqtlRh1PQDOfwqWUjRikEax5YbInb5APmYH37/AP1qrTBkaW5GHhIBZAegxx9amtx5zSPN80gyUETY/ED0z1qORI5Nq2zhmPDKuQPx9O+KroLcoamzTWzgptJOMDr0yK4rXo0WCVsfL8jFTzg55rtbvaryZO1I1565B6D61gX9s1y53oAnl/d6FhnBJ/wpxlaSZnVjzRaOTRfmIPTqMd6eePoKhTcjlCeVJB9ODitzXIrXTdQghitspDGrO0rH/SCQDn2HbivoISTSseA009TOureS1ZVmXazIJAMg/Keh4qvWn4htorW9Q2yNFFNCkwiY5Me4fdrMzVLVCZ6dkgCm5XhgxVhTqBjOWIHBFaGZwjNvv7pG5Db/ALvY9QfpTpWbA4yVGMiooQHnuWJ24jY8c5OeB+dALMDt57NjjmvnKm59BT2LCsVh4X7wxu96txSeZHwCHXlgD1qmGkjXIKnHHNSKwDffQKwwMnB5rPc3TJ94iDO3Q9PpTI4x5xfaQrcdanjCrEVkwWX0GaZHGCh2HDMaaBlgJ5QJyRx8o3Z/CrCABAQ+eDnNQqqyIjNkEjke9Wotu1gDvJ/u8EZrMpIEMcca7S4IXO5hirCzAHfgFVHUmqv+rBZmdkxgrnpinRPEEDKAQehBzkelJlrsWri4+47AlSvG09PxqhO+11O35WXk44HtmrjBSn904yBjr7ms+aUZyGEhzgFRk5/lQtxydiK9AZF8pGPGC5PT3rPuIyT8zKwAzk/xfSrt1NIhVlYHA534IH09KqyYYbichjkEjGKZm3cz3XBIY5Lc7j/Kr2gqRdzSRnaygKMcg5qldAtxz9R0+lanhOMxvcMf9VJx9SK68DG9ZHFjZWpNHTRK0ahSwOOOlKWIPzD8RS5BUEfWm565r3zwxWORxTMn1o70h4NACN0qNjTyfU1G1ADGOQajantgUxqdhkTYxkn61AxaTlcbR1561M4GeaixsGAM0gMLxLE8tmytEcr84brjHb8a5m1xkY6V3F3gwSlfmcjp6+3tXHXERtb5osEKOR7A+9ebjqeimd2EnrykwGQcrkdiKkGeq4IPbNIqqcAEAnjJ9afgf3Bx0HoK8s9IcU2yL8o47j+dW4GVwM/K4GR3yKrMcIxDr6bakt4wAVdvmXgj60ii0++ZUCgrsP3sc1YjjeYhlBZVYFiT1pgjCucljgdAevvV2EqTlSRxk59uop3BK5oRL5cgwwIZQdvQfjVm2JRmUpnA+Vu2apQbo8IVBDcqc8j1Bqzz9mRMlgM4PvU8xqkXLZliLqUBJyPp71YtHIlNxEPLYbSHP+elUUO5AFZwH6satGcKwSQMjAbQQAQzf4GkOxr2S+YqPGzFRjk9cE80Xo8kloXLFuAQeoz+lQWlzNFCgjXCjI+5nb+NXY4Xjj3TDMbcMTwQSKoCleWqtcyKoG0gOwz3P+RWTco3nsGcNkZB+h6VsXEGIFCyCRhw4XOAfQ/hzWfewkDKEgLkJgevoaTQmjgtYgEOoO4UiKQbuOzDr+HSulhkn06CG1u9dtI5o1BEUlt55iBGQA2Ky/EFqZIS0W4yIu7j06HNSXF7o980c9xp+pGbYFd0cDzMDG48V6+FnzwSfQ8bEw5Jt9zM1Yh76SQX325nwzTbSuT6YPpVPHvVi/Nt9o/0GKeKHaPlnILZ71U3mu1bHGz1ICmSqBC+SAMZ570pzjjr/OqeqyvFp1w/BXyyCR1U9KuWibFFXaRxcccsS7JUKszbufQdP1oV264BI5OfQ96RZ3KIhfcqDavH3aVQN4IY9MYx6V83N3eh78FZEzKCEKKMnnJ/iqdGje3+f727AXHf0qIjEbqcgMfu46Yp3Xy2HGWyMGszbzQ6NngYCYkxnIBPVfrV4IDvOSFHXnj6iqp5gDSbHOCHJIyfrTrdYzCMGQgnOCcjBqgXYsQS7csW/dL056+9WY7iMupG5ieMnqaoCP52EZZQB8v+RUwjO0lOGA64/Xmk1cIuxblkbBYIrqvLZ7CqdvI6+WyREpnIC8YyalhkjCcs2T3zgGnsjKWeJVzj5g3apehe5a/eyKo+7u688/melVLjeT5m0fMSOOw96sxtuUKGAc9QfT2+tLdwiSEjDLjBIx0FIp7GVKMfOBlSMEGo1QiNVkDKuOSfSrSsuPLABz79aryjLMjsfkHAzxTZCKFzkTKc4UnGa2vDm5bQoUdozK3zdQBxWRdA7SzADaQfl71r+GH2wSqQQN2Sew46V3Zf/EODMP4ZvtxjNRtz0o9MZLfxUc9enpXuHijSaKUmmkjFADSBjmmMacx9Kic9aaAY3WmNSsc+tRseetMYNjimMeenGKMmjPrQwIZkB4B68YrltaGZoWChW2lT7iurYnqOtc/rieZazDgFfnHqfUCufEw5qbRrRlyzTMiDJUAdBgj61a3fMTgD1561WjJyVGFIHb1qdhwOME+vavnz21sJy7A42gnINWISyvmRhu+6eOT70igFwvzMSc5qfYCTkfORt680MaRNDKuA7A7vug46Y6Vbs1E0iysxdE+QDGM++KjsMfvF4PzdD1xV6DYCRHzkZbnpS3RaROymNEJycc5B5qe3WNZB85AP8RPHNVxJEgO5mOeuOaemxpFyhCc8VJoaVnndOjADa24D0HGP61YjYS3KheGXkDrn/wCvWexdXSaD5DgIQ/Trxj3q3byRrcM7fcAHK9UFAM3EWUKsuTywyp6t7en4VYdzK0Dt/rHUjnjA5yceuKyL27iktlFtIwd3HOCCOeoz2qzI0cSRAbi7SbAxIJwRzgUX1GPlTypvOhfcipyc8Y/rVOV1dsPjbjqDnJ7/AEq5M7lVBKYIwMjHNZU7I07ESAOSOF4wT9aTGVLmS6sbcvaT7HYFSyjkr1HWudfxFrEUskf29yEOB8o6dfSuhvn2iGKQ5ibLDc1cvqNlczXKfZYZJZJMgKqnnHQj1GK7cFO07Pqefjqfu8y6FO/vLi/uPOu5DLLgLuIxwKrYq5fi0jHlR291BcoAJBM4PzfxfLjj2qln3r2EeOz1PNZniFiukz5ONxUcd+avrWb4nONLx13SKKqu7U5PyHRV6kV5nIr8kr5/u5/HNOeXMQYcNk9aCqqfm49KY8bZj384Y/8A66+beh9Ai1AcJlwW29RmnbQqo7LwG7/3e9Rodm8qc92qXeGRSOFzk+4qSxQixff5Rjnp1FSRxAbiMLn+6eD9ahhJZNpyST09KsRYXZH8p2H/AL6zVNiW49gFYFfvfe4APTtUkYJwzsQcZHOf0qMsInwRubsM09Z1bacBcc4wMUrjS1JNxDAFCSc546gVYjiBUBN6g8kjnaPaqnmvJcFomH3dq+9XIJJIyN5Bz144pPUtFi3TY+48j+Ljn61YnkEduF4YNyvp+dQ+YFIJkyp5KjoKrPI8WdjFtx4DDIwfSkkPmKckZkmUxkoM8bf6U91ER2qBjbnNOjO6Rg0u1yeoHT6U25diQvLy9Rx0x/ShgkjPvBtXJAII/WtLw23lvKpwQ/p1yP8A9dZN5ukGQDyeADWt4cBRbkgBwJACCeRx/wDWrty9/vfvODMFembrLt+6SCetNJ9fxpzuO+RTSRXus8Ma2KZSsfamM2BQAjmo2PtQTUTHB6mqsAMevWo2x+NKzZqNic0AIxzTC2OlITzTG5NAxSx71kashaB8DPcZ/WtNmGOnFVL7/UsQMnGB9aiaurDTsc3b7PNORlehNXGYMMZ/TNV1C7D8uWU/d7VKkpLDOAR/Kvm56NnvQ1RIjYHUf4/SpVYHgMfcelVicHGQeMj2qaI7mJRecYy3rWZoi8kvkxljkcc/SpIJIY1DtI5BUFkQDdk9M/41VRRIwQdWwMbuB3NTtJ5kjOjI8Z5XPUCritCJt3siVbqEFWTzwrHlSAcDuf51beUSuskbJIHGYyePwI7Vkh0YttXk8gnrjHatDTJUe5jtXiKx5ZlYDBViO/txVaME3GxpqS0DF3Y/L82DwPpUwBlKl0RgRyCvJ96rRSkxjIPOQxHC1MCFYujEFT6ZBHpWD3OpJMvC6YiKMnMincS3TPt6dquW9yZ42e2RTjG0sfu+p+tZDwK7qz4dCchc4wfX61dsRmHewAcfKWGeg9aLjUS7JcKknzBnO4tuP+FUVIMr85y3pyR60+Z1Jb5tynkHoBioEPG8OcsuBjtzQAl0vmRIEVXz0DkDnkVPrt3F9hvZ7W9h864gS2tkDYMKjG/Pp9ap3RbAKgBl5y3PPoa09RQQafqFvFbxrbwxQPE3lglyW5Oe+fStaUuV3RzV483unDeJp4Z7+PyJhceVAkTzDpK6jkg9/rWRj/Oa2vFVskGprsiSB3hSSWJBgI5HIA7djisfFfQRd0rHgS0dj00MB2NZHic77SBegMnJB9q1ssOg/wDr1h+JmHl2wOdwLEce1GKdqMisMr1YnNztwuQemevQ08uSN5IJxxzSOQVwSMD9TQWxt2AEY5zxXz0tz3UTM2VkwDgCpct5Ocd6qQu7Ax4AIX1zVyNgj7Tx3I/rSsWmRq2yeIKuS53HPbHTFW0IbLdxxyKrzoo+bccNg5H8OP6VNK7KC/Bzw3t6UiluSAhvlZ1B6fNUYXywRuwelJhW+baUXOcd6WaUJG7A7sY4zSGTID5AV2Ct24q2k/ljy2OSD3B4+mazt/yjaDyOpHSmPOTuU5xjOSauxLlY1FmilclpFRkXBXB5pJZo1kYBhgjr6H0rOSRnYsAm7PGTVqRiOFj3NjJ9MVA1K4+Jz5uRHlscbf50M2wP8wJI+8Rz/n2qFSJHVmfA5B2npT3j2Hd1K8MM/rQUkyCRQ65V8gdDU3h6QG9nDkEY5A7+/wCtU5nCgryMkHHSpdDbytQbC/fztrqwTtWRyY1XpM6sEFBjgY7d6iIA5QYPekTK5Xt2I6fSgnp619EfPjTuzzSEA980/NMxjOKAImBBqJ84qduRwaY2KBogIx1pjfWpH68GoW7UAMfimN0zTm60xqBkZNV5wHQk5A9qlbJH86hkOQPrSYzEm+R3yRjNRRkH8OfpTrri4fjJU88023TByRXzldWnI9yg7wQ7DSDCHDHqSO3t61aRgAN+MD9KbHwMN0xnBpvmoHZUHHpWG5sWrUH7XblTjMinkjBx6/hTpVRbqXyT5iHLKM8KM/1qr5skbpInzNGQRnv9a1IprO5xG8C20ufllByv0I/lWkdjOS1uRssWM+U7sMHJPQdxUunzOtndM2yKQ7Y0BGXwTkgenHerY0+KIBr2ZVJO4InJI/Cm3DGeWMlBHbp0XHb1PuaH7qBXk0T2s42MGJORxjt6dauRSq6Bs/vAcNu6Z9v8azFVkTecCPrtzk4qzarGTvwzZ6KR2rB7nYm0aibGZkA+UjaxxwasRhYtsROVwCC3b6+1ZkEys7O/CbSMep7flUjylZFOGIHPHb1P5UFX0J7oxrA5AZSDwACQfpUCzsF3oMEgBV9Ox5oBNxF5khLBjvG7gEdOnpUUeRFIIxsjHzGQd+elMjzElmAL5yVJyf8AZ5z+NbYk/s5FtzrskOUDrH5GfLB6fQ1zR2MNwckLyq+vvmugNv8A2kILu90m/MxTBNsQEl7A4PI/CqhuZ1Njm/EmiiO4vbiLUBdzxos8yMhUlG6Op7jpXNV1nii9a0luklsWgubmBbeMFvlihH8OO7HHWuPyfavdw8r00zwMQuWo0eogiud8VN/pNshHOxj1963wxrn/ABUN0lowxkqwHv0rXF/wZCw38VGDt+UAAHHf1pWw7DHWhhk9CTnio2Zty9jz0rwGe4hFLAheQ2etW42Mh5Jyeoz1quAxViASeckjtSxNufcPlA9eRSHc0UHmRlTtAA2n1ApmyOILhy4BwoNLGEdc5IIHHrmmgmY+Xj7pIyD1pMpMS4O6ME8bai/iMqt+BH5UkyuY3Em4DODg803ychlJxnsTSQNk6sfLDBmJOMrmpDIrPiTGR1wMGoNgKlgc7eP/AK1BkG4fJgkcehqkxdCxGAQNi8HjGOtWOETByueOG596rQyOo2YKg5JA7H1zU0ODGpdtzelS2WlYa+EU+W2F6EdiP8alklUwsRklju6Y4x0pgRAZNnJIIRSPzohTNuOV3EdDzwBUmhRkJNyVJLMOg9f/ANVWbJit5AoYLuYgntyKqs20xN/FnG70qQOUdDjHzDkj+la0Zcs0/M5q0bwaOw+fAyR0phz61FDIxiXI29s5yaeTg9a+oPmxCcUmfSkY8DFJnFAwao2NBYetRufWgEIxwetQsT3NEjjoKiLd6YxGPJphb3pHbJNRFs/ShsAY1G+CKGfBqN3ODg8/Spb0GYl8u27mAOST1/CoQxZiMlT1OOpqS+dftTYPGTnH1ohdHVvl+pPavn8VpUkezhneCJlb7vJ54+g96cv3t2RtOTj0piMzYXO5h+tTQZZR0CYPA7GuVM6Rd6lGJwAPXtT8h1OM7WHTHBqCeEbOAc5yfSnxu6xg5ClfU5zTv2C12acIRFKhFLEA45yPfFSuzbERUAznkGqFo7Qs29wcnJbv9Kt27I+X3AgnqR19PpSbNIpItjLEbAF3c5x3qNGhE5J27uh5NKrhZCTImCMAY6UkeRnblmb14zUmly1E0a58vY+eSSp/yKlVS8YPmbivI3DjP9apbsblAG/P3c7vzq1IcJ8xJAx8ucYz6UA2WZmEpbccDqUHA4/z0qC4LqBvYFGXhAePYfWlhmXPG9l2/KM9TSCQS7k2jOMD1WgCJZCTtz8xXGwL29K6Oa7NxNdRRXsYS7t0NvmTaInTHyE9j1rl5h5RK4wB9456e3vWze/YLQpGmkJcxsqlZmZj5mRknjiqiYzV9DG8cFXuo28xZLhUQXDocqZNvOD+XSuXrf8AETRyxGSK0W1UEARgk8/jXP8ANe1gtaZ4uLVqh6Yh54rB8XEKtozdi3SttWxWD4x+aC1YDlXPP4V1YtXoyMcO/wB4jEUls7vr6daViNv16kUyPGCR+VOzxkHk8Gvnnue7HYYhYfLnGe59KkhXdnDAgetRqM/MCeOw9aSNvmK8MPr19qm4y8epXJ56VHvbzMEBcH7y8saYrfdZQACvI7inozSfMcZX9adholBwOqvnjAPX61BIvT9M+tSxDewMsh64xt4FEhBJwwIB6VLKWwxPlfBz8wy31pSg2h2yYhx061UeQ+dwxLk49AacZG8sIxYqewPSjVC0NCJgqgklhjHsM9qsNIMk7sNjBA7f0/Gs6AEDD8DsMdauoVlJOewAGcUmUmSSFD8joUOM5z1pyeX5H7zhGzt5x2qv5imYl36gnDdPwqOaXCYQNjHBoHzBKGwcfNnkf/qqKUfJv3ZxgikaZ8Dy9mzPY1E7+ZHhgVIHpxTi7O5EtVY62yfNum4YLAMMdOfepW4Jqnp8SR6fC0bEEoD1yM+wq4wOPevqYO8Uz5qSs2hjN6Umfelfio93OO9UIG4qGT9aVz79KYxyKBohOQOetRsSVqRyTmo+1MCFic800ninvgNTGFJjGkVDLtRlLDIHQ96kbg1C67xk/e7Y7VDAwr9M3YcjC7chaIXXnAATnFP1DKOp4BbIH5/4VFG+GPGQRjp09a8PGaVGexhX+7RLJJsRnXlum3PepLWYrFg4DAc5/wAKovGH5QbRnGemTViEsCAFHX73Y1yWOq5eacS5LZXkfMP5UvK7gHQ7jjJ7c1WZyzAMwPOBgUkxCEMUVm52YPQ+tFguXrh9sRQttY8fN3+lCXIDgIRJt6jPFUwssrFpGCk8ZUZxn39auQR+VEApRmXjP9allXuSq7uNxB3DpkdfwqVZsK6OByM5yc//AF6hCtjc7bVzwVHWl2Eb8kcdDjoKRViaOQlxuUggYABwfxq7CWdC86qD/CMcD61CZFYDKhgq4weMH1JoG5iA54z83t7CgZZd23BQfcN0A+lRq7KQdwXJwAB/OokkypXJJB4HtTWYvJkggA5zjgfWhAyYvG2TvLHnJ/pmuxvjqzmP+zr2GCBo12RCdBs45B/xrlNOnt4pJWvLYXJIwFLlAMd8irsd/pQxjRRnOMic5HrVRsRK7KHiYXW2QajOk9wEBLCQPx2wRxXK7j6V0WszQTRzG0thbweXwgbcAe5zXODOOor18C/cfqeTjF769D0cGsbxSQ2nJ8p+WQc/WtTNUtfXfo847ja35GvRrq9OSOKk7TTOV3lQd/K8HNSAoQSD34qDbwPmIHWlPTqBgV83I9+OwgDbiQQB0xTuTIeQcjtxSOdvBOMjJwM1WMmG5H0IFSUy+jbsAHGOuefyqdN6bgnKgZKnms4uwbcOc4BqaKYqW9cdQeP/ANVVYVy8ku19qqCAc4IxTN4Bctyc5BzUYlVi+AMDjBHP5Ux5tx2qGII5BI61LjcOYcGG8gDcOvPUUskjAZGcHrlc1CcbxltuPwpQQVwc7j79KS0K3LAkO0M55HA981LEoGGZsA87OlQQDbwrAkdz1P50Og83GDu4wM8D3pDROrP5xKouRwfM/p71ID2Zhv8ATqPamwytFGQEQuc/P/EPx/wppZQOcA5yWx/OkUQ3JZSvTBIz7fSmBiTtLNgsMjsaddHfFtzwBjGOuabHiRRu4HB6dKaREjqNJ406IdcZGMe9W5G4HrWbpTj7IoRj949OMVZc4GQScevNfTUHenF+R89WVqkl5ji3OKjY9eaQkUjH0rYzGtTSeBQ2cU3r3oGhhPUVGxqRjx0qux56UAOJpjc0jEDqaaWGMg8UmMaT3qJwWHC/iTins3HWo3bcMA1DGZOp7lKBtrZ4DentVBOXJJIwDyO1aWqBsJgEqTn6GqasQW77hjFeNjo/vD08G/cGNuxtD9e5p8aOArbsrjpjg+1QyKEQKrEbucY5H0qYkKihCcLzx/SuLVI7CzaIZ9zZXYh4Udc05QpU4PTqTzUatH5e1Bg47ikCsvBcjP8ACKTuX0LCMnBORzkgnrUm7cCQxzkckjpVdBkkLhjjJB5qUABiVXLdBjnBpAi2pQjguxcYGeOakgXYy53bj2PQcVVVsBvtGFI6BO596lyAueDjG459enFSaXLMEuHDuq+UTgknkmnlgeCq/wB4seOfaqqso5KM8gy3Hb8O9K7gKATtGMgenPXNACxyRq2WBBHWQ9KnMhk+VWxHnoe/FV1lTeSqbecjJz+lSRuvlnAwSML9T3pk3Rd0+2ju96y3lvbAD78pOCfQAVdfSrYbUXWbDIPILNz+lYXJIUc7egHUkd67GaS3txf2y6VaP9ktkmRpEJaXONzE9xz2qoomT7HK6pAlukyJdQ3I8v78OSp9etc3uH94V2PitNzmWGJIY5rVJVjRdu1SOhH51xQPutepgl7rPJxj95HpVV9QUyWNwgGcxt/Kp6TrwO+R+des1dNHAtHc4aKQtCDgYxx6fSlTdkY/XtSQK/zLkZQkEHuPSnMSDjOc+v8ASvmZqzsfQU3dXIpZEY9CjD7wphJYdMj1FKy8hvQ+vSoXbBHJBPP1qUU2Sh9igtwM9DUkbYPJHI/SqYyHyec8jmmvKCW2kBz0Pt6VQrmjG6YVseuTnJ/Kn702gZAYfx4/wrPjd41TGRtPDDnFXEfceD8zHnjrRYB5cgDeAxJwrkdaasuxHQrlyNwOM03cSCzEBlPPv+FPGT8gG3nJcdvoKhoqLJQ7FgWxkj2qYk5Rw6qOhJqjyGYZzz1HSrImAXhS7ZGWAxj2pWKv1J2EhBAbOOQR0H+NN3EKgG7cR09/8KjG4xgyMxjzgBTxT1lLN5b/ADZUMeOQKTRdxiybj82FUdABkmljO0sGXr+VNZWEhI+WMd6IiS+Tk55poiTNzSGItnwcksav/Njn61S0pdsBPH3jnNXSfTpX0mFd6MfQ8Cv/ABJeo3dxzSZFKScU0mtzIaeRTGOOlLITjioyTtFADJDmoyRjGaceDmomoGI3SmMeO1KSOKYx61NxkbfSmnrQxOKac464qQKl+S8WeoHesuWIsQ4P3QeM9q1p0yrYP4Cs10+ccAcdq8zHR1TO7By3RCcxhS65b+9nPFAB3kjOQOBjge9Iq7CfmPQ9qiMkisP3ZYHggcGvOsegW4pnwQwwxI5HSpmLcAn5R3I/rVISngMcIeCp7fhU6SZQ7SoXtUyRSZMspMmEGMddxxmpwxU4Jf6L/jVZGDk/Md9TxY+YBuR3/pUvUZKJFTDAHjnOevtThJ5uSCSoHQnGKhPLDgYPT8PWhN5J3HAPTJ5pDLSZb5tynHTB5/Olh3ADLh2PBbrj0AqvvU4AUlhnPGBn2FTxOE+YKzN6k9KCkx0ZxL824k9QBmphhRkOM9xUQIUMRgDr0pVxjb0HtSBkrHOFGAGznI5P09K2724OmarYRpc3chs4wsnzAAhhkqg9Mcc1hxwtNBclGijES7yrP8zj+6PU+1dPEJZEi+1f2Bdyxoqo8suHAxwpx1x71cTOTMnxiCsskpnlmWeFZo2lGGCt0B9MVxwYeldT4seYm4e7nhmlcIMwsCgHouPTFcluHvXrYJe4zycZrNHpI608H86ZjpRzXrHEchex+TqV3G3ALk5HoarcsOMHnkVd8TgpqO45/eIGBX24NZu8rtHG0jLH1r53Ew5ajR7WHleCFYBVIOTg+tUpGycHOQePSp/NDjk5BGefaq8soMm4jAxwe1YJG7BWVSCeRyPxph+VgFA9ckUgCqMqwyTnikwFldlZcY6etUSWFbGfmAOevpU6uVPOMHpngGqAP3lZc98+lTqUKdTkHjIxgUAW2kQ/fIC5yQh5xTYmV2V49zN90BhtH596ap4BJ2g/xYqQAxESSFACck7ug+lIcSWMhFBccE884B/CnoQqksCcjdgc4FR7kkOFG6M8s3Q1IrLxs5frtGQSKRVx7TkbH3Oo5AUYz9ak+ZiWCIu8YBByR61XExEiOsaIDgZOWz9KlKksG+9kknPr71DsUO3BndQCzeo6fiaRP3Zx1z+dMVlYbpMMfYcD6CnKxIJbBY9MUluJm/pT7oOjA5z7VbY4qlpQH2Xcc53fSrZIxX02GVqMV5Hg1nepJ+YFjTGamk89aYW57YrYzHsx21CzcClZvfioGYdzQMVmzULMO5oZ8E1ExyRjikMUtSE8Umabu61IBnj0FNJ60E5phpABxj0rNmPOfc1fdcj3qhdjaQVwDXHi480L9jow0rTKkgUqD0OcEZ4xTHQiTOeenNSvlhlsn8KbtOwDKgHkD1FeQeruQiOQfMcMB0GakjXaR0DZyQaGBwN+cscACnK+CSpbf07cVI0TbwvCSHcWyeOoqcSfP0LDGcKMfrVNWdmCKcFe/qKsjh/mDAYIO44x70rFD1cOoAA/2ieAKsM6qEOVMn51Xh2u3O4hR1H8RqTjGUUsyjgkdaTKQ4vtHYc555qSLJbn73Yjv7VVMfmf6rAXuT+pqzC42BY2XI5YjjNSCZYLKVCqSrDqCOT/AIUqoW+Y4Ldw3aoVcHBfCqeeD1NNErGLJUnGcA0DbuSkHZ90HHoMdOn510uoz6Xpl4LV9FtneNEMspkYb2Kg/Lz+tcoXkaMq4wfT1rsbO5k0+KC31LVIVuERSkZsxM0KkcZc9/bnFXAykyr4ntLCSxvI7azFrLFbJexspPKnAKuD0PPauBrp/F91f2csljPciVboieWReRMv8Jz2HtXK5r2cKuWmjx8S7zPTATR3peaXHc16VzmOd8Ww/u4ZskclD/MVze4KuQcE967TxFD52kT4GTHiQD6VwbnYcjI44x3+tePj4WqXXU9LCT90cZcuAyAn1prqp3ZTA9aYTGU2gEDrSkEFcc4OM546VwHdcaVjZeHbPsKYVGMB8Z79/wAakTIzgnOOmOahkPI29B3oAUQlgAHGT2FTRRsSCWBU4GB1FQoenCDbnnvTk3bR35xycYpiLkW1CeWAPGBzk1Y2Ropb+IHDDoD+FUQQYnAVQAcfewf0qycl3wCTtHNILlyOSENloCxC8F2wfyqZ53aPo20AdaoRBlbKIAzLyWY81NFkInUHb82OaQ7k2513AHGxuWJA3D6U53JGcqRnPBwMetV0/wBVuKbt3BJNPB/dr8mM+nrU2KTFjG1iTgnPzE9T+NKX3fMSTzwV4psh2g9uOCO3/wBekDALjtnoPWmkJs6WxJFlFn7xGTUpk9aq2jEW6I3DBefp2qRjnvX0tNWgkeBLWTY6RxUZbIpjNz14pN/FWIeWGMVAcg04k5pjHqe9AxG5pjDinseuKiYmlcYjYIwaYeKcSCKY3GKgBGbvTC1BYUhpANeq12oMf0qw3FV7kFo2HY9fas6keaLRUJcskyofkADZJbkHuKZsVWLowIbnB6U+MnLAlsk/KB1FRP8AOqhMKxJxnp714TWup7EXdCTNsU8jBPX0+lRh9vQ5J4HGc03aryZfhTxndwalUIGXgkocjaO9IuJLESBgZ+tTOFfAc5HtwfaqwbeoDbstjhvX0qZHwH27QRyQR8w/GlYq5KsjRBQQoOSRUolRfuvwQW4+8OKqsRuI2Zzg7jz+OKVckH5cqScj/PeoaGmXQrYT0wCM0scfy5DErnBGOtRB2DoFAywwGJ+6KAxDFQd2D8x9MdqkCY8jkfNwAB2prbd49M9etIWU4+9vPIABFK2c7CuCeKBjZJcE5PzHoAM10DXukakI7nUVvre7KASCFVdXwMbufukisvR9PN9M6edbQBFDE3EmzcPY1rx+HJAjEajpec8H7TwB+VaRM5MwvGVxJcatEfIa2gS3RbeNjk+V2P1PJrDzW342eM6xCscsUvl2scZeNgy7gDkZrn93+1XuUlaKXkeLUknJs9TVutLnIqDJ55pVPvXcYjpgHieM9GUr+debTlonMbrllO3OMHivSa4XxRF5OrS/3H+ce4PX9c1wY6F4qXY68JK0mjJdwp+fcvYmmYIYujDb7dD704oNu1Rx1560jJzuKnOM57V5J6aFYuFAXr1Pqah3bWBdWB6c1JIxU/KSAR25NQnBJLFz8vUdQfpQMkUITgbvoRxQAvG0gjrkUkZBZdpLE8/NwKeig4GF5OM5wePWkBIuCHYKGbr8owRVvIkY5yoK4B/xqmHeMbmRS2cDn+dTRs7S8DO0Zx6D096BFuFgVj5bkYIzwalTLFRujbqpGSMVViMhcJsGR6k1IGfbHuUKS2SO9Kwy0uxfKB25OQNvJ/Xj8akMm2NQvzDByOy+9VtzNHknzATjZjP0qZG+VvMwMrnPSkCZGwG8MeRt9c4p67cAAHGODTHJYkDG0dzwP/r0xsmbCnDfpTjuKWx0cbrsUlwAAAPf2qXccj/9VQoVGCAASKf/ABZGTxX0yPDeoxhyaQn3p7fhTSKAG80xutOJwKYxpABNROecUpNRt1pMYmcUZz+FB6UAcfWpAa1MkJ7HFPfg1Gxz1pMBpY9x+VRvyCeae1MbpUgUnJVtrsABhs98DtVdnCli53EnKkdquXAw6vgZ6An3/wAiqsnG5CuFA6eleLXjyzZ61CXNBERAzgZOc4PXHtTlYsYvNfnp/u4/rTXOxQTkHqfeokY4HlqMLkkdTWJui3mR5SpYMBgnPf3zSFWV9xTgnAPeq6FSN0m1FPQYq1DwWbcoRv7x/pQBKjFlDIc/w9BnPpmkQ7Gyxxz3PNIpALcc7sZI9s806TEZ27gUJHXrjvipaHckDkzYwS2MfOc596maLIDPggdcHAB9hVQA71ygYZ529hVqNtzhW2qo6d8/UUmrDTHCTDEB88hQRT8AgNyRySV6fjUTFWyFOWPfFTxuyAYIAHGev4moHcfEuVBZR8p4JHXNSGNBnAyBwAR+dW9AlsI7tV1OLz4JPl3hypj/ANrA7Ve1C70i1Nyn9kxyCHcC0d2xU+4PvWtNXaMqkrI4B8EsexJPFMzVjUbi2uLnfZWv2SLaAY/ML89zk1VwPWveR4bPTlp69aiBzmnJwTmuwkmzXO+NLXzLaG6QbnjYoc9AD0/WuhBAqvqES3NjPCw++pA+vasqsOeDiVCXLJM81QbiV3A44IxinMAMMqsB6g5HuKikl8tmBC5z8wPr61KjqSGQgHGRz396+fkrM9qDurjVJKgKxx9cce1IvOWBYA8c9aGyTk7Tz3OMUig4xlcehOcVJY4qvGGIGP4vWhhjnzFOenFMDhgCSo4xnqP/AK1DEkjkkDmgCaENszuIVs5NSkktHufK8g8DNQW+4E7MEHJB6Z+lISfkyBu3csKAL1vE7R4ZXwORgduxqfGAiNIcA54HzGq9u8gXy2bJRsgA9B61a3FosM5POc5zk/41LGhEdSodSeG2kLwT7VYjYNtEhYYU8Y5qisvzglSG9M8/jVyJsqOO/OaAQTFFUnqcd/SoI2LSIwyACv6miYsc7cnnH1piBTcRZXJQ8Ht6VUdzOex0kY65OcccVKM5piLtAzwKf9a+kR4gPg9aYQMf401jz1pGbIpgB+lNPTrSk8c+lRknIpDQH0phzmnZw1MLVLGDU0n0pHPemZxUgK3NMJoYnNMLUmAMaic4JodiG9jUbtnPI96QivdvkbiTgcEehyKNpkU5wcnoTn86JQrDryTmiMckq2RnH415eLXvXPRwr90jlDLE2wqS2O/SoOWY4XezLg8d6tsQw7NhQQB9eahysEnzBznnA7A9640dhE6/MrMR8vB3VZhgZ8sdvqVAzj2NVh825SpfBJ9we1XUdtys5aMqBgAdfrQMYnCEl9uexGcVKE3Sr8wBxngjpTJGd8EIXIbP90Gm/K+8mPY2NgYHjA/+vSAublDOWVUbOGHTPHFQxLt8tUJBxwB1zUjylWjB2FTg/McnjvSIchpTIPZkH3fekMAHaQeYmUUYAHHPvT1XAUbiGP8ADnrUZYDIUkALxkckUxEU4BHy9eeefSkDNrQtNXULsW8U0MM7jI81uJDnouO9WbzRo47CeP8AtjSkLDDZZhzn6VT0yynvbmL7PGTcx/OnICoB1YntiretaRJepLJLq2ktdzMNwMwXc3XrjFb0FeaMK7tBnIaharZXAhjube5UKD5kBJX6cgc1UqxqFnPp91JbXcRimjxlTz9CD3HvVXdXsnjnpykjmngjuaqpL60vm++K7CS2WFRPLj7oyarvLnkUxpc9aQzjvEUBg1CTCARv8wHY5rNZWjIIIAxwD6V0viiAy28cydYyQfxrmDgqN+MgdOuRXiYqnyzZ6eHnzRJCdyDeASehX1pDlPu8oe7d6j56KcrjoeCKlDuv3cn2z+dctjruKBn5j97HbH8qVAjMC56ZwSMnP4VE0q7SNhBzjpz9KswWbE+WskCOf4XkwQcfpTsS5WGjllyST3zxk0oDMuCQefu+lQMximMUwdJev+fWp8qxIKrlsAH0pWsNO5JCNsLbtpweBmtJXKkhgFU4OEGKzkRFJEbEMP4dvFXIUWVtqtvLDHPX8qkYsxSNzksvzDhhkjNWTvYZIG0Dg/8A1qQwnYwkKqw+YqDk08bGVdxwO4HHFJjK0vDAqOCPxpqKPNQjJAwSfxp9wMo3O3pgd6W3ADYUE96cXqiZI3o2VuQOBxSnjoevaq6MQM7SC3JFPL4FfSpnhDzwaRjioi/PNBbjNK4x24Zpm6kJ98Uwmk2ArPioiRQ3ekxxSGKDmg+tIaQN6UgELCoyRzQ/Q1GT2pAKeetRkAZyKCxFMLAdeD70hXI5Sq4PGT71COJmbJZSPyp8mHB6ZHNRElcY6YPJHFcGMWzOzCPdEol2oxVWG0/eppXC5BA/iweQaTJZAzEYUdj/AJzQskn7p8bmPUY7ehFeceigBzjb16jsT7D1o8zKZySvsDkUkseDEnYklTjoetKo8x9pdQyn5vUUDAqwTc+RC3O5Tnj3HbmkWTySI5FZl67kIOD7U4oZpkhjJWSUhRnkYz1rSn1JLG4FtDBBJEhIJeMHzD6k9apRuZylZmdNNG7qVXy3OFy3QjvVqMq8YJJCsMA9M49qfutNVIjEAsrmMHZsBMZXBJBB7kjgiqdrKdy5IySHxmlKJUZXLQTHzMNxOD/hUTtGXCtjjnI65qQuVVRxz820dDn3oH76UPvGUUAMBjj296hIps1/D13Db/aoL0yfZLuPymeI/MnOQQO/uKZq1hoZtYt+uEIzHcFtGLH8M471e8KqBPqEltAk1/DblrVCN3zcZIB6sBzVfWZU8RRpYagI4NaCMYLjaEWQ9439zjg11YZe+jmxL9xnN+IdQiv72M2ySpbQwJbxeb99lUfeb3NZeRW/44R4NUtIpVKSJYwKyEcggHIrndxr1I7Hlvc9A3+9Lu96r7vzo3V2Ekxam7+aYDkUjH2pMBl1GJ7eSNs/MDXGyFkc4HAOD7V2jNwD3rldahMV43GEY59iK4MdG6UjrwsrSsVXwx+XvTQDtbPDDtnn60vRFySB2I/rUZLBsjk9jmvLPRuSRl5J41Q85BB+nU028KmZnUKVJOD3IpYpvLl8wr8pBBA7Z61NdRoo3RdCMr9O1WjKW462u4nhWK8i850fKPux8uMbc+lS30CW10ojdvLkQOm4ZI9QT7VnRRySMsYO0HkmtWMs1jJGyltmJI2Pb+8v0I5oktATsERdSjEgKB8p4q1G4RisZUFcnjqaz7fecGPpuyW7irathlwQCOOByR6Vi9zoRcEiqw+UFiPlXvn3Hp9aFILCRmDlcgY4yfSqqBY0AGATuU556881ZVQFX7pwx5/h+uKT2BETkSAfewDkr3Bqe1yM9Oajb0wATyDj9algUICepHJNTEJo0kyVBJFBOfpUK71LAnIzjI7/AEqRRt96+mieEL1OaTFL39qQnFAhMfnSYyaC3HpTC3pSYxWHIOcY7etMOcCkZqjZsjNIB278qaTiml+ajZuaBD2IPeom70M2KYT6mkApIJqN25PPFKx54qM45pARykE8DHGM1DuBijOCVAwCeh9amYDPv0quCcOn8Sueg9q5MVG8DowztMmjfYMKFwhwR04ojLDKOxJBO3HXH1qFA2WI5YikeQ4LDI+XjFeY1c9RMknCkqoL/KeAfWkRpGVkUqEBAY9//r1C0gyGYk9jnr9adHKVLY65AA/rSAfbTm2vo3kDLECpJx79qta9bJFcK0Um+OY5Vz0Yfh0quB+6fzozuyCf9r3+lW7C9NsphuI1uIG+bbjhPbNWmjOSd7j9FUyyySkhYUhYFzxyB/kVTtWkKxqUXpgh+oq1eXrSKbdIxDB1ZVHLH1+ntUULCEbM89cDnOe1TJjgnuPG8tmVApHGR/WnLIRMNq42nvwcVE23KhSdrHn60K4y/GwkbQTznFSaMuxSyI8cikqynIkU4bP1qtr2n6q8zXUtheeSEUmVoz9c1u+FkLy3F0hUTRCNImPIiaRwu/HqASazlzN45urdJL+NzI8cc5lPmROo/wBY3qvByDxg114Re82jjxb0SObnuZrlle4leVgoUM7biAOgzUWa0/ECobm2uURYzd20dy8acKHbIbA7AkZ/GszIr0keeztSeKdu45NFFdJIbhSHOQQSMfrRRSYAMmsnxHDm3jl2khTggcH2oorGvrBmlP40c/uKnlW56c8//qpVyxBOMiiivGZ6yJCnmBt3Q8/WtK2RZrJQ+0TRg4GeAO3/AOuiiiJMhqW7xtvdcZGR/tDvSS3CSDy4EIUr1zmiih7CW5FEAWKjjI6D1qwinaflOxehoorJ7nQi2sZlBDAfL93Pqalh2gHptPygHvRRUMcRmDsXBywIAP41MFCb1KE5I3En3oopx3CexbiIXIB4HalLccGiivo47I8B7jc9ck0FsEUUVQEbuKiZvSiipYyJ296iMlFFAhpkOfak3+tFFSIDJ9KYziiikA0yc8dKY7+tFFAEbnuDg9etV1aTz5zx8wB47dqKKwxH8Nm1D+IiVG7Fhyv0psiMSVb7o5ooryWeshuwNOwZjx69KQN5DKCq8cEtyaKKaGSENCuUOEPzDHP4VZDb4kww56jviiipYClg0WN/RcIT0ahF8wjqVI4AP3faiikthjwg3fJlj9OBToyWyF+50BH6miikBqaVdNZTSSGJXidCk0LH76ntkfnkdDVSfXbSSF1kvtYngYbTaMqKWX+40w+Yr+GaKK9DBq6Z5+KdmjndSv5b69kuJQqFsKqJwqKBhVA9AKqfjRRXcch//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple porokeratosis of Mibelli lesions are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21428=[""].join("\n");
var outline_f20_59_21428=null;
var title_f20_59_21429="Substernal goiter scan I";
var content_f20_59_21429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50503%7EENDO%2F66334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50503%7EENDO%2F66334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Substernal goiter: Radioiodine scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-Iodine scan of the thyroid suggesting a substernal component to the goiter. Substernal uptake is attenuated by the clavicles. SSN indicates the suprasternal notch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Substernal goiter: Radioiodine scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-Iodine scan showing a cervical and large hyperfunctioning substernal goiter. The enlarged cervical thyroid is indicated by the circle; SSN indicates the suprasternal notch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21429=[""].join("\n");
var outline_f20_59_21429=null;
var title_f20_59_21430="Factor IX concentrates: Pediatric drug information";
var content_f20_59_21430=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Factor IX concentrates: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/61/8151?source=see_link\">",
"    see \"Factor IX concentrates: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/56/28548?source=see_link\">",
"    see \"Factor IX concentrates: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AlphaNine&reg; SD;",
"     </li>",
"     <li>",
"      BeneFix&reg;;",
"     </li>",
"     <li>",
"      Mononine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BeneFix&reg;;",
"     </li>",
"     <li>",
"      Immunine&reg; VH;",
"     </li>",
"     <li>",
"      Mononine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2644682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihemophilic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F14792302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is expressed in international units of factor IX activity and must be individualized related to formulation, severity, and clinical situation. I.V. only:",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Formula for units required to raise blood level %:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BeneFix&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Number of Factor IX International Units Required = body weight (in kg) x desired Factor IX level increase (% normal) x 1.4 international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     For example, for a 100% level a patient who has an actual level of 20%: Number of Factor IX International Units needed = 3 kg x 80% x 1.4  international unit/kg = 336 international units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mononine&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Number of Factor IX International Units Required = body weight (in kg) x desired Factor IX level increase (% normal) x 1 international unit/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     For example, for a 100% level a patient who has an actual level of 20%: Number of Factor IX International Units needed = 3 kg x 80% x 1 international unit/kg = 240 international units",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2644692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/61/8151?source=see_link\">",
"      see \"Factor IX concentrates: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is expressed in international units of factor IX activity and must be individualized related to formulation, severity, and clinical situation. I.V. only:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Formula for units required to raise blood level %:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AlphaNine&reg; SD, Mononine&reg;: Infants, Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Number of Factor IX International Units Required = body weight (in kg) x desired Factor IX level increase (% normal) x 1 international unit/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     For example, for a 100% level a patient who has an actual level of 20%: Number of Factor IX International Units needed = 70 kg x 80% x 1 international unit/kg = 5600 international units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BeneFix&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants, Children, and Adolescents &lt;15 years: Number of Factor IX International Units Required = body weight (in kg) x desired Factor IX level increase (% normal) x 1.4 international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     For example, for a 100% level a patient who has an actual level of 20%: Number of Factor IX International Units needed = 70 kg x 80% x 1.4 international unit/kg = 7840 international units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;15 years and Adults: Number of Factor IX International Units Required = body weight (in kg) x desired Factor IX level increase (% normal) x 1.3  international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     For example, for a 100% level a patient who has an actual level of 20%: Number of Factor IX International Units needed = 70 kg x 80% x 1.3 international unit/kg = 7280 international units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Guidelines:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     The following recommendations reflect general dosing requirements may vary from those found within prescribing information or practitioner preference: Infants, Children,  Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis, primary:",
"     </b>",
"     25-40 international units/kg twice weekly (World Federation of Hemophilia, 2005) or 40-100 international units/kg 2 or 3 times weekly (National Hemophilia Foundation, MASAC recommendation, 2007); however, the optimum regimen has yet to be defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hemorrhage:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Minor hemorrhage (eg, bruising, cuts/scrapes, uncomplicated joint hemorrhage):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Desired levels of factor IX for hemostasis: 15% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Frequency of dosing: Every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Duration of treatment: 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Moderate hemorrhage (eg, epistaxis, oropharyngeal bleeds, dental extractions, hematuria):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Desired levels of factor IX for hemostasis: 25% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Frequency of dosing: Every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Duration of treatment: 2-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Major hemorrhage [eg, joint and muscle (especially large muscles) hemorrhage, intracranial or intraperitoneal hemorrhage], major trauma, or surgical prophylaxis:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Desired levels of factor IX for hemostasis: 50% to 100% (depending on the clinical situation, desired Factor IX level may be reduced following active treatment period for hemorrhage or &gt;48 hours postop)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Frequency of dosing: Every 12-24 hours or 18-30 hours, depending on product used, half-life, and measured factor IX levels (after 3-5 days, maintain at least 20% activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Duration of treatment: 7-10 days, depending upon nature of insult",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [recombinant]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BeneFix&reg;: 250 units, 500 units, 1000 units, 2000 units [contains polysorbate 80 and sucrose 0.8%; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AlphaNine&reg; SD: 500 units, 1000 units, 1500 units [contains polysorbate 80 and trace amounts of factors II, VII, and X]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mononine&reg;: 500 units, 1000 units [contains polysorbate 80, mouse protein, and trace amounts of factors II, VII, and X]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2644693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Solution should be infused at room temperature; reconstitute with provided diluent; use within 3 hours of reconstitution; infuse without further dilution",
"     <b>",
"      slowly",
"     </b>",
"     . The rate of administration should be determined by the response and comfort of the patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alphanine&reg; SD: Infuse at a rate not to exceed 10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BeneFix&reg;: Administer I.V. over several minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mononine&reg;: Infuse at 2 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2644689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); avoid freezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AlphaNine&reg; SD: May also be stored at room temperature not to exceed 30&deg;C (86&deg;F) for up to 1 month. Reconstituted solution should be used within 3 hours of preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BeneFix&reg;: May also be stored at room temperature not to exceed 25&deg;C (77&deg;F) for up to 6 months. Reconstituted solution should be at room temperature and used within 3 hours of preparation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mononine&reg;: May also be stored at room temperature not to exceed 25&deg;C (77&deg;F) for up to 1 month. Reconstituted solution should be at room temperature and used within 3 hours of preparation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2644683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AlphaNine SD: Prevention and control of bleeding in factor IX deficiency (hemophilia B or Christmas disease) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mononine: Prevention and control of bleeding in factor IX deficiency (hemophilia B or Christmas disease) (FDA approved in all ages)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BeneFix&reg;: Prevention and control of bleeding in factor IX deficiency (hemophilia B or Christmas disease) including perioperative management (FDA approved in ages &le;15 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14634079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor IX may be confused with Factor IX Complex",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F169744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cyanosis, flushing, hypotension, chest tightness, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, drowsiness, fever (including transient fever following rapid administration), headache, lethargy, lightheadedness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, photosensitivity reaction, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abnormal taste, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Disseminated intravascular coagulation (DIC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions: Cellulitis, discomfort, pain, phlebitis, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck tightness, paresthesia, rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Allergic rhinitis, asthma, cough, dyspnea, hypoxia, laryngeal edema, lung disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis, burning sensation in jaw/skull, factor IX inhibitor development, hypersensitivity reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: HAV seroconversion, inadequate response/recovery, nephrotic syndrome (associated with immune tolerance induction), parvovirus B19 seroconversion, renal infarction, superior vena cava syndrome (neonates)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2644685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mouse protein (Mononine&reg;), hamster protein (BeneFix&reg;), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2646586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe closely for signs or symptoms of intravascular coagulation or thrombosis; serious and potentially fatal thrombosis or DIC may occur in patients with hepatic impairment and in patients undergoing surgery (risk is greater following surgery); risk is generally associated with the use of factor IX complex concentrates (containing therapeutic amounts of additional factors); however, potential risk exists with use of factor IX products (containing only factor IX); use with caution when administering to patients with liver disease, postoperatively, neonates, or patients at risk of thromboembolic phenomena, DIC, or patients with signs of fibrinolysis due to the potential risk of thromboembolic complications.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2644686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products are prepared from pooled human plasma and even with inactivation and/or removal of certain viruses, the risk of viral transmission (ie, viral hepatitis, HIV, parvovirus B19, and theoretically, Creutzfeld-Jacob disease agent) is not totally eradicated. Hepatitis B vaccination and hepatitis A vaccination are recommended for patients with hemophilia (at birth or at diagnosis).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity and anaphylactic reactions have been reported. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential allergic reactions, the initial 10-20 administrations should be performed under appropriate medical supervision. Patients experiencing allergic reactions should be evaluated for factor IX inhibitors. The development of factor IX inhibitors or antibodies usually occurs within the first 10-20 exposure days to factor IX therapy; the presence of inhibitors increases the risk of severe hypersensitivity reactions. Patients with severe gene defects (eg, gene deletion or inversion) are more likely to develop inhibitors. When clinical response is suboptimal or patient is to undergo surgical procedure, screen for inhibitors (WFH, 2005).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     To achieve the desired factor IX activity level, monitor factor IX activity assay; in the presence of an inhibitor, higher factor IX doses may be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     AlphaNine&reg; SD, Mononine&reg; contain",
"     <b>",
"      nondetectable levels of factors II, VII, and X",
"     </b>",
"     (&lt;0.0025 units per factor IX unit using standard coagulation assays);  BeneFIX&reg; contains only factor IX. Therefore, factor IX products are not indicated for replacement therapy of any other clotting factor besides factor IX.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     All factor IX products are  not indicated in the treatment or reversal of vitamin K antagonist-induced anticoagulation, or in a hemorrhagic state caused by hepatitis-induced lack of production of liver dependent coagulation factors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The safety and efficacy of continuous infusion of BeneFix&reg; has not been established; thrombotic events have been reported in patients receiving continuous infusion through a central venous catheter, including life-threatening superior vena cava syndrome in neonates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     All factor IX products contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). Infusion of polysorbate 80 containing solutions through PVC tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminocaproic Acid: May enhance the adverse/toxic effect of Factor IX. Specifically, use of this combination may increase the risk of thrombosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5687167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Safety and efficacy in pregnant women have not been established. Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than a nonpregnant woman.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2644694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Factors IX level, PTT; BP, HR, signs of hypersensitivity reactions; screen for factor IX inhibitors by measuring inhibitor titers (children: every 3-12 months or 10-20 exposure days)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2644695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Average normal factor IX levels are 50% to 150%; patients with severe hemophilia will have levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2644690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa), in combination with factor VII, activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2644691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Elimination: Half-life: 17-22 hours (range: 10-37 hours)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2646587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 international unit is equal to the amount of Factor IX activity present in 1 mL of pooled, normal human plasma",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/59/21430/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/59/21430/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;Guidelines for Emergency Department Management of Individuals with Hemophilia,&rdquo; 2006. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/175.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders,&rdquo; 2010. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac190.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Hemophilia Foundation, &ldquo;MASAC Recommendations Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding),&rdquo; 2007. Available at file://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Federation of Hemophilia, &ldquo;Guidelines for the Management of Hemophilia,&rdquo; 2005. Available at file://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13140 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21430=[""].join("\n");
var outline_f20_59_21430=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169726\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169727\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644682\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14792302\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644692\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169714\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169701\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644693\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644689\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644683\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14634079\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169744\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644685\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2646586\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644686\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299307\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220307\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169711\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5687167\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644694\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644695\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644690\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2644691\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2646587\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13140\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13140|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/61/8151?source=related_link\">",
"      Factor IX concentrates: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/56/28548?source=related_link\">",
"      Factor IX concentrates: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_59_21431="Partial third nerve palsy";
var content_f20_59_21431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Partial third nerve palsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 515px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIDAgADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD374j+OdP8A6Na6lqtrfXUVzdLaJHZqjPvKO+TvZRjEbd/SuEX9oPw+wyPD/iUDjrHajr9Z6i/au/5EjQc/wDQaT/0muK+cY335+YYbgcdD7D1rkr15U5csTtw2GjVi5SZ9Kp+0BoMkgRPD3iVnJ2gCO1P/tf9aJv2gNBgA83w94kXJ2j5LXk+37/mvnCK5jhC/M+zlcg8sR1VfQDuemfwpHuPtUqu5A2LtAJ4RepA/r6k81ksVPsjX6nT7s+jB+0N4dMXmf2B4k2E4BMdryfb9/zTk/aD0BwCnh7xKcjI/d2vT/v/AF80skt3MrtJFsX5RHuw2PT3FXIdsK/OMvwO5yfYe1S8ZPsjRYCn3Z9GD9oHQWZVHh3xMSTgAR2v/wAfom/aB0CFgsnh/wARBicAbbQn/wBH18772LfvWCcjnpx/hVqK3aWMzSl2B4QEfgKn67Psiv7Pp92e/j4/6EW2jw74lJxn7lr0/wC/9Sj476OSQPDfiUkDJGy14/8AI/tXhVrEIJwrbi27g8c5Axx6ZqbULmC1eVY2BfGPl56jn8gBn61X1yp2RnLBU07Jv+vke4Q/HbR5jiPw34lPG77toOPxuKil+P2hRsFfw94kBZtgGy1OT/3/AK8Ja9dDFt5VSS/uMdPz/lS2YF28aT4++SGA5T1498UfXZ9kNYCD3bPco/2gdBkDlPDviYhPvfurbj/yPSf8NB+H8gf8I94lyen7u1/+P1419ke2Z5dm4dCq8gemRWXqFuzA3MAARMERgH5T6g9+/pS+uz7Ir+z6fd/18j3kftC+Hjgjw/4k55/1dr/8fqRPj7oT/d8PeJD/AMBtP/j9fODkbmIJI6+hpILiRQGYgsCVyf4h1BPvR9dn2Qf2fT7s+mpvjdpkEIll8MeJhGejbbQ5+n+kc1Evx20dtuPDniTld33bTge/+kcfjXgE2oA2ZlE+1y443HcD24/rVnw7LLesYFhiAC73dxkHn1P4/Wj67PshrLqdtW/6+R7vH8ddIkJCeG/EhI4Py2nH/kxTH+PWipkt4b8SgDr8lrx/5HrzGGwVYUwHO35ufk5+vrUD6K0xlZ1Ledk/JwF//XS+u1OyGsvo93/XyPU4/j7ockvlr4d8Sb/QraD/ANuKevx40ZiQPDniTI4I22n/AMkV49eaM8MCM0as643HHT0PFQ+X9pZUVWzGSDgYZPxHUUnjqi6IpZbSezf4f5HtC/HbRznHhzxGSDtPFp1/8CKcPjlpRQMPDXiXaf8AZtP/AJIrxpbUrkiUFz/DKuM/QiklvJoEQyxJGduAzcKf8aFjqnZf18weW0ujf9fI9ib48aOkbyN4a8TBU4bMdrx/5HpR8d9GMZceG/Eu0ck7bTj/AMmK8MuLxpQ0YdWeVgxxz/noKswWrvsjYEL1EfQuR3b0Hf3o+v1OyD+zaS6v+vkeyt8f9CXcT4d8SjaMn93a8f8AkemSftB6BHGsjeHvE2xsgERWxyR2/wBf19q8YuIFErCIDjIz6H0rEuLdY5Li2Kl45DvRGPfGSuf1HvVfXKnZf18yP7Ppd3/XyPoRf2gNCZNy+HfExGN3Edr0/wC/9Nf9oTw/Gm9vD/iXb6iO1P8A7Xr5qgmNu7IkrFcZUt1U9cH6j/EVeae3kQMwK9cbWIwfr/jUyx1VdF/XzKjl1J9X/XyPoiL9oPw/KgePQPEbL7JanH1/f8Vr+FPjLo3iTxNYaHb6Rrdrc3rOkclykHlgrG8hyUlY/dRu3WvlqRthyMlT/HkqfpxxXY/BmRn+LnhEEcefcHOP+nSeqpYypOootKzIr5fSp03NN3X9dj3z4i/FzRfAetppmqadq91M1tHcl7NImRVd3RQd8inOY26D0rl0/aQ8LuSF0LxKSDt/1Vt1/wC/9eaftXvt+KVnknH9jW5x6kT3P+fxrye0QhVbOBjOM+tdNWvKEmkctDDRqRUmz6nH7RXhskD+wfEnPT93bf8Ax+pof2gdBnJEXh7xK2Ov7u1/+P18wwyAxt8+wN8zluoX/Pap1uGiIB+QbT5a5/1a49P7x7k8Cslip9kbPBw7s+lH/aF8PJnfoHiQYOD8lr/8fpT+0J4fAyfD/iUdOsdqDz7efXzSsplbzW+WFBhVx1HoM+p5Pc9TTobeedzIwBjBxhGGT/hSeKmuwRwUH1Z9Kp+0H4ffG3w/4lOckfu7X/4/S/8ADQOgZGdA8RDJwMraDn/wIr52R/JTLyNv6YBwB7flR5rZGCEIPpn/APVUvGT7Iv6hT7v+vkfRqfHvRHwV8OeJcE4BKWo/nPTV+P2hMSF8O+JT3+5a/wDx+vngpJcqZZ23BfunrntV20gzIrsVKgY9umP50fXJ9kDwFNK7bPeG/aB0FW2nw94lzjOAlqeP+/8AT4vj5okxIj8O+JCQMkFbQYH43FeHXEC2gcscEgEAjAx0H65/KopJ47YRNH/rHLIxx2xkGn9bqdUjP6nTezZ7nL+0DoMWfM8PeJRgkH93anp/23qFf2ivDbdNB8Sf9+rb/wCP14MkYvcE54feV/vHH9KmtbGOKWQuuEY8Sdl+go+tz8i/qFO27Pd/+Gg/D/8A0L/iTpn7lr2/7b+9KP2gtAPTw/4j/wC+LX/4/XzrfQ+RIm3OzH3h0K9xVYkgY54G3J7ij65Psg+oQ7s+mP8AhfWi9vDviQ8Z+7ac/wDkxSSfHzQ41DP4d8SAHp8lr/8AH6+cLa8YbH38dweNrDr/ACFaGpbJLUyTEmTIKknDH6eo96Prk+yGsBT6tn0CPjzopUsPDniTAGSdlpx/5MVC37QWgKSD4f8AEpx1xHan/wBr18+aKGvS1sjoYUG4nGD9M/1ret9KBVTtHyrwp9T7f40vrdTsiv7PpdW/6+R7Kv7Qfh8nA8P+JCf9y1/+P0J+0HoDuEHh7xMGPTdFar/OevEP7CMyuhBDsSUBAz/niq0mnSW7I5VWRhho36EdwKX12p2Rf9m0u7/r5Hvn/C+9E/6FzxL/AN8Wv/x+o/8AhoLQB18P+JPTGy1/+P14mYfLUBcOOhTGHX356j9actt5mVikjiB42umwt7+n5Uvr1TsgWW0urf4f5HtaftA6C4JXw94kI/3LX/4/Tm+PuhquW8O+JQPdLXj/AMj8V4w9isCIflj9SGG76VRuot0BX5g8j55PPPP0zR9emuiD+zaXRv8AD/I92/4X5onlu/8AwjniXapwx2WvB/7/ANRH9oPw+NufD/iT5jgfu7X0/wCu9eKtF5cIthky4+Yf3fUk/wAhVSeyVCwAyoXkf5+tNY2o+iJeX0l1f9fI90k/aG8Oxz+TJoHiNZMA7SlqMg9P+W9L/wANB+H8A/8ACP8AiXBOB+7tev8A3/r5xu7cPB5dyAs9qxRJcfwnkZ9R/I1HDcpteK5DqeBIpHQZ+97j6UPGVLaJC+oUurf9fI+kE/aH8OPIEXQfEe4jIBS1Gfp+/rv/AIe+NbHxzpV3f6daX1olrdG0kivFRX3hEfI2MwxiRe/rXxxcRJOCwdCOyuuAfxHSvoj9ldSvgzX1YMCNZYYY5I/0W271thsTKtLlZz4vCQowUo33Iv2sWK+BtCI6/wBtJ/6TXFfM3nLbxNvOd3deoP1r6X/a1IXwHoZIz/xOk/8ASa4r5Zacu5JUFRgBPU+v4UsSrzXoVg3am/Uuu7sFY8FgEQLwI1HU/h/M1ajiDxhVOR3BOMD3/Hmq9sgVBncdo5xzk+lajQPDFtOWZjvcnqeOce3auVnXEh4VyBhTjOB0/wDrVPHL+6Edup8wD73Hy/jVdYxJNjIALbBzwPx/LmpJIpdPmR5FU5yoLdH9vasmjdWZdtbYLGZnBZVOH5J4POf61vxwxrpkMgw7ONsfbJP8RrDOpgofLxhlzIhYAPg9v/rVQl1V4cxwSFok6LjkE9galJjb0NDUbo+d5cLfOucsenHVvaoYXM0sbscg9Ax6j1PuTVOxjmu/3a8tMQzZPXHQZ9O9dZpOkCGZW4lAXJkHKq3t/eP6UydNyCz06S4uFgRd55GOf19hVrSo1ieW2lRGIcgk8A+hz1rodOtDbxZjtmLux+ZxyTnimX2mmOU+YuzcBIMHkkcH+hpNPcalrYqpZXEKb4CWjOQSTj9asTwo1mQ8WFIxyvOfqK2NOtLgQq0bRsq8YcE4/DvWjHalSzb/ADGBBBK4B+gHSriiXI8n1DSJo3kKQNtTBDYycdwKx4YGAYFGaNiQT29hXtN7Y74JDMCzY3AHjPH61yx0EW7ShdyxOoba3UMB2ocLFxmnucfZeHprvYVbagG0ZByR2/wru/DvhyLTIiwVxIwGc/41oW+nLa7/ACQASN2Se3/662rc/uVHOehA61Sj3IlNvYoFFWQMx8xj14PH9KmZXaPARUQ9SThj/hVvZhlO3OfzqwLdWjLY2gE5PYVLTBSRiyWoc7HbKAcKvTHuaxrrShkyQbkK8IUP3R6e4rq5LcSEKvQDOcf5/wDr1FNaoIyuSR39TS5SlOxxRWU/K8Jcg4Kxnr74PSqrW88sx2EqB0Ujfj8u9do1hHJhTuUAfwnBI9KYsQhysSqQDjpzn2qHDuae07HMW+lFXdpnZSxyWC5P0HpU72SW6mSLd1ycnGf/AK1b0qz7PljQAcBQ/I/+vWTeQyOpjCqCThtp3Z+v+FKyQudtmIkRaSRy33CcHHB98Vn6xD50CzFtzxncNi8fTNdLNAotQoILZ65+ZufSsy7jZI3VlGOjD196uC6EzfVHC3VsFbzlBVslWx059fbmqNpcSROVOcL96LqAfUdxXSS2xaPcDyvDe+OKwbi22b5AD5kZ6Y+8PQ1okmrGblZ3Jo5ImXdG+xD/ABKcfhjsfaux+Cju/wAZfCpfaQZrjB3ZP/HpPXAq3zBvlG4fdx8r/wCDjse9d18DYdnxi8KujM0RmueT6/Y5+COxq6MLVEZ4ipzUZI0/2ssD4rWLkbmXRYNo9/PuK8lQkjGScEEnpya9Z/a0Yr8VrHauWOiwAH0/f3FeRGURRqqnlR8xI6nufrXRXV5s5sM/3aLLzGF12ANKxyN33VP94j27Cp7ZBJHucsUbGSer+pP1NZ8GX+V0G6RsY9uwP9a3beHzGjhi5I+UEdPr/OsWrG6d2SW8Qcbm5Cgkr2z70gfMjEfKcc46j6elW72MW+YYwQin5h3xxis9kJMjDoCQMHj2/lWUjaJdSQsqiNQXPOR8xH4ngGrFvasxbeCQMA7ueeoNLowS4V4+NwGckdD/ADx1q/I7G18xOPLXEidCw9v89azZqtC0lqFs4nk56BAOjH1/Cqd/di1YJG/mFMYVeBkHgfT/ABpl7rsZhQLjbGPuZ+6fp61iRzNKHbBMrn5TjiNe5+p9+lUtCHqaNzePqM/7wjGcMV4BIGOPYDgfUmrAiMyFAdoCkknsO2KTTLFkeEuGVCuUyv3vZfUe9dRp9gqzGaUxZ3fLHgkA9B+VG4rKKMbRLZZU+cjejHYDxyOvFaJbG5LuL5TnDY+7x1p0mn+Rcy+WGLhwQeQADz/Q1t2i70jWZFDMONxC7vpnjFC7FNrcwbjSLd7KUkckA7sggccdDXIXVsYXKk9DtI/wNetfYYLiM4j2KD8zZ/zj61n6lolvLDO/lhM8nj2/n0q+S5Kmup5VFGXRlbIfPB/T/CrMVneXsccSbgmPb5W6HHpW/DojAmKSMF0YYcdwe1dRpth9mB3KFwu4tt6EVKRbaRS8L+HXtrNpJg4lkwGxxuHYV0MVpCJCqRMh/iOcZrVhO6BSo3ZxxmkMAYrhQe5GM1bjbYyU23qU5oEMahNxcYxtXpVC9s0nQIsW1sfL/skV0Kwbo8kkjJGB6VDLEFYCNRu7cdBU8rKUzg5LNreUh4yyLk5HVD7f7Pt2p6FJFILIVPBUnK/X2rqprQXCnMYOOnX86z5tEilI4/e/3uv5+tQ4mimmtTlp/LMmIWYFR/c3jPt6D3p8Fs0k3myyyZX7scceDj19vrXT22jx2+TI6tjnHT9KHjhXIIcHvgjgVNhupG2hhxQrG4zFtGehJ5PqfWqE0Za4lZAxU8bsHAHet28ngWJfKkY4PB6hfx71DFEpiOWyZCT8hz1/woW4OSaOU1RM7GaMAEMjcYyp6Vzk6Mkx6sCp2sOoHoa7TWoBHCxjXK4yjdenaucvYQ0MZAwQ+QR3BFbJGLZnWt4joBvKY4Dg8c+vpX03+yrn/hC9f3HJ/tl+cY/5drevluWB4mBIADjbnHH1+lfT/wCyUCvgPXAwwRrL5Gc/8u1vXThYWqN+RxY2fNTS8xn7XZ2/D/RDgHGsx9f+ve4r5WhRZW+RgFxkg9R9PXmvqX9sJinw60Zh1Gsx/wDpPcV8v6NbNcPmPIXPLdia1xC1uYYZ+7bzOk0W1Wa4Qb1IGWxg8H61o6o0E5dLck7VC7l54/z3qta2ckcSJxlzgEnGB7d60bWJbZcyFNjndyOw4/yPeuOx3XSZUtbNfs4SXCm4QNknGCv9Kc1mLlTbzDzDzt7DHtWtbW5uX8+dGyrZQkABR6D/AAFdBDZJLalHgRAGwu4bj7VmzRTseUanpN7aNmIb4SezZP0HrUmm6LcTSI06BI93b+deoL4fiuLgG5WSFR1ZOr/j2H0FakXhu2EGCSFXhSvH6VauyHNI5PSILTT0BjWB8nDO+HYn39PyrsbC7twFcoIs/LnGfyNUbnw/5L74wGHGCBgmqux4GOC/TBU9D9KLWDmUjro7mGRAFPOe/wDWkvLU3JUnAC8BfauRiuynDlhjkfSui0++XyRsUMDjJ3ULXRlOHLqjQsA0czMyDA6dsY6Z9qsRgkKXGcnOM4zVcT5ZW6N6Zp8UgBK7sbhgU0ZtstSopyQCCAOO+fWqTxRspUrhQM8ck1dUfKN/KqDznkCmOuY2wOowMjHFXuCZTaFUEePujoGORx0qWJQTnJOB/DT7hSxU8HGMVKE2r8oxIfX9RS5SmyGLzAflCkDkMTj8MUq7jGS2Opxls0s0mxT9cZHeoo5dysuOM1LSC5IflUgscHsOOaieWKPOTz3yahuGIQ7eM8ZyaxLmWfdgYIHqP61DLjqaNxd/Ou0HPT0z+PaqVzfLEhYMFYcew9gBWed23BYgkdF6mo0tSwPlqB6sxz+Q9fep5RtpCS6is7DbIznGcFdpI/z+NKJXQqAX4527cAe/0pqaNdOVWRWePORyFJ/nzU0mlz7F3IrID1BKlfx71LTRalErG9y5LhWLcFtpUmm37rewloOTGDwcA475FPvLBh80jnbzg43YNZ0ubYBgQUzwTSTsN2exm24Urcpk8Ace2Oax7hQZHHOCM59xW6F+z3YkBzHKM/1NZ14u3cyjLbzj6da3Riznbu3wjOo+UHcQOefUe1dl8Cjv+MPhSRHyrTXGQO/+iT4P86wiN7SLFkI/X/ZPatn4Fx+T8bPDSbjnz7gkdj/ok/IrekvfRyVpe40bH7WbBfinZknBGiwEf9/7ivFfNO3eMZzwPWvYP2wH2fFTTxkZOjQYz/13uK8WtW+03K9QoOB6mtqsG5tmVKolTSN2xRFUY/1hPzLnj6A11WkGCEeZcEBmGcDnv0ArP0rTFdBuDdju6VrxWkaOxZiNo+XbgVztanVBqxBqKteCWSMbVBxtxyaiW0Z422qwGd319fyrZiQRwbHVRksV9M+/uKajB5Ua2iyidm6e5rKSNoS6HMahaz2kiy2pZuMqeRx2/A+9UpNakZ1EiNvHpnH+TXdxaW0kTrMG8sHIQJkfQ+tUX8OW88ruy/Zok6jb1Pv6UopdS5SvscfaeffTqqK5JOSEAJY/0r0Pw74WuIlSS5MSucYQrv2fh0OPSixsoLWNPsyDGTltuCfw7fjWil2VcjzrjK4+U5X8iOop2RPN0RvWWiosjTzs80h+UFhggDrjHQZ9K04LCG3IIRducgdqx7bV3KjLLKo6AEAn/H9KvRa1EykPtA9O9NWIakS39nJcyl0wqkhc9DgZIqzYxqyeV95c5VGGdo/wp0V0lwoC5I69+KljZVcE46YBHaqstybu1mCIWZycAM2Mk9KZdwKV2KMKVwR0pY3VW2gcDJODUikMMMdpOA3oR1qo7CvqZctlG4B6ODy2PoP6VP5O0qzMOo5I646VZZQJMAKSAcmiQFgORwARRa5XMRwrtPyfPgZ2njnvinoyDhgyY5OeD9KmI2oBna5qtdOQvysRk+3NJoL3JGnXyARIVXPIH+NQGQNkICE6k/3qITwQ3JzkbuajuxuXHRal6jTsRz3YHBIHpjpVCbUUjzl0AI7c59qqXcbgnMjAdMAk5/CqM8fmEAn8zk/QVFjTRIfdao86nyhvx14wF/Gsue8+cK6xgHkc7s/4VqHT2njCMpROgA4/SrUOhwW8XyiRnYZJU8Ee5qeVgqiWhgyyO7rvYRqeRheMepqpJO6yKTtKE5yowT9fX6V1R023WRCoZST8wAIX/wCvVO/ska4YwD5VHQL19aViudGQ7i7t3jbBcgkMG6H6VjhA1jN/eicg/Stq9ha0jFwMEA5yvY1k3IVTmPmOYbvcVpEiRlXsGQynkL94eor6I/ZQXZ4I15c5xrT4/wDAa3rwKaL5mJPBX+Ve/wD7KpB8F6/jp/bT/wDpNb114b4jgxnwopfth5/4Vzo20gH+2o+SP+ne4r578MRbo4i3PAIr6G/a/jaX4e6JGn3m1uIf+S9xXhWibUhAjACKNoOevHWtMQY4c1Z/kVSGyw6GiGL7RdIgOVUDcDUVydyoM4zjNbWgxKkLuOC7YJA+Y+3sK45bHatGbmnWSBEG3CAnlvp+daljHuUO4DMOCR2x0qnEwSNSVzwBj0NT2TESMcHaTkD61n1LtdGkCiMGDkjoR6fSpPMAUknjuKol0idgSOT2/kKbLcuDxCRn5fnYLmr0Fyl8vuIBBbnGCKr3NnHMCTgEdcVXW9kjj2NHGCO5fJ/lTkvcj96cZ6P2z+FO6FyMpSacoflPoRVy0tkhGMHB/CrKuZGJIwB0Oc5PqanWPk4wQOd3Y/SpsiueVrMaEVeUz+dNBxMN2M1YKDacMRjnpVW4G3bnGRz/APXoehKeppxsGXceq9OaRnYcnnPOR3qC2myuAeCccHpUs20FDu3H+761SY46MR/u5Cggnr6Usp3AYU4PBI7UgZANrbj7Hqaa24KhGCc9RQ3YpkNwwYL3xx0xio8jJz17Y6Go7yYoxwfmPQZqvE75O7GB3Iqd2HQszMAMMayrv5jgLkZ/Cr/mb+FBY9v896bIrKFz94dRjgU7CTsUEsw2WlLHHUDpV9YIVCqAAeMFf6VTF3Em1F3yNnkIpOT709tQwSfs9x05AXdj8jS0FaTZfO8jZuBA7Edf8+tRyRO5C7mx/dBwfr71Ti1KOR/LZ9r9SrjB/WrXmbgSjZHqfWjlTGm0R3DI0ShnwvTIGAPrWBrFtHDG5IDb+nPzD/IrbxEruHyecjJztPcVmai8V3KNqgxICvTO5u9ZSRpF6nJzyMqqjnKI2UJGNvqP/rVWuXCxyLjIC8f0rSv4VkidduCpIXPWsefLRRk9+GPt/wDrrRLQT1KfMMuTwCBk+9dF8F1I+OPhhhjaZrnvn/l0nrnrtg1wIiAQwxj3rc+CB2/G7wspOT5lyf8AyUnFdFJe+jirP3WWf2xFz8VdNPPGjQ9P+u9xXkmgRmS6ARQAq5Yjqfqa9b/bFOPilpwxnOjQ/wDo+4rzLw5Ds8sbeXbLfTsK6am5zUjt9PURwooAORnmp1x5mWP41FbnsBjApGb5iRyVBIFch3paEh8y4na3Q5APPtntXT6bpxgiWPeSCM4zgL+H+NZug2ghRHdgZm5OBnbXUxMqoQQx+XBwOlZM1vZWEtbbLgfO2Bhn3cZH/wBapotNjaUNJCkwHIYnlf6VJBOvDAjG0cYzjFWY5wzBkXAbt2oSJdwksrbycFA2eCO9ULjSoy2UYjHHritJpuPlHsT2FGxhhmG0Y5NWTytHOXGnNGchcH1AwfxrPaK4hfKjcCewPFdqpXH3QRUcltG7dVyRnrUuJpGo1ujB0y5uNm1tyY5yMYNaiTOeG3Z9+P5VOLQKCY8Yzt4oeM4JwSB0wKEmgck3oIkjFgFIHrWhGWdcLwf4sd6zAp4I6k/5/Gr8TgLjqKaIepIzbQMLhO3ehzldwAI7+1NmUKq5bJzkKO5oG1flYMc+tUh9LiyEuBgZHfNVrhslducDrnsKmcEINvIzkY7e1Zl5LhwoOGY0mwRaVxgjPHY1HM+BgA1Xhbqc5A42g1PHHJJlUG0n2/rQJlCeKSRxwPm9s8VJFaxoN20Ng43dcj2q7JEiBjkhQMHceoqnNcbAojRmxwuFzSeg9WSYZXyAD7k9KZGxEuSh5PTPB+nvVaa8f7pjIboeRUUd2jEgHkDAB4o0ZXK1uX5ZlcFOVIHTPzH/AAFV2B3KygBGGAMdfpTgPOVh8u4nP0/GoVkZiRIc4PJ6k/4UmtQ6GJ4hjIjU5AZzt9Mf4iudmgMUirxtbge3vXQao/2y4YA/uo8AHHAPesrUCf3SAdG5yM9v5VMSmzNkclQuOSGz9Ole+fsqHPgrX/8AsNP/AOk1vXz7ckRyyHJIIzz617/+yawfwNrzA5B1qTn/ALdreuzDLVnDjHokN/a2IXwHoZbgDWkOf+3a4rwPTF22iDqW6+1e9/tcYHgHQ8j/AJjUf/pPcV4TpSkwqT6daeJepGFVy/Ou0xSZ6N35Fb3h4HyVkI5ILDPX61iSIrQt6KOB7mug04eXaxHknAz+VcjOw1IpRsY5GG5GKbazSN5Yifkgg5PArKa6AiliUndjKj2PepEKyKId2y0hGZpM43H+7Wb12NoabmqJy7Mbdwka/K054+oB/wAKsWyhTmGOVgejn5c/ieayluFAR3Hlxj/Vxjoo/wAail1ZhIFRcqeRubOfX6UJFpXN5XzjIYYz9yXk/nTVKpIXMJJxjdgK2P8A0E/TrWJY601wRsR1HQ7Buxz7cVfjv1DHdgN0Ixgn9MVoopkOLRf3FkU2wyoPIHBH4VpxzMqglgwB6Z6H3Fcy1wI5CUcRv9eD7Edv84q1Z6x+98qVRHNjkdNw65HZh+RoS7kyTZvtIHIJHTk845+vpVO9b92RwM888VEJS3bCnoOuKjuJg0O9znkKP89qq2hk9Nh+m3BYhRjIPc1qxOTzux9B/WuUEvlXoDDg5OM8Vu2k5YElCR2xxmoNPMutJmQ7gc+p9KR5gqtyMHnHemi4GCGU4x3cVn6ncBICdpwBkg0uYdrlC8u/MudmQdv6VctIG2h2JYsR0YcisezQO6hj+8kbOD2H/wCqugjbMhX5Qm3pWkY6XM5vWyLkkSJh43+qkYP51lahcQWoIuWbnBCgcD8elLqWomOMbG3ADAUdT/n1rCPmTXXn3pLzsBtj+8Fx3A9fc0SKhHuWDd3FypVI4oLYcgnOWH9RT3u5l2Zu3H93aoA/Ks3VNVhtI5GupkhVSVJZ+h9Pc+wrjdU8TWhlRYzezRn5iiERq31J+Y0lTuDqRi9TvGvpZAUn2XC+hXBpBM8Sl7UySKvLwv8AeUexrgrTxBb3cpjhnkgmPCxTrsX8CODW9a3l3GIXlj8pwflfOT/+r2qZQcS4yjNe6dVFK18N0ZG0jG7H6Y9ageNIhwQFB25x3qtHclXa7tiNx/4+Ih0P+2PerV3IksPmJ0UYA7VO+hO2xiX43tIqrncPmPt6VggE2seAeF/ka6JuJgzfxAgVgSjYDGD3P86pAc9f3Gy+hGejc10/wOfd8dvDSn+GW6H/AJKzVxXiE+VeIx4A5P512PwKbf8AHbwwxP3nuDj/ALdJua6qS1RxVtmaf7X6GT4s6Yo6f2ND/wCj568+0Ef6QxGOmAB2FejftdNt+KuntnposJ/8j3FeeeGYWMZcnk1pWdmZ0Fc6mzGCT6mkCA3ciYBQjvxxU8S4A2+lTLADdRfLyvXIz1rkud1jXsyTCF3BQOARxmrnn/uw4OF7iqjAxxEZUnHBqsbgeQSP4uMe9Qyo6s3I51jQYbPbgVdt5N6cNtA7ntXOBkR1aYkMcYQd/rWrDl03yMuz3OBU81nob8umprfKXC+bzjJGepoEoP3pOncgkfrVe3uolBAdm941yPzp7T7gAqzg98stWrsiVkTCf0dXGP4RzT0kVQSeQT1Y/pVF5HQ7lT5iMZdAD+YNVJrpC22eR4u59DT9SdHsb8bDGdwJ/vHooqRySdhOM8/NwQPU1jwzgqoR0K8cg5q2kwkQrGOSBk4z+NUjOSFu3CjIJz/KltZt23HPNZ006yOFG4BhkL1JHqaZbT/vShPC4z6VLWoLY6CM7juBH1A/rSs/7z5gc9j7VUtrjIJZDgdMcVY88EEFCcDA+YUXGiK6nEcbkkZPY8fSudSc3c7v8xTO0e/pVjxBcsVWKMfM/wAvPqaj04IgG0HbHhRnuTVQV3qEvdRqWsSRvGSFYZ5z3rRb/WYQ9eMN0zWRb3CIC0zFsN07ii7vI8EKTMxIO1MjA9z0z7VRKiPu51jlKLFK5z8uMHJ749qzmuWnYxrGWxwyxvx9C39BVWKKSWV2mICMeEQ9T6E96uRusShI+McAKM/lWTTZulYkIlAGbe3Ge2aoXYjIJaMw+rKdwqS6vdkO8MgCtyxOKoSahFn/AFgb0Pak4FJ+Y5LiSzdQzboj91gchvxqwZDdRsIdys/GcdKynuUR/uq0T8FOze49DV+xCjiMgjG4HrmhXInZFW7h8kfM3yAYA9fc++azbxSsUDE5zIR9K2NYYgRKMnjJJrIvQzwso7NmqViG7swNXO23kI42jivff2Q23/D7W29dak/9J7evn/VctYzeu0mvff2Pv+SdaznOf7Zk6/8AXvb11YfdnFi+hY/axTzPA+gLjOdbj/8ASe4rxPToPkAH04r3T9qJd/hHw8P+o0n/AKS3NeL2kWEQCoxbs0aYKN4tk0UXKKoBIO456ECrsQddwVtoA474pNPieWdmXgZ2jmrc8RWF+Rnp16muTmOtozJQcKykgD7xPpUTXWbZYV+6vLD3PepNX8y3gjUAuh+9juKw5zMZsxdAQ3NUhpGvc3EqwtJE6nHDAnBA9OaydauTY6ct4bVgrNt2lsByfTPOKnjSY3yNdKEWPDqAcqT+NS+PoTqul/umyUIlVO59QK2pwj9oxxFecfdgccvjPU7JSlkkERm6rgnP15+nStSTxhrtjqT2V/HbGVTveLBBT1Un1ripoTKihcpJGeNxqfTYWSQ3N1KGIOF5yd3v65rdwjazR5/tqjldM9b0XX7fVbcyG3aBgwDhx8ue3NbbQRzJ8jDePnHPOR6emetcz8PUFlp1zJPbu5un4hK4BUDjOasywX0c7vawqkOcmPzM7R6A/wBKwmlF6Ho0JSqL3lY6W2yYyoBLHk4+6w9farN/+40n5gQzsCnpgdao6Vdy7Vje2YEY+bcP8ml8QyBYldG27lwyH19falzJKw5Rd7FISGScueB1Fb1jIQD5gAya5eB8KN3Hrn2ro7FHniBj6HoxHWuapKx006dy5PMgQg5XvnNZeoTGWORQ2c9OKuvbyiJyyjOD0FYtw5zkn5cfkazjK7NJU7EujSg6hGkpGArAH+Vbc0coYbF5JKh2OF+mBya5qxkEd8TKpIABGO49q6G8v33Mluiz4jDmNjtOD711xmrWOKUHzaFNLVY97u7IQ2WY/e+pHr6DsKqwB724NvZIBjO5zztHv6n2qvc/a52DNbpGn90SY/Xr/jV/SLi4syY/s8BTdu2wkgrntzmhOPVmlSM1B8quzzr4kWptNYRGLNGYhh39cnJ9u3SvOrizc2813PInEnlhPMxJnGQQvXb7+tfQHi61tdXtwZYZIbmNsRuVDrk/wnHY15hqPhjUUVT9jSUMTtMYyw75x1ArqjJbo8qdOo/iTOWDytbQySlnmxjeTk4HT+lesi3VrC0a6LbJFXkdUYj+Vc5ovhaR3W4v9qiLpDzljnofQV1uqO0lkI4YpN3ckYA4qJyVrM1oU6ifMkyG1c6dd+WXVg/PTseDWmMND5KM3Xk+grlLiac3USOwLcEEdD6it+0lXcUBwG+Yj146VyNJHe07jZiUUNwQG5IrJ1HCyRsoHNbvl7yx6DH3fWs/UIQ1uAg+70zS5rFRRwPiyJhtfAPGCzV0n7PMhm+NXhNwPlDXKn3P2Was7xRbmawywYLkNkfrV39nZm/4Xl4YVVAiD3OD6n7JNXXh3exxYqPLdnS/tdDPxY04df8AiTQ/+j7iuS8OwbLaPI5bk/Su4/aqjE3xd05CN2dGgGP+29xXM6YipGPbjFViHrYWEhdXNOMKEzjkGrMMUiru4OTuz0xUKx52R8/MRnFaq2pES4Y+gGK47na10KM09wYfmVM9znkVmJJMJSCDwSVz0H0rVlRxK21mbA6Ada5+4urhZ5CiYK9O+B6/WmtRJWNtHjtf3shDysMhOpP19KtWt15irJcsSOoUD5VH0rlormNeJ0m3tyXbnP1rRS+t4FBNwkZAwM8j8RVKKQ029zpX1FI2UIzOfQ9B+NOTVoSymWZQ55CkfpXL20xvZmEUdxJtALmIgDHoc9PrT5rO9eHdFGIUUYXcNxJPfPtW0UZTqQjpc6g3yyKGV1bPTHXPtxzUVyJGQMPNJOO2OteYav4t1iC/ngtpljSH5EKoMnb3yawW1/WrmKInVrtriRsbFblvooq3Texh9agtkexRxzqQVKh8nOBwfqKuwXDpasSsccj5RRnPPQ4/xrz/AEZ/E8MkhuyzQspaNZMGTd2Bx0HuenvXa6JLPKfMuYWRT1BYc/UelZW5Wbc3Ori3Ny0U2VJI27M/4VJZucgkksT0HeqGsMBdCOEgoWLAY6ewqW0kCOm44C+vvUTfU1hG501o4MY34z2wT+VE0qKBhipHOCKgjWV4w0ag8ZGeOKiuldYN7pjn0rmc7nSqWhlalI0kitv5GSCP0NaOkA3FlNzhxJk/TFZM5JkKH73b3FaHhq4EYCupBb5Sc9D71005JHNWi7aFp43RyCACcEEc5H1psieVAh3LGo5Bzx+Hv7026mlljDpEJY3ztfJVs9tw9Kzntrgsxu4zImPljDcE+/tVtplQi2rluAtfSGOxgacqMGRjiMY9zx36Cugh8ITTRrPe3cirjBWBdqAnsD3rLsLiB7kLci6iVUCoeAAcDoF4HP8A9euzh1e2n02GzS9JVRgpkAA57Drk9TV0+RuzOTFupFe6cVrvg3Q7LTnurs3BMClgfNIyK8P1bWXS5dVuZEDHhSobA96+gfHF/Pa6BevbJE0vlMm14xIuCOeDxnHftXzLqUMrXXmhN4bAyOenat5KNkrHnwqT1bdzsPDmom6DWZVUuB86OGJWQf0Ndd4fuj5+yf5AmcD1rzrwsjpqUZA3eTHz9fSu30d2N68864U5x71y1Elqj0aUpTjqbd1I0zu38R9ew7VnSqS25RlSDxV//XBmHQt+dEsJBXPAxjFZG6Wpyd1GzW0oYdOMAV7z+yF/yT7W+CP+J1L1/wCve3rxe8iw8i46jP1r3D9lJSvgrxAG6jW5P/Sa3rpwrvJnNjY2imWv2mxnwt4c/wCw0v8A6S3NeNWS78DuRgV7N+0zz4Y8Of8AYaX/ANJbmvINNTK7iSG5AxUYz4kVgf4b9TU0+PyVO3GQe/rUl3tKqrMXOe3TNIgXylG7A4Bx1NSKvnFQwwCce9cDZ3KPUzNRiM8K+acAfdJrLNrlSzKSCMgHsBXSXKGRz8uEHAAGfpVN4xGAWODnPNVzdyorsRwwkwrG8e4Yz8w7fWmLYReZ5cUJDDq24itSOCaUBgfl7ZPb0qdIESRcLhj7fpWiqImUG+hzc3hTSrq5VpLJhJIT8wdgM4744ANa2m+HtP0wL9ntYRnAT5cvnvkn/OK2oIBI5Cphe45wPrVw2kZcMwDOnQnsK09tdHP7GzvYyZIi24CI46HOQp+marf2eJIyXyDICqshw3vz2Nb/ANnUZGQ7Af8AAR7/AFqAwF2OzKYyOnX/AD61HOzeMDODLAoSIMygDBfk+n41nXSPO5MpxGvP1rfS0Du5YE47ms6+RRIVH3AMn3qHVT2KVJ3MqCEXErK6ZQ446Y/+vXWWyGCNQvAxx7Vh2aASAgEsea3YHymThSR0rnm77nbThZEkpLcKeT1Ht/Wuc1hUSTKjCn9a3ZDJ5e0qNo6E81k6j/qiM8ngnFESpR0M2AmTyyBll43CtawuC0BVST/h9PWsjTpDDc4H3cdOuRWvHDiTzIySoO4gHkVup8pxSp3JJLbzUITO7ack85GPSoEtvKkZ3ye/BI4+taYBacsFynUH+Y4oeIsmFG4cgI3Q/jWimZ2ZWiwmPKHzD+f9ajugSdiIiIck8kjPvnnHarsYI8vEeeCNrdvSnylH+8DuHtg4rRVDJw1OXuI5fnKMyE9cHpnt7VVe2uChDkmTGMHpit6ZYy7BQVPciqpRpH2hSSD3qXJM1V0clPaN5yn7pX0q5pSM14PM+7xjnsfStWa2XJZMOxzx9Kr2kImlDIOQSU7cdway5imrmk1t5RG1lOTnmqUyYB3AhTnIHODWqIhJCMZVgePrVO7xsLbdrd9vepvdijGxyGrW+60nR8nGQB6U39n9Wj+OXhdCgCK1yAe5/wBFmrW1NAy7lxnrVf4JwLF8ePDRB5MtzwOn/HpNXXhn7xy4xe5c6r9pOLzPjBZHsuiwH/yPcVyFomNuR0ruP2ilz8WoD6aLbf8Ao+5rjrNcupPr+dViPjJwi/dpmtZxhgmBmTGTx0rRXazEKNxXtVW2kAIJ9MVb5JxkAZ5x6VxNnXy3KojLSnaqqw6kDtWRPZiS4zjj+Mnj9a6QqfKwp2lj6c4/pVcQKQCMEZznrTTKsjOjtvMlUbASeDgdKtPpcMikNbx8cZKjrUsIAn2KCCec9R9a0EtJMZJ3DGSMZrWFRImUGYltaeTKRaB1+XllbANSFJiGjS5lDKm8DjO3OCa0ktm3SbUbH8WKlt7CVh87Mic8EYzWiqxMZUW3dpHH/wDCLaZd3D3Fzas8ztgl5DyfXANbFnpNran7Ra2MMMr5LuIwMnp16/lXQJpsKM0nBdhjLdh9KkMSCM7eQMli38gKHVkyVQinexiyWIJIlmkjAIYiM849z/Snu5CbUXoMZx1rQ+zO4ZyWAPJGOf8APtUiWQWIM67SfXk1m6qWiN/ZdWcy8BjzNLzI3AGKfp1oLiVTIrEq+VIPU/T0q7cJlmJ9cL7VPpyrEwxnIySKxnO500qdtTahzGNmORx+FRXK712HlD19v8KlOXi789jVeeXKsUUhuhPQGskdXLdHMXyiKfapwVPyg+lSwN5e5xlVyDnrn0NP1WMHA4P+0Of1pNMffE8Tjgnj2reLsjlqw1NdZC6IDu2eg5OabNCwjLRDb0+Y8n6Z6YpbFPLf5j8rDAI6VajhIQ+YpDH07n1rVVG9Tm5OUzbcPGCC+BnJ44z/AEp1zCrRtvYtwMbW5P0xVu5jLDcfmAIJKjBH4VFtCkgoQp5yOnv9KpTXVCcW9UZN00ZhaF95A+ViWOCD7VylzomihCZLSVc/3JTjNdzcxK65yoyMAdcCs1rVOrRpKOhwar2iIdJPVo5WKzsrNtthB5bE5Jbkkepq7Z28n2couN3LKM/jW09svlMI1Vd3AJHT8aZIiwIFThsgBj6jtWU532LhBLSxYsY4mgAzuBAIP4c0yeEEApnGSDx0q1Zx+XGpAGxjn6VJOuGJTgN2rNyuXy2dzm7+KTKuuMDqcV7T+y4uzwh4hX/qNOf/ACWt68guv4lx7jBr2P8AZkx/wi3iPHA/tpv/AEltq68J8RxY/wDhr1H/ALSwz4a8Njr/AMTpf/SW5ryCzb93yeM9u9ev/tK8eGvDf/YaX/0kua8bsJMybT0Xn8aMZ8XyHgPgfr/kaobYoRTliefQCr1spAzg7jwAOw/z3rMtoyXyT0rYs+pXPyk4/CvOkekkPazUEEsdx4GBwBVa7t0WZVzx33c8+1bCdN3JP8IA/X2qGa2jJO85b070k+g0iS1hIROFUHqMZNW44Qx3Yy3riqkaTRj5RlTxubirMMrecDJkqOw4AreMbmUtNS0loedhye/fFIyBYi0m3IPCAcew+tTPO7x9P3eRnd3Prx3qKaWV13Mo85uFRR90HuewNXZJEXbIYV3nzEA5yA3v3P8AhUyxBWwASeh9qZAHjUmTk9sdFHoKn3jy9w+UAfnWEpX0NlFrUo6jIFiZQeegArnb5iWC9yMnmti93TNubIUHgD0rE2+dedflzxx1qLdTWPYt2acBWAUjsO/41qQRgE7MZ9+ait41ZfmzntVxkIDHv0AFSzdSXQrOrKcMSc8jtis+6iLEhiCScj2rSaE7CpJPf3qnOpyAQAccEdqBuRzt1Hsl3LwRyRitjSiu7J5DDHXpVC/XIJPLDiptMJCxv/DnBrXdHLPQ21Xyd5XJHDDH+FOSElnlR8jGY0HIb1/GpIl3g5P3qiiZkcqc7VbcD0xWkGtjCSYvmFX8u4K5PK/7vvRIS+0xvkY4BHH4GljcqxSTaFI+Vm5AFTbIio8s9PQdPatXG5F7GbImwHci4PXHpVePasmI1259BVxWCkrL8hB53Dj8KrSSRNOfnVccjjisWjRNW1Kuo7YkO7G89MdzWfpiMl1KQOHwwB9+tWzaC5u/OViAwxtfsfUVofYESJdykFeBz3rOTLiiCfCMCOAewPSqN3IfKOMcGrtyFX5C2c1l3TYUhuvQiiINGRfMArL2zU3whUD44+FSAP8AWXPI/wCvSeqeoyYbBzlqv/B4q3xn8JkDnzrnn/t0nrtw699HFi3+7Z037Q5/4utFz/zBrX/0fdVxttxt56HrXY/tFHHxWi7/APEmtf8A0fdVw6E7ML19RV4j4ycH/CRvW7hVDFc+g9atW+JMliSCc49aoQMGijDcdulaUAwNpHOPyrhZ3pGlBCH4f7pGcDvUhhQbnMagDpSWjArt7/yFXDGTgFQFxnnqahOw7XMi3RftGAADk4z0xWxHGMEhixPT2qIW4kk2JGdwGfenrDMh/wBZkjoFraGpM0WkiDcY+tPa1MaZTA4yN38/pUNsXg4KHJ756/WrDvcGT5WG/HBPO0HuSfatuVdTK8uhWuysIA5ZjwcjnHbHuaIbY7cMAvdgP5U+VJHwIiQuM7z3PrUqny1UYJAOBjv/APXrKclsi4RbFjQIp2qQo6E1majIGcKD0FadzIY4yedx421h3ny75HJyF6+9ZNX0NUluzLujvmwFJANaFrHuXgbc9cdfxqhZIZJyxHHWty3hHysMAZ6DripaN4tIdGm1SSM+/SmSBj98AMP4asYKIzABc8DvVeUMRlsAjqR6VJpzGReQhgC6DAzx7VkxqYbnGflY5roLjBLNjkjle1Yd4myTdzgnNaRMqmxuWCq0Hltwex7VoRvtRI3JG4bcnpntWVpuRkHGCuRmtN0zA2eSBg8VpHRnJJXBIJViGGDuRz/sHtUCTBjiUoJBw23oTUyu7Jk8SYwMEc46fWmx+XLlZdind85I5Prg962tfYz23K8ql2IAVweemKpyxoowVKqO4OOa0rqPEZMfJ7jFVt8fl5cjOON3BrOUbFxkV4gJY9oA2r1yKzL/AGyl4k5OOD6GtAmLymO/KyHbhev1qPTtOKhdzbyp+Ynqc+tQ9ClqyazAa3AbABAH0NV5H9ODnHTmrr2yRMwUkGs6dlOW6g8GoRTMi+J3t25r2b9mL/kVfEX/AGGm/wDSW2rxXUWO1z3Fe0fsvtu8JeIT66y3/pLbV6GE+I87H/AvUl/aXz/wjHhzHX+2l/8ASS5rxSybD5AOT+le1/tMf8ix4c/7DS/+ktzXh9jwgI5BNLGfEGX/AAP1N6xOY9ucHua0o2AIXHOcflWNZTASY9Fq9IQCMntnnvzXDynpJnRWsytlGOCefTIqzIeAQinn8R74rAgl+VcP3x17irqT7WGcbT/rCRnn1pOIJmkJDIC8hLAcDjB/+tUiNuVCGG0jduPSokHybosydSR6+oqeMlkBIwq9ePvHrz9KpXQ3ZllYxsDH1yAeAPfH8qaUAY/3mPPNJu3ID7+v5UjYDDJx6e9J6hGJIwAOAe232xVdx+7JxwP4asOCqMx4I5+lNcARs7nCgZJPGMd6Sjdg3ZGPqwFvaMrk/MAQc4PtWZZbYowX4Y8kmn6hP9rYyPlVU/InoPU+9ZV1qtlCDHcXEUfOOXHFaKKltsZOfL6nT2b5Tdu69K0oI964PJPtXKaXqFvMwW3njm/3WB4rrLC7ROWUdPTrVKkgdfQWa2YDHQgVnXUHy5OQxGK2TfB1CFlCE5O2sDV7wqSFGDRKiugRrt7mdeRDDoQOBxVTTSDFJHJwU5x/hUEty0pdmyecGm28rw3cUyqGVT8ynow9KlQsNz5tDrLLPkgnhv58daJ0BwSB83pU9tEr26XEBBDKDx059qcNoUk4x39qhxa0Ki0zORiX8qQAgkhPl5/D/Pep44NuWOQSOnf35p7QkyscHnB68flUjuSrA4BJyTx+B/xqoyfUU4K+hXuYFAD7OFGCR+v0qpPFxiMK6novv/StOXDxcMDIvcGoJIYk7Hzeme5FOVyYpFeCEJGNwACnG1vWnTrnIwNp4IzyKAUT7uSpHfn/APXWdqN8+dqkFuinH86xsakF1hQwAHyKSD61k3bghgD1wc+vFXnc7Qc/M2eD2rJujjIzwrEdParjEhyMXU2LRAg4YHpWz8Hc/wDC4fCORgebcf8ApJPXP35/dZ5zmuq+ESbfix4PJxkz3Gf/AADnrtoaSRw4p/u2bn7Q+P8Aha0Wf+gNa/8Ao+6rg1f7mM/NxXoH7QQz8VVI7aLbf+j7qvPo/wDWIOMDPaqxHxsMH/DRq255XJyQev4VrwMCm8Dk4PP8qwoSQMjrjNathIWiTPA25Gf5VyOJ3XNS2uBvPzc9RnvWtbXIZTuwGxk89vWuaiJDgBDkH1q5FMquSGxj5ue4pco2zckkYNuVsqRkYG3/ACKdnZszlgTgtVC3lKyMswZlIzjP3a0MsrhkZduc4zyKFGw79CxDksVbq2RgccVYZFC4yMY/P1qupKnGcu/3iOfyqYEM+eDnkf4UCSFVVGduAF6e1JIBggKTg9PeljGSVXOepJ/LilcEOgyMHjjvU8pfUrTR+Yypz82OfSsLW2xtQZDL8vXgmt6/lS2tTI4G5eB6nPauXunEkyyyHJOcAfw1aSWi3Mr3d3sWLRUjQE4LY5rTtW+Tdhcg8Vz5lWQAI+Gx69a0bK4JZVc9+1P2QlXNwRF4wcYPaoZ4yAcLletX7GaFUZiSxHQjt/8AXp080TqAFKsQSzGn7FD+sanPXcRJJUAg9MdcViahEoiZlByv51tanepE2fTsOlc9NetKT2BPT1qfZNbF+2ujSsCrpCwPB4wP1reA+QHjkDIIrl9CuFW9MMqgpKQFc8bGz/UV1hh8lAByh9eeKGnuZqydihOm3fjhhyD1xUcZ88MGQ+Yp+bHB/H0rScKRt43Hke9V4Y2jGcfwkcnOfb6UotrQpxVhqQ7cA5wD823gVWlgjWUhl25yeR0P171c35dWBwFHU9x0/wDrU24jVpPkOUIJAzn8PpVu5naz1MtoD5o3IDjqwGMVfSNVyONxH3un502SOFCFiYhAeP8ACmG48pMjBYAjmsnvqaJaaEF2OjlfmBwPesS7cAf8BBH51Ynumnl2g4X19DVC7f5QewOB+dEYjbMu/fByeh5Ne1/ss4/4Q/xDjp/bT/8ApNb14ZfHnrnAPWvc/wBlj/kTfEH/AGGn/wDSa3rvwqszzMe7xXqTftN8eFvDv/YZH/pJc14pZjdGPXbkAV7Z+01/yK3h3/sMj/0kua8U0s70UN6YNLF/EVgPgfqX7dSs4J53cE+oNXycjkbwM4PsKgtkJUEgcdwOKnUYbK8n09fauQ7yWRS0Xy/KQccdvQ1PCJmwPMARjk8VFgDdtZSMj19KmGUbjJGM4z1oeg4o1IpAudzZyc8nr0/T/CrUUoxuOCg4xnrzWOrlJEypOO3fNX0OfuqNpGSF9al6mySNATLIxXt0z61KJOFVcHjIJ71QUhsZOwt/M1dtrfBJcg9iBx9KSuxOyLAyeD1/kaztavH+yx2rk5JCk+o64zWgjEAybcnBwM9PesfXIJ5o0miUFlPmBc5LDvxWqWjMJO7Mu8tXlCxRty/Uj0riPFWjx4YBUDISVBHDexr1LTntpVimGCMcg9j6Gs3xRo4u7R3VlK/e4GSRWkVZaHO5PZngVvpN6fElvJpTy2qH5mZW+4B2x/jXsWga1PNbtHdDE0ZwxHf3rM07SGSVrhUAOQNnXI7n86uXFqYbh3hGC3XircuYhQUb+Zt/2qqxszPsAGSScACvNtc8T6lruoyW+nhraxjyGlY7WlI7D0FdLLYzXEPlyqWUngetZ58LtJdrtVZFJ+ZW6Z9aE11Hy32Kvh7Rrq5+a4uJ9uecS9TXWWVnLEXidmbbjDEc49DW14d0IWUahwqtjJHep9SMNjFJMxAGKmS0Ki3ew7w8XeOaIvxG+MegIycVeuwUGdrDa2apeHInFiZpFHmSN5r56qOwI+la90NyJtXBz35xWUl7pvF2kVsHkZzjr34qGTPUEbD17n/PrUsirHk7iGGAe5qN2XLMvAPUdxWLR0bkfyFC23BXgAdcemfTpVaeZ3aRZFAXI5BzxSO5Qbcgr/nNVHlbgMS25cHIxgj/ACKpMiUHuR3M4SIhW7HOOlY9wzSOQr4C9T/eq9dkDIbHbqO/Xj9KrlQQx435wSe/vTsZ3sQzMQWDtkDj6YrMkkLAjk56/wCNXZiwhfPDMu0f41RYEkpyTnB9MfWqQmY12u6cIT0rsfhUAPip4Px/z8XH/pHcVybLm/6cY/Cuu+FXHxV8JD/p7uP/AEjuK3pfGjlxC/dyNz4/KG+KJB/6A1p/6Puq85TmYjH8OQK9M+Owz8UX4/5gtp/6Puq8zlTyrtATyRwaqu/fYsJ/CRqxruUZ5OOPSrcC7UYHHUHJ/nUEA3BFx06VeZdqgnnPH1rnOwWNjt3bhg8fTmpHjBm3A4Hsex/+vTU4JXk7lzx39DU6j5uSQDkDPP8AnmgOpPaxomdzFj0XJ4FX0nUDg8jjP48Vm2/OCpUgdR24qzaysjlW6d2PvSv3NUjUjnEXGNzY/wAirEcqvtZuvbtWehYAE8g9/QZ9KsxpvcgHDD5iDzU+SK0L0crOc5AGecU5iwwYzhlIYHpwKjSMRRfKAzYGM+9K5ZVEaANvOC2eprSCsYzkuhi6rdNe3m3ldozg+prA1C1muN6KSsajnacZP1rYuomttRWabaYJPkZl6Kw/pWvbW8BjkQBSzdM96uMdWYTly7Hhuv6bJG5mWaVE6fK5BQ+vvVbwZqniSy1OfzZZLiziI3rPyW/3T2Nek+KtC2TLMyjYOyjn/wDXWdpGkm1jVZkAWTJJHY+laqVlZmTjzPmudJY6xFdWqyxthWGTnjFWjqIVCzMNo5yT0rkVR7NZI0HBYkD0qtqMdzfW32eMsiScOo/iH1peYW7FPXvF73d3JDokXnhThpcZUn0Hr9ak0iLWLmFXmkjRQMqPK+971W0nwvMLjy1RyFHyshwMf54r0vSNH+z2eHGCB9TTsgu1uc3aRu8YZwA3Ib2PtXZ6a5urCKWUhtyc4656H8aw9V22MDKgBlc4QAZyTW/pMBtbSKNhnChQVOeepKnv3rO2rNubREbEmcDuV9PTrTiBjqOTwTUsy5nJXgDuP51CQsfyEkqw49qxktToi7ortkH5x06e3v8AWklPkKxiUlipO0cDP/6/50twBtAbgg96pSysXXJ6nBPXjvSQON9Rs8m/Dt8ntn+tZt9cnJy3ygE47n6VZeTfGC2crkE+uKzptrOwIXHRgO/pTsiNUVYzJh3LjBH5VXunxj35P+NW50KttTBGMZBz+NULk/vN/JQAKMdTVJCbM3UD+7yeM171+y6NvhDxAP8AqMt/6S21eDaiPkUNjJPI/wA9699/Zj/5FTxD/wBhlv8A0ktq6sN8R5+N+D5/5kv7SIDeHPDYOMHWQOf+vS5rwzSztPlk5Ir6h+Jmp+ENL0O2l8fwWc+mPcrHCl1Ym7XztjkYQI2DtD846Z55rzePxX8BpOY9I0Nx1+XwvIf/AGhWlaiqju3Yww+IdKNlG5w9p/qQwJxyKlVCYnwvLH6DnkV3B8SfAsAE6Ho4BBIP/CKy9B1P/HvQfEnwMDIp0PRwzjKg+FZcsPb/AEfmsfqq/m/r7zp+vS/k/r7jjIuF5Prj2PBqBJGJRx1GRj2zx9a7n/hJvgWSv/Ek0b5hkf8AFLS8j/wHpp8U/AgPsOjaKGHb/hFpc/8ApPR9VX8wLHyX2P6+45hGAILEk9Rn9Kt274TsDxwP0reTxN8CnOE0TRmPt4VlP/tvSjxL8DCcDQ9GPf8A5FWX/wCR6X1SP839feV/aEv5Px/4Bl25zgOeR6DNXY2GTzg46mpj4m+BYODomjA/9itL/wDI9C+JfgWwyuh6ORyePCsvb/t3oWFj/N/X3iePk/sf19xDB53mbmHU9Ou70zTbhyqnDbjg5Y8Z/wAmrCeJPgZISI9D0diOoHhWU4/8l6WTxJ8DI22yaHo6n0PhWUf+29P6sv5/6+8lY53+D+vuOUuoZopDLalkY8kAZDD3FMa4u5ISrDaT98jpXVf8JV8B84Oj6Jn/ALFeX/4xR/wlXwHP/MH0T/wl5f8A4xVKglpzA8ZJ/Y/r7jG0S0ESRAgMcYq7dWa71OwY7lu3+NXx4l+BZ6aHo5/7lWX/AOR6efEPwOAydA0kAZ5/4RSXt1/5d6aoJfaMZYmUnflM6SzRbfOM/pWNdIYmDRgBjwM966v+3/ght3f8I/pW3rn/AIROb/5Hpg8SfAwsQNC0ckdv+EVl/wDkeh0V/MOGJlH7P9fccnLe33Q8ORx9KhSGe5mjmvX3uvKofuj/AB+tdkPEnwMPTQ9HPb/kVZf/AJHoPiT4GBN50LRwvqfCsuP/AEnpOgn9o1WMkv8Al3/X3FLTpI9uVASQHtxz71c3hlVnUKQeo/hP+e9B8S/AsLuOh6MB6/8ACKy//I9Ivif4FNwuiaMT7eFpf/kel9XX8wPGS35H/XyK1z0O3GTxwapEhk2t8rk4HvW2uv8AwQYgL4f0kkjIx4Um5H/gPTH8SfAxM79D0dccc+FZR/7b1LwsX9v+vvNFmEl9h/18jnL2YCHnB7dKpTsXRsSHnqRXXjxN8CjjGiaNz0/4paXn/wAl6D4l+BYODoejA/8AYqy//I9H1WP839feP+0JWt7P+vuOCld2jk3sCBgc9h2pEJEjcHHTDfTpmu+/4Sb4FdP7E0b/AMJaX/5HpP8AhJ/gV/0BNF6Z/wCRWl/+R6aw0V9r+vvM3jZP7H9fcefPGdrHbycnIrOkUJC7cBmJ79sV6m3ib4FrndomjDAyc+FpeP8AyXoHib4FnpomjH/uVpf/AJHo+rx/mF9cl/J/X3HiqDN4eOMetdZ8KgR8VvCQPT7VPj/wCuK77/hJfgXnH9h6Nnp/yKsv/wAj1t+C9e+E1z4osLfwppml22uSl1tZItAktXyI2ZwshhUD5A/cZGRWkKMVJPmMqmJlKLTja/8AXY4344Lu+KMuccaLadf+u91Xm+qAr5bheQcfQV9D/EjW/hpp+vRQeO7DTrrVRarIjXGjPeOsJdwvzrE+BuV+M+pxzXKDxX8Bmzt0fQzj08Lyf/GKqpRUpOVyaWJcIKPLc8ysSf3R65PJPatVkyRtIwOa72PxD8DpSoi0HSHJGQF8KSnI/wDAepH1z4JxiQv4d0tRGwRyfCcw2k9Af9H4NY/Vl/Mb/Xpfyf19x5/Iu1uecfrSXDNtXaT8rYznrzn+td83iD4Hpjf4f0lc9M+FJuf/ACXpB4j+BpJA0LSCcZwPCsvT1/496f1eP8wfXZfyf19xwVsQHK5wp5Uenf8AGr8Umf8AV/3uTjNdWPE/wKJbGiaKSpwf+KWl4P8A4D0//hIvgaRn+wdIx/2Kkv8A8j0vq0f5ivr8v5P6+451GyF5xjnJFXIGB7nI9K1m8RfA1M7tB0gYGTnwpKOP/AelbxB8D1GW0DSQPU+FJf8A5Ho+rx/m/r7w+vS/k/r7jOcs8G2MjJ6ryBj3qWGNljPmM2BjOPTsPz5q1/wknwMOP+JFo/IyP+KVl5/8l6lOufBIJvPh3Swmcbj4Tmx/6T0/q8f5iXjZfyf19xh6kPOXYwyCT8tYWby0YKhLw9g/JQexrtn8Q/A5AC+gaSueRnwpKM/+S9RjxP8AAo9NF0U/9ytL/wDI9NUEvtA8a39j+vuONupLi8VInJCZH3utbNpaIYnDoOmc4zitoeJvgUemiaMf+5Wl/wDkepF1/wCCDZ2+H9JPGePCk3T/AMB6fsVf4jOWJk1bk/r7jmW0uJrhl8sYyOvT9etOuLCOEAhQCe6jrXSf2/8ABDAP/CP6Tg/9SnN/8j05dc+CbAFfDmlkHoR4Tm/+R6p0o/zEKtK/wnD+Y9nKDChbnIH1pG1e9+7GmSTyDwM13Q1r4KHOPDemHHX/AIpKb/5HpDrnwSGc+HdL45P/ABSc3/yPS9lH+Y1WKa3p/wBfccPaQu119qvSJZMdOyfQV1ETosQ8sDy+MrjIHHXH+FXzr3wRBwfD2lA+h8Jzf/I9M/4SL4Ghiv8AYWkZHUf8IrL/API9T7GK+1/X3lPFyf2P6+4pNgBiBtYgZUnkj29ao3WUYBVyB6d62x4i+BxOBoOkZ9P+EUl/+R6VfEHwPZwq+H9JLHgAeFJsn/yXpPDxf2hxxk4/Y/r7jnH2qwZCGUcc9Oaz55Q0zKMAkdR3rsv+Ej+Bu7b/AGFpG4nGP+EVlz/6T03/AISb4F/9ATRvX/kVZf8A5Hqfq0f5v6+8tZhL/n2/6+RwN28iksrdsYxVSUkO3ZtoGR+leljxF8DmIC6DpBLdAPCkvP8A5L0DxH8DSwUaFpBYgkD/AIRWXkDr/wAu9UsPFfa/r7yXjZP/AJd/19x5o/7xVG0de3GaqTRgyRhwAo5PHavV18Q/A5igXQNIJcEqB4Ul+YDrj/R+aD4g+B4bB0DSQeOP+EUm7/8AbvT9hH+Yj65L+T+vuPD787pFA/vA179+zIc+FfER/wCoy3/pLbVRfxB8D0Yq+gaSrDqD4UlB/wDSevQ/htqPhLUdFuZPAdtaW2mx3TRzR21g1mBNsQnKFFJO1k5x0xzxWtKmou6dznxFd1I2cbHnf7W7MvgHQygyx1qMAeuba4FfOWlbrcFsgZ5Jxnn2r6P/AGtBnwJoQzjOtJz/ANu1xXzXC6qyLjgdPb/69c+LfvJG+CXuN+Zpw3BBG0BpRkgk/iPy6/r1qw7JGjyO5nkcbeBjfx0Hoo/zzWSZ1SM453HCgdZW9PZR3PemxSyXDHdIVUfKzrx9cDsK50jqbLnmORuuJFBdhlQPlwO/0HQUBhOS6MFy24lhgn6/4VVlXzfnZjBGxx93OQKsLHsOI2V3wCEUZqXoaRXUvJKsAZI1O5uhBzgen9eKkhGyNnb92rY3NI+GyfYCs9mbBV92/HK57ep9KvW1oWVTMxVMbgpOMj1qL3LsJIkTR5y+R90H7v59T61YVZPKAgz5jfKmRxg9Ov55pIbYmQk4VeuOnAqZ7lBbpjaZjklj/CuOefQKP1qoq5E3bQqWUPkzyGQfLLhSc8c45z/nrU2riGS7do+AF6547Z4qKSdrsMwHIDEg8bTxj8hxUUaG4llLgsg4Yev+eKeiQkm3cyZImMikAncc/UEdqsmIwENPwEO44xnH+f610cVkkrJLGURolwhYffPtUF/YPMrnywsg/hP8XHUDt9KWxe5nafKIJyZWUL/EB/ECOlX1u1uQo8wHDhjngqCNv49Aaw2Zguxj8w4JP161GGKO+Cysp4I9D/gf50XJcNTpYd5jfMwOAGxnH1qublRIQrZAyrIeSD9RVaG/gjtGeQDzmyoXqM1n6fZSXt2v2ZD5efmbOAB7+9DRpFGzNINhZBH5hHI2gqT/AJ71VbU54mK7IhkZ2suQfx6V0lto6zOvmvlQOCO/t2JrQm0GCUHATeuMArgE/wAhUtFJrZnEPeNcZZokjlAwfL6fhV6yhEm5kkw/XaU3Y+ta9z4ZTyy1vuRQCGB52sPSqVpatDKIiZdy8LsIVx6jnqPalaxenQbJHISGCTFsYYoeMe3oKoXqPM6RrHJyRgk5NbcYZnkBQuSdu5flY/8AAT39qtR2luGBMjxyA5xIpDAf1qbNjuluYBtAYcrE67R80jNyR04FRtbskyADDAHaOu72/Wt65jtiuzaWYgks2c9e1QSCN7nfLgCFQOO57AevahgmZl5BslVlOCcdR045FVZEV1EMwGzcQjDjr1U/j0reaD7Qjuw5QDC9dv19zVOe3WZGjccMzAY9exoXvEvQwra7kUNbXAJeLK/MOTjvn2pwUxsnltjd0IPB9j7/AFo1OAeYXOVuI2ALbuvpn+h/Cq1telVAkjQq2VKkdD7U3HqhJ9GXTejcY7lNuRjcASuPfHSux+D6oPi34TKBl/0i44zkf8edxXDsYuDEdsncj+orr/gs7f8AC4PCiuAP39x0z/z6T1WH/ixsZYpL2Mr9jov2kyP+FoIOrNotsAM4/wCW9zmvJtPihuLrJBNuOmDjcRXpv7UY3fFG3Qfx6NbKT7efcZrzmzcJCSqADso7iurEu03/AF0OXCRvTj/XU6nTr0WsjlBHJMw+WRl+57gdz6fnT7iZntdqldwPyoTlYz6k9255PXJ9M1ix4WU+Y5IA3O+Oc9lH1qy99HHbFW2bEOWA65PRQe59T2rn3R0uyZM5WJ2dZPMYtyScBuOvsvtUcrhIMRqWab5mduAUHpjnrVCS4eXmQjfKOBj7i+3pnoPbNWreWNtrY54jUdDx047DPOKVkikmyaHyZBGi2z7QOFbp+Iq15YjuCjRjOByuXIPZf89KVJooFR0UE9pAcszHqT+HHsKSNt8jsiSE9DkhVA74P+c1N0XYZOio0xuNsjqSAq8hmH8wPT6VFCjzgKFL7cfixHA/LmrDxqxBmk+b+EAZx7gj8amtURYw6v5TFvujk/56D8aSWoN2RmXSFbyOHaSoAVRnq319K3r/AHx6UyOqiRnbDE4yQe3pjH4VmXMLzXSTFDuSQnA4DDv16ZJ6/SrF7KklpBCpJ819zAnHfoapR7mbd7Gbq74idnALOQqL02qBWNzu27eSPyq7qCFpWzneOvGTn09qZBAzxE7CAQcE8c+mfX2pO7Zqo2RPp0Sbsnk8MN38Z9foK27NFW7mDugD42dcE44wfqD+dYafI0WzOEG3H+16fn1+lbEd0BIyuix7128jkN1DD/gQqopIyldsu3aLuMkTHJGcKvX8PX1qm968eWWEsgPJRwCPwPWpra8KyBAMK+W5AIJxnp/D3qveyxvMXURllPIPHP16Y5pSVzSGmjNqy1W2IT94YsHByM9e2ehrQudTjwBFDcufvDAVW98D0rl7d4mt1zmN15IV9of8uPxpo1KOJtskdyVPGG5X8CahaDdPm2F1S9la5ODLGueVZcms24YyzHMjhT0TIB/KrzXVm2RFHLHJjqSD+RpbOKKR8ny4zzlZB96ptroaRVtxIbcxwqsUQiDnJJPJFT3kUUNsJIWKHHPODkelTyKYXkdmGTjHljIPtjIxVS8nYoWZ5ZH4GSuMU3oUtTJjWR5dwG4Jyc8bvWpVhVo1IDHkqM8ZH/1sVesbJXj2qjySkZ2AgAfU0stk4gkdiMbuuc8g9vWkVYqSE4t2X7seCp9D3P8AntUkqhh+7Yq/mh436bHPc+x6GrslufsSu6htuSD7Yxn86rhD5bMU3goA46ZHr+FK3VEvaxHuB8sw/KsnzE9djjqOO3uOR9KnE6vGUd94Q7djjEiewPRhWXcyvYXavEXNvcDdlAOGHc/T+tTO4nViBmXAAUdvTH+FG3oTa5fkNsSondwT/s8N9fQ/lXtv7NQC+GvEiqFAGskAKxYf8elt3NeAtdTW+Y8CZVPzR7uSD3H+Fe+fsyyLJ4X8ROisqnWW4br/AMettXZl/wDEfp/kefmS/dJ+f6MoftaH/ig9C/7DUY/8lrivmLesaFm7c4r6d/a3bb4C0M4z/wATpOP+3a4r5TMjSSrub5FOT7+g/rXTiVea9DlwjtB+pdtS8jln5kA2gdMDso/nWhaQqV2OCyewwD7fSq1rGUjVjks53bTyeen51vz232PTw7jayg7snBJPcVzs6k0Zc0nzY5256dBSwOQWUN97g5/nxUXzTSLjdgfL6/rStCVQOgLL3PvWTN0+heSJQfLXlT0fHU1p6XcQyLJ52VmQYYZ4xnpXPi9zAd2HC/xAdP8ACq0t4QwYsBKTncDjj1NHLcbl3Oi1LUV+ziNQBJIct/ujov8AjWXHIzMyglmPL/nnH0zj9KpwM0zmaYBQD8vv7kf5zWzZ6fO5REiMW5hjeO/+1+Gfzp2ZOhYt7WTaqAHc4BJFXLaI2moyxrndgHdnOPUce1allaSW4cs4kYgZOMfrV59O+dZJAxd4iw3d2U5x9CM0cocyKixoSrQvg/woB19sVet7a4fcZ7dzI/3m7/QVvaGkOxJFRVf1AwQO34VsLECpj6EnucflVKHUzlVtpY8s1vQrnzRMLZ1SUFt2MAEcf1Fc8LaZJ5N6Z2jbKMfdPTP6V7rNslg2t8y7cE4HX0I/rXFXmgGa/nnVGWN1Kuq9x249RTlTtsVCrf4jkdJ0ZZ5FR4tyyHcvzADPufTFeh6FpcNtalUSMFSRlVqvp+niCxgyvzJhxxyc9f61u2wCSBCSdxz6c+lEY2Cc76FdrYp8wjymejetX7dQylfmU4+6RUqKC5xuBJxz2p+FLMNhbAwSeAfpRy6kc2hQmtlO/lTG3DAdvrjtXPa3piyOPs+TORyV7Y6Nn1rppVlbOxUGevp/n8KrNEIgSNvPXPSpaRpGbTuclHF5YK3A2ovGdm5cfzFR3BhWMt9oim54QNnAz/KuknSJySyIQByR2NZ9zBbg5XEQOCCo5NZtdjb2i6mGlrJP8sccwLd2lKqfTA6n6mrVvpbIyxoERgeWOWJ/GprjUGtwyoxkOOf3f9R/SoFvJpFJXeyn6dKnlG5voWbi3NvBtJGCw3YHCjt+tVXsVaJihG5mIJI46VUubiUz5Vm+Ugbg+cH/ABpftzPKEJMmBkg8/wCTTWhN7qxi6vGBIT99HG1weuK5y5je3MiAhgNrKT1A55967PVY/MiSVBgqw3LtxketYF7aZgy/zAfKPzrVLUyctDJiuv3YE6D0JIwQfw7e9d78Eyo+L/hQAkMZ7g7fT/Q564C5h8orzgH+PHQ9jXafAgFfjJ4VDghxLc5H/bpPyD6VpShaomjGvUvSkmdJ+1AB/wALYtD1b+xrcAdv9fc5zXmaSbmXjvke9el/tRc/Fa0QAl20W3AIHAHn3Oc15bLMkIIXO7gAdee1PEq9Riwj/cr+upd+1bD5agF1yx77fc+rHsKkhG+VVYcJyQex/wAap2EX74bmVsfO5B7+/wCNb1hbycOB8ytgZ7n/AAFZ2N7jbmAiFpHwrsMFupX2/AUL8scSxOkmwEAqfmI9SDUOoXPmPhSGUfLgnOT6/Sq0bbVVivzAZ25xmspG0UrF1cg5kfcX4zGc49s9Ku6ZCs2GkKgEgBZGxuPbj25rOhV7jLo5eQ9+pPrUsXlRTAsWkUgM+3gqfYd6mxVzYmhUzIxIVX4GwnHHU4pkt5DAk4RfMLcKucKFHOSeuO9UdR1QCJ0GOgjVgeVH+P8AhVC3y0hduSpACHkE+/0GKpaES95GyLhyiq3D45Hqx55/D+lRTJm48sv91yd3c1NZRpIWJ3HDAbh1ZieTn61qahpkdra20kTh3VwGIHByc4p6tXBJJ2I7CxgZJYJUCuzbnYjIGB0z3NWL3T0A8iNf3ScK6+oGefb+VXY1kuI1iW2eRl+UBR978f8AGtK10zUQcTxKyDtnj/PvTSvsDdtzzuaKSxuCjAqD8wOD1/8Ar1Ul3KysCSWOOvvx+INena5oV3fQAR2XzxjcF3Dp6AfrxXA6rpc9o4ikUJ8wKkdj0IpSi4jjJT2I7W/e3SRim91GQO4Ge/tmobGyuL68BhDQqD8zMO3cj1PtWrY2AluSzrhsZKAfeX1/OvRNE0tY5IpXTcVTKjbtVAehHr9acIuQOSgc9HoLyoiOiR7FwCEGWHqK0k8OW0kSxGJiT1Ltz+FdXLa9wFbPJx2PqKmgQqVDAEbup6tWns1cy9q0jgLjwTjiNn3KPTg1imwudNuGQldpOcHgg9mU9q9au7gZ3RqzMvBx0NYOoad9u+YBdwz15256g+9RKml8JrCvJ/FscikjiTZIvnjPzEjY/wCK9Pxq9Ba2spIlnZZSOI5oyuPYZ74qxJC1mVhdVaIDAcfMw9iD1Hv19ajeWDDI9ynlj5RFk9e/B5FRbuXzdhLlIIQUll81cKqZwB+OOn1rMuUTy47ZAoEjZJPoDnPsP8KDN5pYQC4U5wMOu0epJI/QUsFsIw7Sxl5GGMTPkL9AOtS3catHck2rO6QwKphJClj1fHoPTuTVSa3MSfuxxsJz/wACOK24JYbVHkDYkCfeA5Htj0pLWBZVMjujhU42ng/WmkS5HH39pGFFq6sY3+ZDnBB61gI32V3QbyYxlfm+8M9Dx/8AqrstegSOPKfNtO4FeceormLyN8LMNuHyD6bsfpTcegubqPFzBPjzY0AI43dR+PpXv37MIA8J+Igudv8AbLYycn/j1tq+aUuGh3blXZjkFfunuOOor6S/ZZYN4N18qCAdZbg/9ettXRgoctV+n+RxZjPmpL1/zKf7Xuf+Fe6Lj/oMx/8ApPcV8tWmz5TJ8wB49TX1J+1+Gb4eaKq5ydajHH/XvcV86aRpEbKGlBJPSurELW5xYZ+7Ydp7p5iOVGEO4bj1NdBAJtUuAu1YrZTjLjJ9e/SqpsYlvIY40BPv0HvXVaXZwxWaSYGTJnf1J4OMCuZxOrmSMqPQ2klkS3ZxEPnTcvUjitqDSba5tY90S79uGA459h65zVwfKyls8gDAOMGn2hYEoCAGzgD+tRbUpNtHE614QG6SS3lEE/RcDh/f3rK0/wAJXc0/7/ZECPv4yxA68CvTjF5rxuWAkBOc9qkaJEji8tdvlNyR6d6qxXMzE0Xwta2ipK26SfHykrnb7gdqvmydJG+UDk439efpXQwRlUDHAA4HOTTnEbnBH0x/npVWMuZ3uc4LaVSNij6ntV+KwkuVHnKPlwMKO1XQm1wB0NXYWxjaR74/rU8po6mhDaQyxuVeMBCcBuvAGBVzlGBJyTwcU8t0z+FRucLux8venYzcrluONFA2kKT047+hpqxhS7YCFgSakgbcrbjx1zUM+VGM8njHcVSBakPlBbdRkDC8/Wp/LAX5l+Y8c/pSf8s92Bjpz2pznKcKSRwccUymMk8yNcH58DOe+fSmQz4cgqcsMdKlkIEZGc7faogASoxwRxjtUNdgvoMlwcmONmPvxWRfC4VjggE9QOT+tbLNgZ3cduP5VQunG3ik4oqEzEKvg73yfXGcVQdMs24FuTtBbkj/AArWkQyYCfKM4yfWnQ2KxBnzk/xMw71HKW6hiCymdwI5F54woO36L3p50if7rvtz75z9c/yFb6RhVyhJ/wBrv+HpTkbzMhtuAcKQMZHpz0NJxQKbOeGjAB1ZUBXH3DjH1qgLAxyEleR93B6eua6uZYockYLN0UDp/wDXqtHE8kJVoxnJJOcc+tK1h8zOYm/cuySAhXG35v0NZdwPLjeF+inPpWxrayO+xwWYD5emce3rWXc581BMDu2gc1cRPVGVcoHj+YZHT2NdT8EojH8XfCaleVnuAD9bOfisZkV7eUjk5G0V0fwdKn4t+FOMOtzcDr1H2O4rej8SOTEfCy5+1K4j+Kds3Rv7FtwD6fv7mvJrVGlkyoBcHCqfX1Feo/tXnHxWscnj+xoD7f6+4rzrSNOurtgEwobuRwKdaPvtlYeVqSRegjCR+QgBdnwSR1PqfYV1At2h0/yIMiR1ABIwQOrf/WNZH9n3VqiBmDHIGd1dFp2lzX7PPqMrYVQFjHO/8Kxszo5kjlxaO7sHx8vIVsc8+1XRpjyQ72jYx5wsq8BWPQ59K7caXEL6N0QbtpX5vY9D26VbsoljkkgdQE3Hhem01HJqV7W+x5LdrcafOY3RlO7A2jGT7VTl1SMKQsWJOwxzn3/nXret6VZ3UElvdQCY/wABHX6Fv8fSuWbwVHFcMWkLRqQSDyRn3+lHs7Giqc25yOnJLeTReapKLwuFyzH0HrXYWHh64jjM94q2428Iedo9x03E12vh3Q7XTk3Rw4YnCnaCQP8AGtq5s47pQpUhfc4H0OKtUraszlW1stjibXRra3ijMis0hwzfMefbjpV6Cwint50WNFdc7SQSeOevTtXRNZIjYYAjP0q3b2yqgwB6EY7UuQftdLmVpFx+/MLptUEAqM4BI44rpEIQA59jgdarrp8G0eWuG37iwPPrU7p8gDPntnuauKaMpNNkigANxv3HIUDp9Kxdc0mK+VImAYMc4I+bdiugt1XYEHynHGPrRKBvyV4Bz9TVWurMmMrPQ5Ow0M2QvEVA3I8o98HrmtqxgKQKWzlfkO09BnA4q8o3PI3Y7Qe/SpVA8r8fvY601FI0c31ImVXGcH0yD96o1EZkBcZxx1PSpsHyycj29D6mol4ZcqRzjJGRUsSY2W2AyQfzGazb15YxuRRtHTHGP8K2Wfk4Rn/HBqjdncDkLnPH/wCqpcRxn3ObmLzsxli74yWrMuIGZiIIV3Yxknj+db80fUsc+gzx9KqKGaZl2Kqnksw4GO9ZuBr7S2xhu1xbYDMV2jnY2cn8qbbT3BffKpKrwpwck/yFdHFYRyECUnyv7ucAn1NSS2UTc28QEfqgwD/j9aThYPaX3OU1GWYp+9VkJ6AEHPvx/OqryGNIwVCg8AHkn3xXXRadbwuGMD7mByCep9BWbLphaV3QMVxgknJ+gqeR9SudGXIFu7aWEhSWU4ZRjB9qxPszTRyA4Gwgke/Q10OoIbcLOCGUEfd/lWXOVEjzRYKzAnGenPStIohs5u5scRkg7SeoAz+Fe+fsqII/BevqowBrL8Zzj/RrevHZYGZHxjcqBvrXtf7Muf8AhF/EeQAf7abgf9ettXVhvjZxY1+4vUp/tYMq+BtCLDIGtJx/27XFeB6eSYwcjJA+gr3r9rUZ8CaEMZzrUf8A6T3FeDWhGE29OKvEHNhi+m37ahOT8pP1rptJ+a0RscKuR/jXOsqmMEdSGLfTFdFYELaKCcApj6DFc7OrqXAgkt5MnnO4Y9PamIxQJuOMDIOO9NWXGnZQgsPl6U+PMgAIG0DPPbFZyZvCNx0Y+YMxzznOMDH+eaujayJgNj3H61RGImCc5U+meOvNPQHfuLNlehB6UKRo4F5Zs8EFwv8AeHT8aso6uCjLgt0+bIzWYEA6swbqKkjDoWLSkp2HpVcxDgjREGScnIzkEn86kSOSM+3UZ71n/a3AURgMM/e6VsW92pQLKM9wT0qlZmUotDS64wy//XqNmwpBzjvmp5Y/MGUI4G761nvLgHJ+uaGiEaFrODFnqehz2H+f5VZlI2q27P8AnvWBbXHly4OOvHpn/wDVWrvJOMj3xSuWlZlhdqnaR8p7H9aaQQmQMZPH0qDzsvgnp/KphJtDEk7fX0+tF7gyO5lK5OMcVRNyWYdOf4QKh1K6HCEe57H2qos0hYY+uCetLcZqPL6sPcAZxTFUys4RcYGOTn86LS2My+YxBPcA4q2+EhCEDIHToMfWq5e5DZS8vYQR8q4O7v8A5FMeWNWJf5SfyAqDUb+CJgJ5QC/3UXkkemBzmsrzhK7MtrMinoTjcfzqH5GkUnuakkqB8RyEHq2OlR+c3ILI2emBn6ZqgRbY2lriE/7SggH6ikYT26q6lXg6b1+YUrotIuEFGLEu7dQCen0NKZi247gN3Yc/nUYnWWMhsLjpUVxOkVsDj5m44HWkBj3pL6iGT5gnUnnms3VIwbhVAO8qT1rQt8q5Zh8wJP51W1Zf9Ki28qyk5B600J6GTaMjSksMqBz7HvXQfBt1b4yeFwvGLm4wPb7HcVzUg8ou2Mb+Ritn4ISb/jX4ZGf+W1xn/wABJ63oL3kc2Jfum5+1BZ/bPjDpyscImiwOxPTie4rn9Di2oCEUKQe/Wun/AGnHCfFW3LD5TotuD7/v7niua0sGO3T2Xmta27MsPsjTlTe0CDDEsOOw+tdBpmTDOAwMjMcsfQVjmFWiV+4ZQB6mtrQCRFuYAlnLMex56Vh0OmW5dkTJYRglU+YHPTPWmRlOSx+cnBx0xU9tyshcnKsRgfxD0qnE0cq7Ap2scjb1H/16mWmprDXQvlQY8kEEcg92A6Yqb7JujcvtO7nJ7g0yFDHDnIYg4PPcepqCS+8tdqSLg+gzzTTtuVymnZsUjELBQwHHPWrKsDjeWGeMnisI3UsmAPMJUZzsANTLc3AADSYU9fNTH69KOZE8prMHLBT0PIbFPjLBgrDIPTmqcd2Il/esSB1GeR/j9RWnayR3EQZsKTyGNUtdiWrEiYZeG/A9aZuIDAgHtkd/aiZNmQA2ewxiq7OO+PwosSXbJsL1+7wT7VO43Iduc+3f3rHtp9kxUc56A/n+NaImBjwpJUigdtR8C7Tn+96dc08LtY4IYYyP8Kh3jCjncKkD5wDjBHJzRfQbuIzhVXbhTjkH69Kqm4VR8mcAkA0X06pGy5wegrLaccZwfccUhpGoZiy8BsHvVacqeCc57DtUO5pBuRTt6dKiklWJSxPJ4p2F6EbbVyeCzdOelPSEM+48nGefX6Vk32orC5JZdw7txWfF4g3yECZMA4AUHrUFcrep0xj3qRLh+23t+NOSQghC6sD/ABHOeO2PWsOLVFkYbXG8fwg4/OrcVy7k4ZEYjnIzuFOw15l64kACnblunXlvaoIoH8x97Y3c8Hj6Cg45ZnPAxgjkfQ+lIZZACRn2J6n8Kh7j6GJr0IEqhW5Y7Sccj8e4rnrmBrfyxkMCT2/zxXQawN80SHqTn/dHpVDU1YvAjDjJAHpx0FSkO/QoQkZO4Z/dlR717F+zWpTw54lVuo1ps/8AgJbV4lJIVmEfIdSWyK9t/ZrYv4c8SsTknWm/9JbaurDfEceN+FGb+1qceA9CI/6DUf8A6TXFeC6cMqvUYFe+ftZf8iNoP/Ybj/8ASe4rwqwjAUc9BVYjcxwq0ZoISybQBlsLmtmOQi3KkYwu0/jWVBHumRB90c1psPLhkJxg+lczZ1W1F37UnRFO5lVsH8qvQToluCTjI5b1zVHIRJFJyzRhRz1Ociobi7EeE+8i/wA6lo2g+hfDtJOW3YjPSr8MbEHYPz4qjprLs3swDe54Fa0F2j/KhjLEAcd/fNTFXZs2SRRbmJJ4PY9BUpi2L91m56cf0p8e3bukZtpPZcCkkjhVGO5lx/EMjB7Gt1HQxctSIbWfEW5mP8IHIPpipGVkT5kZc4HzDj86ri4VGBD+24HP1q4mpxGIRuwIyRt+vT39KIxTE20MgnYd/lPA9RTLwkgS8BBwfaqrjy1d0lBBHrkHHp6VbtislrdR5GPKL5YZ5q1HozKp3Rl3Mhj+cEjA9a1bK5VyFJPTrmueuJd0Kr7citPQ3CxgEgNisZWRcVdG35kZA3EDA4JFV7qcJHlWAyOoNMmeQAkdqzb2ZWik4wQOhHSoUiuUqlzPcO5zt6fXFaVhHthSZskSfd4yP/rVgxTbo0jBIYsFI+tdFN+4iUITlMY3d/auiC0uYz+KxYLC3jIPc4U9MisjUtSM6PbwfczhpSw2g+3qafeXM7lo42Chh878jYPb/Gsg3ltb3Eal0EhAwWOAB/T8KVnJ2RStFc0ixFHDByoHmYP7xurD6nk1Uu9SEGE2zebnICLuz+PSuo0bTLK4UyGT7QztncrYH5d/xrXk0izDR5toiuCu0rnA65/Oh0mtzJYyKeh50dSCyFWByBlge31PShNQQRmW3kjGeoPQ+xFd3eeG9OuYzmEIwAA2ZGf6Vx+raP8A2YjhAhikP+sxyD23D+tZOF9jphiIy0ZCW85PNgDHAy8Z5K+49RVm3ieZcuAx6AnGBWPC1xazxrLlRjAYdP8A69bOlTLLFKf4EP5H0qUhzdtUV7pUS7CgAgDoKztTYlYGYAFeuOlXbhxJMZDwzHj6ds1TuzuRkIHAJqidzAviWAJHyr+tXfgJJu+OHhpT2luf/SSeq04xEPQ5/CpvgKpX48eGs55kuT/5KzVvQ+I5sSvdOt/ajcJ8V7MkZ/4k1uR9fPua57R8yWqDOTxnPet/9qVQ3xcsM9P7Gg4/7b3FZOjQlYU4HTNXW3Jwy0ubEbKEBPVRuA9TWrpZWO1VScEHJB7VkqmFC92IAPpWrGDuOc/d57Vhc6Gh9tMySMGb5ZFOQPUHil0uZViMrELj19utVY8Ews+AFf8ATGKZbyI0gDFSg5KnjOOn4VLNIGhPPJOcgmK3f5gMfM30prGGCPLnC+xx+Ge9ZtzflnaQnkHg9Bj2rOlmkumdopEdVHVjyp9v/r0krm9klqdHHqFqzbTIgI/hUc/41oiaIJ8u5M9z39sZry648T6XaXKtc3iMqnY6W6F8f7OQOtbEPjfw2ZYUW+a3WQFl3Bjsz/C+RgHjp6EetbxhpexzzqQva53Ssi/wh4z2zyn/ANb9PpV20kQKhSRGQ87c4B9uehrm4LhLy2jns5o5YzyHU5wKsRNPGRIm0O33hjKPx/PGcVNrO6H03OrguSCofJ54Y9R7Gq96wB3AnJPJqjbXG/GE/dkcgDBH1/CtC0X7SsiNn5lyMdelapXM56ambK+1wfvH681oWl0JY0PAGOBmsOeXEGWxnJGadpMhcLuY/LxgVkxrVHTbdxGSQR+VDSmIEnHuDVEzKCMFuOetQ3FwTHkOeeeeai5ditf3RmnSNO3JHX9afaKXY5Hyp3FZkcu3fIMFs9D2rcjjMdoIyBkYfHfPf6VpBdSJPWxcRPKt5cnHQ4PcHuK5nXLvZGfKAeVjtRV6k1q3l2dkaRRliRkAdT+NZQtGeV2kyC2QXzyB3Cj096J3eiLppLVmI2nxgCS9X7RcM2ABkjPXA9fxqprt5pljujv9RFu7DiK1HzhfTA6Vt+JPtNvod1JYrs2IMSLgkjuV/DvXiWrTG1ZWRXeNnzKd3zkf7xzyfU01HlWxhUqq531le6DcqkNnfSwP0RXJBb8TW1bPe28jJPEjWy4JlQZA9j7147pkwvHnjmlO5F3RDy8ljnkEjgYHPvXpXw/1drvT7iyu2LpFhd5PO09M/jQ43uuoqda9jtvtCxoArecrDIb1H+e1WIpo/IPmcKo3MR1x6GsKKCTTrlVnLPaOOGyDitOOIS/I/wAynGAFwCPasHdOx03VrmVOTLf+c4YmTBRcduxpmphjJZs+MnKtg8DitC9QR3ahRgADJBz+FZ1+HaBFB3BSeTTSE3dmFfDbKsmeQNowOMV7P+y9J5vhPxG/rrb/APpNb14xeAupPOK9h/ZTO7wX4gJOf+J3J/6T29dGH+JnJjPhQv7VSb/Bnh9R31uP/wBJrivEbePaigV7l+1EM+EvDo/6jSf+ktzXisHJU/hSxL1Hg17rZb0yLfd8kYGFrTvYgsGP9rH1qLTYjEWYcnrmrV1tEaRk7mJ6elclzq5dTI1VXtryPeCYnUAgHn/9dYs8jpMquxx5mSf5Gum1JGmRC5wR8yk9q52+srhR50MiKx4wwzx61XMmUotWZcjuWkIjjAMnox4erEly1vG/muibVGESTJB/wrhvEWn6o5D+dLImeVg+Xj6Dk1gW2mzCYlILwtjj5XPNbwpu1zCpirO1j2LT9SeRGd7iNiMR5kPJPse1a0UytFg3Fuu87gpb+dc18PIo9L09n1GGRppWyd0eSB6c119vcWMuFi0+SUE7QquFBz26HFXJcvUzVacvslRo0dVZ3jZ92fl6KBnBzU6yWyqPMAYdhjG04xu+tZ2oWrzqqtawwKTjKx4IqpbafDBG4b7RIQDtJfd/n6VndnSveWpqxwxl2KImOuSatS3MlrYT7VDrJhG29QP8Ko2dshRJpBNEcbikw2kfUU3U7seU0UChQw5x3ocmtSGuZ2M4TCTOOhNbVgfLhXkKcc/WsCKNo9oAy4GcV0GjQsYVNwMOf4R2rmqzOqlTuiwZjJny3GfrWddSFh1BJHb0rbaGJdxVcA+lYOoo0eQRxyUasYy1N5UtDODZuUC4zkNXV5iFkpnIM+3I3HHeuUVAzxyqOnyv7VpSRf2hapbTMCiZzkZye34eo712Rn0RwVKd3cxfEWvixtJxbEXL5+Zl+5vzgfN3+grze81jbNvuZnedzlmx/L0Fegat4flv4zAbmKAAhtgUkEeq1zOp/D3VY5WktHtrxXA+SQ+U/H6VrFxvuc9eE7aK5peA/El7pV9b3EySNpksgjaTadhJ9G6bhkHHoa+gLeSOSIvu3bhx6V8xf8I9r9pHY2c8F0IEYuIwxZImJwTjoGIHXuMV7lZanBHaxobpAyoFOc9cV03TgedKnLm2NXUrtQgaIs2Tzjj8K5TWbkSb1mA24wcntV+61OF4/LUM79covH4k1g60kt6Vy6wKvBzyT7VxVkk7o9DC05y0kjCa43WDxOzfu3wp9uo5+lSaFcectyCTtJGQetV763SOGSPLM3BLk9aqaY7RYI5Z22njrz1qHJM7ZU3Y6Hqc8Et39KhuYxtYclsdfWr1vD+7Q9cdahuTg4K4IFS2TFXOYuInIZTk4PQd6u/A+PZ8d/DWRyJLkcf9ek1JeRnzWyBgjP0q38HIvL+O/hYjBBe5yR/16TcVrh376MsVH922dD+0vEZfjFp6gZ/4k9v/AOj7is6yi2QA+wFdD+0FF5nxft2zwmi235+fc1kWwDBF7DrWtd+8RhI+5cmt42a6iAB+Xk4rblgZIpMj5gKqWEWJ9zDrWnOd1uxbAUnrXOmbNanO6o72lrCfm2MSCR2FY0t8scznduUjC+4rp9WX7TZrCByncVy8trskZWjBwMjP8qG0a04llLhYFQ58x26RgBtx9PaptQ8Px3uiyrcOI/OjPyR8LGf6mi101N6XNqVV1H3G5H4VtWMrrKPtEBEf3gFwfm9a1puKMcQqj+HY8T1DRrnTJDb3duVjPTCnn3B/pUlqJ766gjmM8rQxLBbnG5o1H3VAA6cnr619B+bp8kRWe2dx3DoCM/Q96k0u5sLSZ2sdFiEq87lABA98ZxXXzU3uzzPY1d1E5TwJ4Cu7GwluLmWS0uJzuSLOVA/2l6ZNalxJLpkwgvoQHPQg5Vvof8mugu9dvtpVLWNMfMpOScGuc1aa5v8AMdzKfLc84iBAOP8A69YVWm/dO3CwqR0nsXbJvOkZrdmRc9R6H2rXjkhsLZ3fcGKFUJ4wT3NctpLTKh+yTQeXnaxWLLAjggE9K0L24RLN45j5m4Dhv0pKTSNpwTduhmTSbndQcjPT3q5pgJIYMcA8YrEgLY3NwCc81s6O5uIyYhhAeGPGfpWFSVjWnTbNZpcDOAfY9aoTyj+EEDGDmrgt3WT/AFhIPIBP6Vk3hZHYHqpzg9xWKm29TodJJaFUkpL8ueSPxruI0F1Gs0TGBGH3sZPT0rg2LB4pB9zOD7V0Ud3JLZRRquJA4UlDgqP73v8ASuqE7I46kG3csELbMZJ+Bn+Jsc9M56n+lREJPMq3QKxFdqryue3PcY6gH72RVFhdRTu0l0HOMByPmx7en4VXE8lvMZXndpDglSud2ehPrQ5+RuqN1udeNPEtt5RX5GGNpGOPSuRu/hZbtfpLFI4tmYl4I1DMR/s59DjrW5a69cqoAMUpHT5DVlfFt/C8jLb2jBtoyUbcuPTnGK2hUjb3keZUwlW/unlR+GGtx3LfuYIUYkErxW7pHhYaBHNEBvlkUF5McMPTHtXZ3Hi67dSxgthnPTdXO6lrsk7kO6ozEj5U6fnSqThb3UVSw1ZO8jP8/OkTQSOd8R+Q98dhVvS76OSGGRcnYrAYOc+grm78ooeVHkLP1OemO+Ku+Hp1FspPQksCT61zt3OyVNxWpqSs0jOTyerk/wAqo3JwxJPyFSfxq+qmRVO3gk/jTblD5hGOCM4xSFFHLXDgwuRncBjpXsX7KyhfBviID/oNyf8ApNb15NdwAeeuOevWvX/2Y12eFfEY4H/E7fpz/wAuttW+GfvMwxytBPzD9p4Z8KeHf+w0v/pLc14vpy78E8bea9p/abGfC3hwf9Rpf/SW5rx2z/1eAAMGpxfxIMD8D9TSt0/dY3YJ6tUyIJmA6KOM1BF+7iJPJboKtW77QCO3TPc+tcLO5IjvAryFdo2Lxg1nyRCTZ5nQegrXNtKcE8g8BT1PvVO7gkFwqg7emcdxTv1HFdCgbZN58rLd0Unp+NSWUEgZvMEzSZ4AYYArbgs0IA6Ec8DpUqaccsSxOegArVVWjN0UyjDEN3c/LtC4GAc9frVqFJljaJFCQD5jgAbj/PHtV+1tliUHHzerdvyq2qYQPwVx1YECj2jkCpJGQtnuVmkDHB5ZjgfhipFiSIIqpsz1ZR97/PrWpHGxZvMwcD+7kj2x60i22MgdT1J/lQ21qy0lsYNzG8ku3LMF9+KrSxBCGcZPQe5rfmtFi3SEkkDp6VlXeOGI9QPrWbqtlKmZsMBa43MMnr+NdHbqvlIBkADqKxraMsFJOB6DvWva7l4C4z3asZO52U422Jyd0XOMc5XOM/Q1kaqomRirAY6Hrx6VpuiFjj73oDxVC+BMbKhBI5A6YpI0krmFZAPIEkO3Lf5zWksZilkSQkjoCOOKzZB5NwrHHXt6Vs27rMUVgTkda1vbVHHKOpI0abUSdS46qycMvuPr3FVo7SeGSQ2lwJJGO0q/BPpV4Rl3VH3DYOoon8sqBcCMqeFLDr6c9c1tGV0c8lZlOSdyhFyJoD9xsruX65qQfu4sW4tih+719h+BOM1ajilUuEmEiEZ2u2SPcHvTQhAzu8s/xhhhTVqdtzNwvsZFyk3mBTx2GDjNVUsmBLu27/ZY8g+tbFxCzAeWEOOgVsj8qgkt2LANCw/2l5FJ1EXFSRjTWa5AUs2fyqGW18nDZAKnj2Paum+zLEF8plfHLZHNZGqLhUwMsG2E+uaxk7miuaFoTLCCMBmHK+hqvcx5HP314xjg1egQRxq69hg1FcgMpJ44qea4ctjnrm3Uru/iANXPhHFs+M/hI4/5bXIz/wBuk9QykbHHbPFaHwrB/wCFw+Eie9xcf+kc9dND40YYn+FI6T48Lu+LCnGcaNa/+j7qsDTF8wAD15ro/jmufiqf+wLaf+j7qsKwARDt69/etMR8bM8J/CRqwFsFgPmPAWpZAZECucsOwqK3J8tt3yqO9WIAp9ifmPsK5W7nTGOtyK4i2xoh++eTjsayL+2VgQAeD1NbsuWclUPXkg/dFUbxGCDy15bJ56GlcuKKkCJHsBZjxjkY5q5bxM05dxnsNx/SrdrYgxq0ignHr0qyLWQSgIFK4xuz2rWM/IHHzGQW5DoWJ3RnI5HHHb3rSUGOSPy0IJXaGC9B/d/z71HbQNvJdgQBnHfirjDH8Jx27mtY1NNDGVPUz5kLMRv+XAKqq8getVjAFJL8yMSMNwCPWtVV3OUjQgH06/8A1qa1suTuCsCflAHXHv3pOTKUUtDLuFKAKpAA44HJFZ9xDvYbj7nmtx7WTzt5A2Y5J5JrOv0D4UfdzyfWodToUqZjbTJdKE+RB0zXS2FuI4E2BVPp0rLgUs+UUEk/gK2LZ8DDEkdOK55yuddKnZEzKDGeuOhOOlZOrR/uxtUMV/u9/pWo3mKcoQB1ORzVC74jcncT1yalNGzimYVuSxZFGefukdPXFadm5WVgcgrjOe/uKyTmOdSCR82fxrahCzsG3YduOvU1spNao45w1LIBX5nUH/bYfypDaRsePm4DHnOT3q0kfmoirgOPvCh4SCOMY6e9bxqMxcSNUIYIMZxwP8ak+xBwGRSxHqPzxT4VKuMdMd+3vUuZIww++rE4/rWilchqxjXdoFEgQNjO4DP9aypraOXG8AADkHtXSX0jFCQu30yOax7kkqWOQx6AiolPoXFdTndWtgVYn/WDjj0qDToXhRE+6gYZJ7A9a6GS2IUGVCS3H0qrcJsdEIwGGfz6isZS1KRrRKiwqpHzLnkVVuhgjacjHGTV6yTCCOQYwOvqKZcJ8pRuV7Hvipc7kqFjmbxT54PAyCOT0r1n9mkg+GvEuP8AoNt/6S21eZXiK0OMdMg5616j+zioTw/4mUYwNaPT/r0tq6sJ8XyOTH/w16/5kX7TH/IseHP+wyv/AKS3NeMWThiq/ia9l/abOPC3h0/9Rpf/AElua8UsSBk5zntRi/iFgPgfr/kakZZ3H15rUtF3HkDcDxmsy0JZQerE/kK1rY7GXBxXA+x6SRdVQcuRkLwPrVOaGRpg5G4d19a040DonTA7+lIY1WRS8mV7gcmpKSEhdSoBOM8cDoKtWpEjnCnC8A//AFqhCIxLRjgdSep+tSxrsYbWKkjBP9K2jbqZyi0XSsYcLJt29CSP5D0qG5IeInedhPykcZPt6CpBEXUbo9ijhucH6f8A1qSSLzVAlX5FPyr0GPp3+tW5JLQzUXJkdo6MvyL904Ln+I98VYIXALZx2ANNaMIuACMDt2PpUeWVCp+90JrBybeptGFlcpanLjIU/X0FYN+wMqx479M1tTrtt2kwxxycdTWNbxm4uDKTn5upFLl0uXFq9izawFFyoyCMkYrUjTawDAYwOO4qK1GCVVh6dKvIgYNtwTjFS0bqRVkKYJTI29eMZqnOoYZ2jnk89K0zCFVc9O2apTxAYw3uT60teo+Ywb+IduVPfHSpNNf5E3DBBxn0qa6iYq20Lz0qHTlBRw3Y1pHVWOeo7am+iBymfvgZBqKJAJQHVWdclc9/Y1btvnQN34/PvT7mAM4c84qoysZONyjPbxScoMSD5k3ZAT196DDOvBMbLjkj5h9KlkUMdr8MOUzT1laIFWQehb19Oa2XLIzacdCi8UYIDx/N1461FJbsoJRvlB9ea0JohMARuDj5sgAVTl80xZyAo6kDOKzlEqMitPN5Nk7lGdlHOOuKykgku3LMM5G7jt6fjWs3myOis2VAwSo6/WrttCsce4oMA9VPas5aFxXUoqxEWx0Iz1BqrIxwQeSP1rQui2XVRwRw1Zk7EEHvn9DUopoxbrCFx2zWp8Kj/wAXe8JD/p4uP/SO4rIvznIHXsa0fhE+/wCLvhHnpPcA/wDgHcV2Yf4kceK/hyOy+NoB+K5B6f2Naf8Ao+6rnrVsuFXqa6H43ED4rsT/ANAW0/8AR91XL2BInZ+nFaYj42ThFelH+upseZkBFHA4A9au267ztHHfgdaoQsGyw4AP1zWpbcEMRnJHFcTO5IuCPKKoOB1qnfKWlUquQvrWkMsrYOCe4HNI8TDACd8Z9KNdikluNtVj2KQMkc7mq0gXcEJG4nOOtQPAquBuBPop4qWFWRwyEfnit4JMzldal3yE25Yce3JP/wBamyQeSGjC4kIJJJ5HufT2pNzMB8xMgONoHT/9XpUZQmN4kbnILuecn29q0fKjO0mNgG4AsQXx91eSB6n61PsyeCB7/wBBTIYPLyynl/mJJ5P1pytlDvH0FYSm3oaxp21K9/J5aHPQjFYF62FVARknPSti5UyK7yEYHXPQCsSVTPdHA+UEDANQ09zWNtia1jYAbslTz6YrSiTheO3XFJbR7RgrnHABq4IuhIPAqDZSK0iAHdu3nPIz+tUrpB13cHgDtWgYTjPQnrjvVWZHQAAcHjHoKCuYwL+HBAOcjgGp9MYHY2QSOo/nTr5OHByce1RaaGcOF4bPFXHVWMKnc6SAASI6gZ7g1KyxzjEm4BWyQO6+xqG3IZVYc4H86cxaOdSvQdc1tB2OaSuJcwOg3xSFVT5go5yPQ+1RiUHI2sGPUf8A66nckr5kWCFGCP8AP86dvSRcuSz4HXt6jP0rVx7GaempQKsf4gR6HuKqzMQfu7j9Ku3UTIwZQTH3A4/GoLmVAnJzzzgVlJM0ViNwpt95OBjpWDMRLcRMBlVcc56g1q38cdxAbdWY5AYMOMe1PttPG1t4GGUYIrOV0OKTJMDyQ/8AEOtR3Mm7OQCSPp/+qpGUxAAvkDjmqcrYBHbGR/hUK5TRkXL/ADHnrXqH7OH/ACL/AIm/7DR/9JLavKb5tuW7Zr1b9m858PeJSOh1o/8ApJbV3YX4vkefj/4a9SD9p3jwp4e/7DK/+klzXiFgxEY3AFsd69u/ag/5FLw/zj/icr/6S3NeIWf+rU9ulPFfEicB8D9TbsGxkA9KuxSMsgHPHFZlgNrMSSSDnHt3q4Ml+Gwp7GuPlPRubVtNsJGCQe3TmrO8Stt43rwccY/z61iC4KSgOMqRjP0FXbW5Vpo9jNvx83H+eKnluNN7mpsJQAlkAAPHGatRxbZcA/NxkgYA9vqf5VWWQSRozLl+uc9/88CrEZDqEHrlsnv3/wD10WHdstbvlG0LjHHsKTcd/TP60xjgYGGI5/8A10rdjuwDyQe9Nq4R0Fd8nJ4xmo9n7tgvYA571K+GQgAD0/xqPUZ0tbMSod0jDChh0Y/4U1DqTKVtDG12cACGLmXGG56dsn39qzoT5EYA5A6io7qUQwOzkkE7i3djXLat4ju7Jx5doGDHhWfB+laRjzasycrKyO7sLgFQf4yMVu2cZcYVRyM141Z/EazjvlttStprQnqw+YA+9eo6ZqUbwpLBKrxMoKsDkY9RVeytuiPbm7JZjaxJChcZDe9Zt4gijKn8s0Lf55OOu7qcE+9YviHU4oImlnnVI+pZjgUOmmhxrO9hLyaJJBt9OgrMt5Vt7kOCRG/Ueh9fzrnx4k0+WZwkzuMZBEZOa0LO4hvF+Ri3cgjB/Ko9nbY19pffY720V41AZTkjHByAasMu7IGPasvw3eAxfZZedg3IR1I9Pw/lWvIAm7gFQM4PXFRKHVDg7OzKV1CTtHLEcDAzj8PSlhiBRN7Zf7v+RU24SLl+TwaH46fKR681C0ZrJXViMIGlZCMnuM4B/wAKqvG+9hGpYkYII/rVpNxbCbSOApPr6H2pm7ducrsOBkZzzn171XS5lomZ4h8tw7Rtv746CrO5QCX2qpGQCOP8+9Rzyt5vXJJ5INULu6AGwfeIPFZtal3TEvZk27F/h7DqKybuT5jyMMBn6ikjuE8xmLZI7mq1xJwMdc5z7VcYktmdeOSQR1xWl8HsH4weFT0P2i44/wC3Oesm8OMseQAea1vg0M/Fvwo/rc3A/wDJO4rqoL3kceKd4M7T44ED4rNwTnRbT/0fdVyunnKbzkc4rqPjp/yVNj/1BbT/ANH3VctZDAGecDk1WI+Njwf8Jf11NqwPzcjIxmr6ybGX0z+hrKsy3mtj0GMcZq/I3z/KAwOMEVzcp2pmvbT4br8pxVtmWRAAW4OPY/hWKswTYJOCeCfr0q2kw3rICpKnbj1HvRy6WBMvIp2HZjzSD9OPSpUjYBCw5PRQep9qaHV4+G2tnAKjqf8AE1LGQVyDliPl46D/AOvTtYd2y0pCJjp644z7e1JlSQOQKafkXDE8d+ufWnHdgFQCD3z0oeugRSQrkE9OO9R7SASSC3t0qV1Gw4Jzj6c+lE7La2pnk+5syNvOaFC4SkoozNYkW1tQFwWkGCuOprIsx5MeWAyTknvT7uVpDJLcYMh5z2UegrntQ8U2VlnzjIyk9VjJB+lUlzehk5OKstWdbZSI3z+vb1rVtUBHAJJ6V59pHjHQ7q5SCC+iSZ/upL8hPtzXf2F55ZXOCAMVapi9uy09m7KMAke1Z9zAFT5uo6GtL7eHVhuOGPI2449KyNYuyM4wM0SpKwRxD2ZnXUYQhS2R71nafhbxonxtcnaRUU1y8szgnJUdKgkDsFMZ2spyD6VmocupbqKXus6qw2lOgCnJHNWJQSCCc7fzpulst/arKQglU4ZRxtIH9anwQTu6jtQ42CLvozPkZ4nDJkLjngkf/q/lU+wSEOwIUjdn1HenyR+aVdOR2OcU5WMYX2/Dk04yaCUewyRMo3G49OeeB1xVF1BVgpw6nHI6/hWhGEwQWBDdOxB/xqFreNiRLkqM4Oc49KbuTFIz7eEmZiU2k8Ano1XQuxMKPu/w57U0qFJYM3HbPao7i5EUZ6FM5z0P1rFmtuxVu41Unr82MegrMuHAJ7bSRg1Ze4abc3QD9fSs68Y7mPAznr9KUUJvuZd8c71J4r1f9mck+GPEZPX+2mH/AJK21eQX7ZZucfL+deu/syf8it4jz/0Gm/8ASW2ruwq9483H/AvUb+1B/wAij4f/AOwyP/SS5rxSxGEDD8+te1/tP8+EvD//AGGB/wCklzXi2n5ES+h7UYr4hYD4H6mlbptyV6EVPGNwJAw2Mge2KTAWLA47VIcxso6Eg9RXId5LneUbjdgfp/8Arq1BJtPyjDH1qtkRlWzwBgdvanwMjNggja2R74pMuJpQyFn2A4AH5dqtKSFVQV3A845H/wCqsyMEuGBOMZPPerykMrM3XGDg9sUF3LUcrICTk55z/n3qeFjI5+XPAH196rRn7pBBUdfcelX4mVR0wOufb8KaVyZSsSLy5B4AHJ7AelYGtuEuoVU/IW4UngcVrLIjL5YOD2Y8Z9z6D2qnqVrDcW391tu5XAw24Hr/AJ7Vpo0Yt6lA6ebmdAyfKOceprkvFOniMSb0JQ9NuMg9sV2VhqoRxFcgJcAYwTgP9DTdZSxu4HZhtlA4JHT1+orRWtoYPmvZnikvh5dT1e1e8O7y8+YP7wHQH8a7nRPN024ktsssP3kXsvsPatDT9IW4BkG5pH+6x64HQVZvNMlLDK84259TVc3MTZQuiJ9VEMTySEso7L1P0rz/AFBLjXNd87WLox2MfzRwAcL9fU16DHocpQse/Xn9aq33h6Jwgxg8YbHQ/T0PpQnysSSkYmh6dZSX4a3meUHJ4Xgn0H09TXXvpoE8Looz3PtTtB0a3tkEjS5yeVAwK2tQu7O2hZt6kKOPrQ2Wrp6GdZARarCnUhG3Adq6uRC6HDMOPmGOg9q5jQIJJZpbyeNh5gG3DcqvoR3zXR5KwlQS6joB0/LtWVtDXZorLmNBkZIPP0olxkHAZDwM9qsMfLVdq/8A6/pVLzCCRjIBwBnpWLjY6Iu412EbqD0x61WvXjkDCU53DP5c1KxEgI6DpzVJ22k/NyOgHfPWp6FONyK4kKABDx9M1k3LM5YAgbhx3yf6VbllSPKlzwD83pVKZsEnsRkEDp61adzNxsV2GxMEDcR/+uqd0cMgz1Xd6/nV+ZdyhyuR7c5qhdKyktg7+AMdQKogz77iBj1PrXQfCBSPir4ROMZuLj/0juKwdRXbARyT1Jro/hLgfFLweMf8vNx/6R3FbUviRzYn+HI6f47f8lQkPpotp/6Puq5uxHyEEccYGf510vx1Un4mzMOi6LZ5/wC/91XNab/qPXjqaeI+Njwf8KP9dTTt1ImDjB9B2xirEfzNgHpjgD35ohjCxnpinR8BXI6sAKwR1j2USQr6j9eamgSIOHABI5xTSAQG246k8+9KpVpWVXwRz9B/+qhjiaMUhyFUZJ9f1qzG7L8wDByR14P/AOv+VZo3eblTwQc/QVeTLZfJVsfX8aL3NdCzHMwYl/oAD2/w7VMr72wcgAAY9D6VXjGdoZcjv9PWr9uiJ9wfN0zQlclySHqAW2jrjH/18Vi6vMyyQ2+QY9+RjvgVrBiYmCNukJwRjOfYVlarZvMiyJJmWPEgycL6Ee/1rW142Ri5alG6szclYlzs6t7+1cX4s05dzlwUKZZG7A+h9q9K068gkCyAYZRhlPVT9KpeIdMgvbZnWQHHzbQcZ9M/SrSVtDByadmfOmoeG7jWNftWjxBvz5pUfdA5OPc9q9e8L3tzaxtYTyNIIVARmOWK9gT3NNsNFJd7hNu/gBVHBAPJ+pq7d2jicyIhWTbg8ciq5m9CVGMb92aX9phVZpGCKo5JPArzXxP4l1bXNV+waaTZ6Yh+e6LYaUe3oK697CaaJlkUsjdAfWsy68MM8qlMFz95SOGH/wBalezBJPZmNo/h+SW5O85i68T7jt/Pqa7O0057KVYlLNEV4DHO0+1X/Dnhr7HtcrEm7oFFdBeW0UIMhI+Trmi2hSlbQzNF3JftCHIDx5wRwSOn8637lDtICk7lIye9YGg5vLu4uBtKn93GD1Kjqw9s8V0rHdb8qQehP9cdjWaXumjbUtSlCCyqckluxpJBnOzGe4PFTPEMDccN1FRFgwBA+YDknvWVjoTvqQqFYlXAIPJJGc+/1FMkmZNoCFhuOST3+lJM21yynr/Kqks7KGbPCkHBHJ9efyovoJx6iysEZjnBIxxWRfXDHcSQSTgD/Grs7BiWGOT0PGe/4VnFFkcDjrlcHknvSaRN2iEPIIgGAznBINVLmT5gM52j9KtPy4UDAByPoetZ8zBpZDgBSx2571SRNzN1E4RivfivY/2ZRt8LeIh/1GW/9JLavGtV/wBWhyRk8D2r2n9m0bfDfiMD/oMn/wBJLaurD/EcGO+Bev8Ambnxo8Iar4y0DTLXQ3sVubS/F0wvJXjRl8maPAKoxzmQHp2PNeW23wd8cQoB/wAU2xzkn+0Zxn/yXrvP2jfFWs+EfB2l3vh/UGsLibU0t5JVijkJj8mZyuJFYDJRecdq+ff+FzfEBTufxZOIx6WNpk56KP3PX1NaVfZ399HLQdZR/duyPVW+FnjY4zF4bwP+onP/API1L/wq7xv2h8N5x/0E5/8A5GrymL4y/EI+dv8AFc+I8EkWNpjBPb9zzV6H4q/EN2iDeLJxvyc/YbTp2x+55NZP2C3RuvrT2f5HpEvwt8byKFMPhsAHOP7Tn/8AkalT4X+N1cN5Phsnv/xM5+f/ACWrz8/FLx8zny/Fd5s9TZWZOf8AvzUx+J3joRgjxbeFiOgs7Pj6/ueKlyw/YtLF9/yPQf8AhW/jj/n38NYxj/kJz9P/AAGqVfh744UAG18NEDt/ak/T0/49q83PxN8fFxHH4svGk74srPA/8g1aj+Ifj0ZWXxddl/RLKz/+M1PtMN2/Mrkxnf8AL/I9Ej8B+OIyCLTw1x/1FZ//AJFqQeCPHA3f6F4aweP+QrP/APItefWfj7x3csEHi+93sw24srP7vcn9z2qtffEfx3bXpi/4S2+8sk7CbKzJP/kGq58Pvb8yGsXe1/yPSYvAvjSMjGn+G/f/AIm0/T0/49abP4F8czA7rTw3k9/7Vn/+Ra4NvH3jgWc8w8YXrGNioUWdnycD/ph9eap3HxL8axW3mDxhes2wcLZ2Z+b3/cdKObD9hL630f5HcXXwx8aXAO+28N89f+JpP/8AI1MX4XeNgFUw+HCqjAB1Sfj/AMlq81/4Wz8QgqsfFV1g/wDTjaf/ABmpYfip4/bmTxbcqP8Arxs//jNP2lDsNwxfV/kepWnw88aWyqEsvDXy/wDUVnH/ALa1NN4D8bS4P2Lw0CDnP9qz5P1/0WvPrX4ieOHkiFx4tvkV8HP2Sy9Tn/lhVp/HXjcJ5ieML94920sLOy6/9+Kaq0EZuniJPV/kdyPAvjRVIFh4a57/ANrTk/8ApLVeb4e+N5Rg2nhoD/sKz/8AyNXCn4ieNlPPi3USpbG4Wdl0HXjya0bXxx4tuIwV8a34bGSDZ2XT/vxUuvQGqGJjqjbPwu8cbiVj8OAZztOqTkf+k1MT4U+NRL5kkPhuQg5AOpz4H/ktWLP498TpIY18d3qyDqHs7Pn6fuKybz4keOlm22vi27dO5+y2R/8AaHFHtqBaji31/I9EtPAPjm24W28NlfT+1J//AJGqz/whXjgOWFl4cHfjVp+D3/5dentXla/Er4gmQJ/wlt0xJ/hsrPA/Hya1YfHfjpABd+LNRVj/AHbOywPr+5pe2w/b8ynRxe7a/A9AbwX43Yc2HhoEjBxq04H/AKS1W/4QLxwHLraeGwx9dVnP/trXC3Hj7xwp2w+L79m7sbKyIB7D/U1Wg+Ifj+aRlTxXe7QcFzaWYA46/wCope1w3YapYxbP8v8AI9BfwB44YcWvhoHuf7Un59/+Paqw+G/jncxMHhsg9v7Tn/8AkauQHjvx8WT/AIqy9UNnhrOzBOO/+o6Ulv4+8cySuh8X3px6Wdn1J7/uKXtcN2L5Mcuv5f5HVz/DDxvKCDD4b5/6ic//AMjVC/wq8bnlYvDSnbjI1Kf8/wDj2rCi8c+NnEh/4TK+wCQP9Dss8f8AbCobnx943iAx4wvjnv8AY7Ig/wDkCqU8O9kZyWM2b/L/ACOhPwn8bkEeX4b/APBlP/8AI1RyfCLxs7A7PDfXOP7Sn/8AkauNn+JvxAjbA8WXZHIOLKz49D/qaoyfFb4i9I/Fc5JGVJsrTB9v9TxV3oPoQ1il1/I7a6+DPji4zk+G1z1/4mE//wAj1u/D74U+KdD8b6Fq2qvogstPklkk+zXcskjboJYwArQqOsgPXoK8jk+Mvj9XcP4pvIQvXdp9mSvt/qhn8Pyrqvgx8VvGPiP4naBpeq69Nd6ddPOs0L2tsoYLbyuPmSNWBDKpxxWkPZX91GNV1+V87/I9O+KXw/8AEXiPxe2qaJ/ZD2smnwWjLeXUkLq8ckzEgLE4IIlHcdDXM23ws8cQrt8rw23p/wATOf8A+Rq+g6K1lShJ3aMYYmpTXLF6Hha/D3xuFx9l8N+h/wCJpPz/AOS1L/wr7xvsVfsvhv5cf8xWf/5Fr3Oip+r0+xf1yt/N+CPDT8P/ABx5bILXw2Af+orPxwf+nX3pqfD3xwrI32bw2SByP7Unwf8AyWr3Sij2FPsCxtZfa/BHiY8DeNwuBZ+GwMY/5C0//wAi1KvgzxuF2mx8Nntn+15//kWvZ6KPq9PsP69X/m/BHjsfhHxumP8AiX+GiPQ6vP8A/ItTf8Iv432kHTvDZ4wP+JxPx/5K165RT9hDsJ4ys/tfkeOxeEPG6nLWHhxjjHOsT/8AyLTpPCfjdgQuneGlXoANXn4H/gLXsFFHsIdhfXK3834I8NuPh/43kl82O18ORSDoy6tP/wDItDeAvHjpteHw4SepGqTjd9f9Gr3Kin7KC6B9brPr+CPFdP8AA/jazRFWx8NuFHfVp+f/ACVqabwb40kIP9m+Ghg9P7XnP/trXslFCpRXQh4io9WzxxfB3jQJtOneG+Rj/kMTj/21qtN4F8bSYK2PhpSO/wDa0/8A8i17ZRR7OPYFiKi2Z4mvgr4gAACDw0AOmNUn4/8AJaq914A8fXahLiPw40Q/gGqTjP1/0avdKKPZQ7FrF1l1/BHjlr4P8a28YT+zPDJAAAxq04xj/t1qwfDPjds79M8NNnudXnz/AOktet0Ueyh2F9aq9/yPJH8MeN2Of7N8N59f7Yn/APkWq/8AwiHjfBzp/hsnOc/2vP8A/Itex0UvYwfQpYystpfkeNf8Id442bfsPhr8dWn/APkWq58DeOT0s/DQ64/4ms/f/t1r22il9Xp9h/Xq/wDN+C/yPDP+EA8d97fw0RnPOpz/APyNUQ+HPjgMMW/hvGScf2pP/wDI1e8UUfV6fYTxlZ/a/BHgsnw38cP0t/DYHcf2pPz/AOS1V5Phd43d1byfDeAScf2nPz/5LV9BUU/YU+wvrdbv+R86Xfwk8cXBHy+Gxg/9BKc/+21enfB3wnqvhHRNVt9caxNzeagbtRZyvKip5MMYBZkQ5zGT07iu9oqo04x1RnUrzqK0meJ/tYW1xd+B9Chs4mmnOsoQi4JYC2uCevsDXyrcQyQXTxX9rcW4B2rsQrke+ePxzX2V8chus/CY651kj/ySuq4G/wBOhuY2SWNXQjBVhkH864sVNxmtOh34Kmp03rbU8BgwsaBWjdQcJgcsexq5Csg2gqilhlldhke+K7HxB4NtnuAthCbVjnIU5VeOCB2rmpNF1Cw4RUmgzhmx0HqR398VyOSkejGLiiv9pVcCXawHGR1qz5xIPlqpQgN8/AOf51WudMaEGR4lXJ+9G+4A+hB6U63B8kbRwARk+tZtFo6C0ECIqr5EUpH3gScf59KkuIxGo2HfkcYGCfcmq2lOkcZJk2yL1Xb8x9wD6VHqN7Hh1Rvm6O2cDd7etLVj0Qn2toFyj+Xs4UrwR+P51BI7XWJm24QkoQcDGOB7+tZbyfaJREicdOvP/wBatu2i3iEHiBScOeNx6Zx6VfQytrcZPKfJHJyjEMM+vJqjdEyHCqWI6gf54rZvoUmlLoAtoCsRf1b1+lXbK0aEqxXfG67MjqPUUikrHKwW0rRh1jLL0LD0+tIsZHCnLg7vr712JtA8Z8kBY34EROSc8Yx/WsjVtLktSZoo2MH3d2e1MLXKaXRSYgjejJ5eM9jwSPQjg1ftrny2keQkuSc49Qe4/wA5rGuJWbacCMFgDtGMfU1Ipnj8wRt+8X5x2BGeRj9aCVE2L94pIY5WUlDw5Xn8CtN094Y42a3nYhW53AkgfhzUGi6Rf3dyp3gJJ85JGRiuuPhmOJUaJ2LAcBehPv8A5zS5b6l3UdGzIiYXb7SbeTByXJGT9QeD+lQXGmeYw/fe4XgZ+gzXTLoCSoXCxLIed2cH8qfNYXUTIl/YK0YPEgG4Efh0qbNFJp7HHw2j292qzRpITjarDbz25PFaca27uVjjEMij51JwR7Vt3OjQTw7oogUwclunPbk1j/Y2R1jdXlVDw4XIjHt/ePuOlJprcpNPZjk0ueYY23BLDCoPT3PpWjBpCaeqG4jbdu3ZdwF+uOpqCKeKFNtvcrGo/iVmDfiM1m3+oRiT93Mjt3JVj1/2qVgcm9CW/m/0iRw7YB+Y5wM/57dqqrE6wKEVjNK2QvTHp+Pen6Zp13qbBkPlwKTlghHI+tb8XhtlUzOzSPj5ckqBTjTbE6sY6HPPaNCZAGD4xznIzjpVUOFDRtG5yeuOh9a6y008GZo5I1UA7SByMDqavCwjigMiIhDHCbe9VG8WNxUlucHNaSSvIyxs2cAYXOao3fhy7uW/0a3diPu5bbXpEMIVVIGWyBgDrVq2t1VPK8vzGGd3bJ68eg9/Smpz6Il04bNnkh8GatfwmCZ4IiSFyzFh7dK6v4NeDrjw78YPCtxcXgnzPcRbQpGCbO4PU/7tdq8RjMbsBncCCB0qx4ZGPib4Rz3vpSPp9huq3oTqc6T2OTFU6XspNLVI+haKKK9c8EKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA85+M4Bj8IBun9tH/0iu65ZrYbFJIyRzz0rpPji2y08Jt/1Gj/6RXVcYLsqBufHbiuPEL3j0MJJqGncSazRDv2jbyDn29qwbyxwC0YyM/MvfPrWrNdbjhCcZqONxuORgeneuV010PQU3Y4bWNMExMZDKT0YjGR7+tcTqCSaXKwk8wx52q+cHHv2NeyajAk0eIl3MB0H8q5zU9NS4hZbuFNpHLryOnUj19x+VJU11H7TqjzgarujLklSvCsTgk+nHUe9Mgdp23uRsGTyep9P61tah4dFtmRANuM7TkAD0FdL4b0TTLm2Ro4mWYD5/P8AmYH2XoKSh2FKpbVnKWFjIQzFPk4LyPhR9AOtdLZ2Et4u9LeXySdoYDO7HGB7V0Emk28AUQwqhzkHGc/U+tSWc32VljjJ+TkD0PeocbFRqXWhS1DSUTSJEVGDD5j8o/l/npU+jWtxcRx+UEI2DCuc5wO9btuxuDIzpkkEfKRycY5qC2tJbeVPKOY40AbHykkccevFHL1Dm0sxsfhpgGmlk2zN93yumfT2qaXwvDcp5UkzKSvIYgAfjXSjOxANoA5yaVSwbbkgHnZ6D6/0rSMEjN1JM8n8QeE3tYt8MomYkI6A5Ziecj6UzSdEknMkxQZj+8p69MEV6hdW0ZCBETzc4JYYP41Xs9PSJbjyVwzOfmP0HA9qTpq+haqu2pFp9qiRRsFDZQYIXjbVqW1RlOCFXHOB/P2qUQ+XtA3Nz0zgYzVhCdpGMA9jjBqrdyLjIbRPM3qApI+7nhv/AK9SSwRGMKRt4A29Ofc1NG2wEcZHTjpTZHVoyjY9h/Wly2JcmzNfTYAdyqF4/h+6R9Kzb9Ake0YKj0IxWrMoKnaNxPbOB+lZk9ikkhMjE49T19hUON9jSMu5zs+nR3DAj1zlWz/Sn3FnHZw7YYhJKi5UDkKff1raaPy02RKu7H3QOKz7xhBaklsyP931NNRS3JlUcnZHT+Fr6EaAkSxJIwYvkkfMSBmn3WpwjfF5IEnU5H3fc1wsct7pUhltG2huWiIx/wB8nsfrU9t4igu2aJmCyLyySLhge/XqfetU2tDONNXbNtSkjyOqbFc7Mnpgnr/Umo9UEcKxrJMfIVWOV/8ArfjWUdZ3zKsT5CckHgZqJr1ZX2EDGckkfpUyijdSaZqWshlgaRVMILgqWxkLx0Hrjua1ra5ht3lWIfuyihyTy565J9PaucS4jRQ2V44A7Uq3JkDHcAnVj6+1NKxM5Jm7dXCS2pYnDJtfr0Gen5VJ4bYP8SfBcg73kwP4WV1j9K543i5YbuP51o+CJ/M+Jfg5M9L2c4/7crmtaS99HPWb9nI+k6KKK9A8gKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8a/ai1UaJ4R8PagyO4h1pcqnU5tblf618/j4pWrfdtbrnsQP8a9v/bDj834c6MmcZ1qPn/t3uK+ZNG8NpKVM0hwf7tc9ZK92deHm0rHfWPxBsLgAGQwt/dlG3/61bMXiOC4UeXMpBPVSOa4aPwrZJLmUSNHtPGe9b2heFtK8qUT23QDB3kHP4VzOx2qor2Olj1WNTw/B681HJr1u7+Qge5mzkRwruOf8+tVo/CGkqg/cytwODMxH866S2tLXT7RYrWKOCPptjGKFZhKpbZHNTW088qSXiCNBjbEpyR9T/hV+0iEcobLIQOoHT39/pUGp3xW7ZFwWTgccUWGoK8iIzKr+nrQ10RfLdXZ0ke24AjnH70DI54Yeo9aiudNV+nykc5pI1TytvzeX94bTyh9q0bWTcypKd5P3Wx1rJruKLcdUZ9hZzxsykswPqefzrUiLKu2TcQTnDciraRAjjIOeOaV0K8PwPpily2G53HxyYUDkYPSplCuc8g9cf561TUY55/Cp4WycHg56en4VSJZKCCeoYepHIoRRgdQCd2PWkkww6j35x+VRs3zYXsPTtVXKRKwBb+MZ7+tDNtxuB2joAKjkBKhkVznmmFsqDnGPQ/0pN2GTO2Rkd+2elRO3Q5yetI5baNxyp7GoXkARsdAcYNSxDnbbyT09KrkmQncdq+o4pssjHk544pwHTt9e34UCuRSRqkb5G2MjLAdcD1rKmzNKSoYICDjHfFaF3JvQqgDKGxz/wAtH9foKI0CIc4xk5+tLqUlZamRLFukLOOORxyfxrK1PToLpU86NGXPyknBX6HtW+0ieZkMOc1FO27K4BX27mtRN2OSj0CV7aSW2v7hWz9xsOE55JP0ouvD2r20ReDV43GM5kg6fiDXVWACtJHj5TwB9add7msGHYDHvUXsyXJ9Dy+6fxLAjOPJljBI3AZP1rFn8R67AMMyqF7NHxXpBjzBMjYbncD0rAuI0aFlZAx5U5FaIlz01ODn8ba0jHbJDz6x/wD16779n7xFqOr/ABp8KwXrRmNXuXAVcci0mH9TXn/iTToomVkXBJ5xXbfs6QLF8avChXqWuf8A0lmrpglpocdWcndXPueiiiug5AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDw39rshfh9opPQazH/6TXFeA6CfNiVh3Ga99/a//wCSeaL/ANhqP/0nuK8E8OKREmB2rnrnTh0dAuTGPRQWz+FalghMWOMMAT+VZqqRA2fTGPXmr9s3lseT0GM1yS2OxKzN23bKAn1/SqmvX3kWxVTl93AH86nhkHyjIzXP6q/mX8fHQ9DyCaIlWuyhHp15ezSNu2RsAQWOD7/jVtdAvmceTLC5OflHXn3qxay3FwjSREJCOFYjc7kemeAKtWkeosTtuw49GiU/yxVN9TplFRVmx1je3en4hvVIAIG4jr/9eugspkkQFQcHkAfzqrbzX3kxi5himA7AZKjnsenU9KhtIVYsbYnYDjynblRSsmZyVzrLaYOoWQgv6j+L/wCvU5lbO3O7PQGueDsqfMHAwMHuP8//AF6uWl/vCpIQXIwM/wAX/wBehqxlaxrbVH3WA45OOlQFwmQwIBPXsf8ACq63I3BTkkdm/pS3JzCzDk9+en9alofqXYWyfl59AfWpSu9x8+3uAOaybO5UsQSxPT8fWtSGQY5455xxmkmUK8RDkeYSO5IpIo05BHI6nApSrE7lKkdcAUySQxp6joM0mxtDbiRI0IIIwef8ay5HZmOw7doyS3HFI0rXlyI0IAB5IOMVDLLG7bIDmJBw394+tUlcnrYmhUq6vzwMjPOPc02SRZCQ27bjt1qJpz5IwxUdwTy1V2Yhtir8/pmixcYkhYKWdiAMBQAeAo7VjarrEMAcBzub5VRRksx6AfWrs0MkzI88ohtT1K8swBwcCrKpOqM+k6csUZBw7YXPYnJ5OfamkVzJanMPdXpjBFjOgYfdYYI/CqthqUi3LRSq0bAbtsgwDitm8i1qNHKx2zc/dLvn86yJZhdxSR3UBSdBgoxzgeoYdRRHTYqfvLQ14LwG4VgcjPX681YupQIJIzyWOa5azm8s7XYAjAx6VtTybk3g5Yrj6VMlqc6KykKpB6cjisO8ULOyjofmwa3Nm6PbnII5NZWpR4nBPpiqTFKOhxfiuIm3DDg5rd/Zvk3/ABn8Kj0kuR/5KTVV8Twb7NwPrU/7OClPjj4ZXtvuT/5KzV1UtTirKx92UUUV0nKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeG/tef8k/0THX+2o//Se4rw/Q4tlvH9K90/a0Xf4F0FfXW4//AEnuK8W0pQLVfyrlr7nbhVoaHXywe5Aq88ZWFiF6DIxVeCPM0QIBxWtdhfs+B121yNnXbUpQyEjcGx0rP1RGikMyn5ip4B6Z71qabblrMFuhY8+gqJ4lN8nmDKMgyD02mqTLTSYy3Cxi3jGQSeOeBxXX6TaoI9ycn0IrlpYfst/CwOYQMKe49q7PT281BjggUmnJ2ROJqJNNmnpWmwyt5/3gchcnOPX86ju/DMEt6zZ8sMuVkQgFDnAHuK0dMYpbxhCBgYqzJI07PbuqtbxlZQrKMl+xB/pWqgranC8TNTbTON1K1u9NUJcfPAfuTjkfQ+n0rKW6AcfKDuOCOxHb6V3rSeZDtmAcMNrAjg/UVxniPTEs/wB9ZnCHkxsen0NZu6O2hVjVfJLcUT72DANnoMn/ADzWjHciSFomAVwCVJ43Y7Z9fasLSJZLidre4glhl2hwWXIZfY+tX9YIi08oRhkf73r6EU0yqkbOxWguWW5JUna3AycY5ras5mXcxcZP6Vy0MoLbj3GCT61tWsjJ1Ytk1m9ClG7NgXWAW3t6dcVV1C5AhbDE4461A9wVGCu76DJFULmYtnjGTg4NZJ6luHUhW5YPHaoAJJz8zD+6avzIVk8tDt7DI4rJspAdWDZwVG4H0rZ1idzppltgv2lvuoxxvH8XPbjmulPQxa94zDKsk7KZF/d5OeoJ/wABT7eRnkSK2QyzMcKoGSf/AK3vVSG0u3I89YIVXn5OQBnqp6Hmux0K1gs4cwLulf779zSV27F16saUbrUs6P4bUKs9+6zXeVMSdVQ5+77+5PFak9uiLKmRvBIPsabG7CJjvwccMDg57c0l48Y2kvkkYJ9a25dNjyZ1ZTleTMHU1RZ8KPldPmA6cd64rXoIo5Q8KoGTO4j+JT1FdhqbhULq3PXPrmuNuCs2oFX4hXmQn+VYOLTO7D1LvQ5q8jf7XGV3LjGeOo7D8ua0YZiZfL6EUkKG81Cd8ZjDE5/lTpLdrbUVZ87HA5pvU2djRhi/dZY8EdDWfqMW5SQMkVux7HjCqDuxzWddxckDgkcioT1Ha6OX1iLzbVuOq1H+z7EYvjr4YBzjfc4/8BZqvaijLGeM8UvwOhMfx08MZH/LS5/9JJq6qL1OTExsrn2rRRRXYeeFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeL/tULv8ABvh5T/0G0/8ASa4rxWwXEarjoK9u/ahXd4S8Oj/qNL/6S3NeK6cmWHoDXJiNz0MH8LNm0UFVGPmIzUl0+8mJOMjBP9KakgQAkc9MCprdfMulY/dXnFcdtTp2dy+sXkWcUQxnGKz7+LLRN6EqcenpWhPIFC7s8+nao7gZhYkEjnIq79CI33KEv7zNvOcbcYYHp71p6feG2RY52w3QN2I9jWdLGZrfco+UgDPcehqG1DpA8U6eZGOGU8j/ABFVGaWoVKftFZmnf+P9P06X7PC6zTJw2DwKWL4j2zKocKST0B5rzrUfA6SuZdKvPLjk/guAWC/Rhz+dJp3wwMcTyahqzrcqQUNuu5R9c8nvxXSq0XscEsLNM9gtPE9hd2pMcyqw/hPX8u9ZF9eTXkrPJGYrMcAyOEBPufT2rP0bw9b6OGe2R5ZXXBuZzyfoPT6CtgWULYEx88tgnzPujHTC1hOak9Ed2Ho+z95vUsabiFTLM6SSFdpccAADtWX4hvDMrIg644Iq7NueU5PA7KOKoTQqZWd+g9ahtWsjazbuzNRxEuWIGO57Vv6eWnhBiyoPAOK57Z58zK6ZQjnPUemK6i1jMMar04GK56jOqlDqK8cn2Z9xycduMVj3LkHcp4bgj0Nbj7icLk/3gOuPU1jamFWQ4U7T0IH86zWjNpQGxoBPHOuORg471t2k4EZWRQVHQYz1rF0sJI4V+COVPsetaECGDcuCAD39K2jU5dzjnTvoQXFnDA5Kq6KwIUhvlA7jHb61ZtbubT4X2oLlQCyxq2CO+AalcruNuyo0bAZV+/vnsapx2bWkp+yt5bMctFL0Yj+63+NaKdndETgqkeWRx2u/Ey5tpWWYNakNjymBDD8KxR8RLydt9rKzBeoJ6V6LqdvDfRyC9soJXkUpmYAZU/eGcdfoRXNL4V0SyBePRV3kc7ssrH2GeldKxF0cDwVmaHh/xHc69pqSyQmFUbBkPCv7rVbUbhZc29ouSThmA4+uaiu5JpUWBP3MI42IOg+grV023SOE4jLH0PU1lOpzO7OunSVKNluGkWy2tqJZR9/JJNT3EH2i1OSC6n71WGCshV1+RlxtPaqllIVEkJ52twfUVmn1BpsSDhFI4cc1Fek8NgZ71JcDypjjnPNVrxywVuMGpsVFmRqAypGOvSpfg5Ht+N3hQ+stzn/wEnqtfN1NX/g/z8ZvCh7+fc8/9uk9dNH4kYYn4GfYNFFFdx5gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB45+0/wD8in4d/wCw0v8A6S3NeK6fjCnPevaf2ojjwj4eP/UaX/0lua8OtX2xgg81yYj4j0MI/dZuh16nGB+pqzY/PKxJ9OKzITujQZx3JNaNthYm2nBJrltY6mrmpb4fdK2SR90UXShbZQOM9vrUkCMI1xkbjzntRdw+emdx29ARUNlRiQWEH7lcZOeMDpTpdOl80vG+BjAOOT7EdxWlZDy4ArAKwHQCrC7TIIx25JApXuaqNjJtLNCCZIlUjglCcf8A1quwWcKIdqS9c4PzEf4Vo+QjYBAznqO2e9Plh8lXjjUKQM7ycsPqaaiyZWM6KMMxRI5lUZ6nnH17U9YVZuUGckjnOO2Se5q1CodcMwZu4XovtU5iyBtwAe570N20GlqZZiZXctgJ2/xrM1RgGAUcYzgVsai3lo4x171g3oPyg8nuai9i1G5DZRASBjyzEfSuhgHmRHAJGORWdZIpRdqnjjJ6CtWBNow7cDsKxlK53U6dkQvgrtC5dRwemKy78MsXJGT1welbrEtkbeh5z3rOu4vNBGzAzlaFJlSjdGDbP5VwrqcAjH0res5fOfYQMFeaxL2ICTIAxjOB2rQ06XhTjAz1PatN0cko6muITvPmYPGVzxUTeajCNYTNERn6D3Her8XOAfT8jUDgxS7RkehHY1SdjJq5SQR7DEjuBnO1uV/A9R9KjmtIjh2tg30PFXLnadpljGwclkJUj/61SR2o2k5CjPALZ47c0+ViVupkCyiidnWBlJ7evvToNqtsUMAT1zV9wySkPyvbjg/WopWhDKTkj1UVDTLurGdqDqZxBHktjJ+nrSRwMFWREzxzk1fVRM5fYCy8A98VcaIJCwQYPWjmsTypo5y7DlcEEFORWXcuNuc8HkVs3wbcHPy4B4PtWHd9HX8a2g7mEo8rMe/fax5+X1rX+DZz8XvCZH/Pxcf+kc9YGouDE2etb/wXA/4Wz4TI/wCfi4/9I7iuqjucld3iz7BooortPOCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPHP2n+fCfh7P8A0GV/9JbmvBoJBgc9fave/wBpsZ8LeHR/1GV/9JbmvAI+JAPfNctfc7sL8PzNeIk4ycVtWvIBJ4PSsGBgI8sa24G/dAgdMcGuWR3LU27fDbeTgnp+FXDbnycpgHAzj3NZlqw2psLkA9WA61rLKrw7GGMhevXI9Kxmb01YmZYxtIO4/wAqQYjkWVMDnBH+NIiBWZj9/ecH2qRInO1pOT0IB4J9BSUmi3FMnID/AC/MWBxx2pHi3IYVONpBZvU+3pVmMCOPAznvjv7Ug27lUkgdR71TkyVG5BFB5YxH3Bbnv9alQ/uiXGc9BVg7c4xweuaikUrGxbG4Yb261BXQx7pTKC7c/wBBWJO3mXpCZwDjjtW/qO2K2wAG8wYK8nmsawj3sXzgK3XPWiUbIqDu/Iv28J6qGPHIH+FaSHY+Ccgc4A4qtbFckK35irqr5isIwTxj3rKx085XkYMoIXDKOBnOagmySG3HI646E/Wr5j2heoHb2qnMgG0gNwCcilZofMjE1CMOC+MY6U3RjvjdXHKmr08IYHPU8/SsqwYwXgIQ/NxzWsNdDnqrqjqbQu4ww+YDBHuKlmwecHdj60yxifYGXaW255zxmrTICxGCRjH1quUyTuZshCYPysrdc9v8+tORScNHnYRnI4wPrVi6jGB5eQBj7tLETGgB4VSW6Ywf89aaBrS5E67kYMGYdh/nrVOQLj5iUdT9KvxsqsxlwFPUE9Pf/wCvTBGgJMgLoOD3x6fjSaEiC1iKsfMIyeQRU9x/qQxyMHAP9KiLplsD5+uc1nandFUIQkH0z0rM0KuoujTMB0I/Oucuic89sc+tarSjyDg5LGsi9cFmOOwBremjmqGDqJwr5A6103wZTZ8U/CPr9puOP+3O4rl9S/1ig9zXW/CAFfiv4RBHP2i4/wDSO4rspbo4K2zPriiiiuw88KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8g/aXGfDHhzPT+2R/6SXNfPrjZOMZr6E/aTGfDnhsf9Rkf+klzXz/eKy3CMPWuWt8R3Yb4PmXoVzCePlx0rYhf9wB0yM5z0rJtcfLjk961AuEXbg8da5pHdA0LdiiEg5PtWhDcJJGNzAEDcAf1xWXCQvA4Vh16HrU8KoMBgPXpWTRvE6GG4SSP5ztIAJIHHNTxOAnXJAwMj8zWPHNgAgHPTHpVyCRl3MAQQMCpaNVE0wxCfMeeufrT9xOHVd+eB61QinYyAuOO1WUmBICnGMnHp70rjtY0Cn7tlVuMZ4HWmE7I1kwcEbcjn6imRyjaoGWY8dfvelY2q3k1vEY8qU6ZHXn3FWktzOV9ipqdy05dU4CZyc849BVKGQxp8vJX9aguzIqHYu4twAD1rmNa/te2LtDeQwnAOJEG0fj/WnGPNrIiUrK0Tu9Ou8/eHznj2ro9OUOQrBVDdz2rwew8eahbXKx6np4lj3bWe3OGz7A8GvVdI1iG6to5reTfEQOvGPqPWr9nYn2zaOwMduEYO+AOg6k5rJ1BkjToFI6g1SF8Op2g9c/1rB8XeIbLSrPz7qUjdwqDlnPoBQ43EqrT1ZbvtQUykRnkDBNZUztKBtJzkHP8AWuKtPEGqaveEWMUFrCflLupcg+gHrXW2+mahbJHJcXBn3dQVAx9Kn2dilVu9DqtD1CRNqEbxgbgOSfQ47it6RSyLKW4fr2xXG2OY722U79xJHy/e6Z6eldlbzK6APIGyMnuPw9aFqtQbs7oqJuIbOQSeabKGAbAXcB0zUxXcZPKyu49T1OKjkwy4OPMHPFZs1WpVBy+GXJPH09vcUydzEpWAAjI+8e1FwORjAIqlI5Y43MAQckc/Sl0Hy31EnkCsS3Ld+KxbyQvuxk5bBPatKZiybmGGA556c1ns/wC8JP3s7TnvQkidUVXCqgULg5wcdvSsu7YGaQZHykgHPXFbFzHhtwHJ6Z/nWVPHmVRngZb61tEwmYeor++jyP8AGuu+EpP/AAtrwiMf8vFx/wCkdxXJX/zTp65zXW/CU5+LPhL0Fzcf+kdxXTT3RwVfhZ9bUUUV2HAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeS/tHjd4e8ND/AKjI/wDSS5rwPVANqs3RTX0d8c9B1jXtB0VNA06TULi11MXEkUcscbCP7POmQZGUfekXjOea8avfh744nj2p4Qvgfe8s/wD4/XNVjJyTSOuhOMYNNmBpzbtnbIrXBMko3MOBjI4q1ZfD/wAcwbd3hG/4GOLyz/8Aj9aMXg3xorBm8HagT3xd2X/x+sHSn2OuNemupl24y4VmbZkrwP8AGpRIo2Kc9dpxWiPB/jQHjwhqXt/pdl/8fpp8G+NN7keD9Sw3P/H5ZZ/9H1Doz7G0cTS6yIeVRSGyy/zzWhES+wNnK+vQ06Lwv4yRQP8AhDtTJHf7XY//AB+p4/DvjFc58HaqfT/S7Hj2/wCPio9hU7GqxdL+YamShLDdg8Y/pVyBEXByTkcA0yPQvFynnwdqx/7e7H/5IqxHpPitNoHgvVgM9BdWP/yRTjQn2FLF0ukhJXYSMGdQSOAPQ+orN1CyFzauM4k5APZTjIA/r+VX/wCxPFZkLN4M1cjsPtVjj/0oqZ9J8U8BfBer7V4A+02P/wAketWqU19kzeJpvaRzmkmGXb5y7J4z88bdR/8AWq/q2k2mpWr7JECkE8AU698L+Krn5v8AhDdWEg+6RdWIx+P2iq6+GPHCDjwpqrH+8bqxz7f8vHNVGnO2qJlWpXupHCzeHkW4JhiDLFzwMZP0qa3tfsNyLi1JEcwzIueAw74rt7Hwv4vgZzJ4O1Riz7uLqx/+SKdeeEfEszFovBerIT/09WPX/wACKapz6oiVemtEzjl1GTe23cSem7vWa/h6bVJHu79wzucL1wgHQAelegWvg/xLExL+CdUI/wCvqxP/ALcVck8P+Ktu2PwXqoGe91Y//JFN05dhRxEL7nP+G/DlpZqJJpEBXGQB/nNb+oz2EVsRvQKoOSTzVOTwt40ckf8ACJ6sqc8C7sef/Jii28IeKIpBJJ4M1V3Hrd2JH/pRS9nPsX7Wju5FbRbT7Te/bLkMgU4iTOCB3aujLLESu4lXGcjGCR69j/Oq8eh+K1UZ8Havn2ubEf8AtxUx0vxaQd3gzVz/ANvVj19f+Pis1TqdipV6T15hVY+SEBJBx834/wCfeqkz/vuSwB4J6Yq0+meLmO4eDNWVzySLqxAJ+n2j/wCvUbaP4tYc+DNXyf8Ap6seP/Jik6M+xcMTSW8ik/yMWyCDxzWbLMrSuM4HH0rYm0Hxc6YTwXqgOc/8fVj/APJFVJ/C/jCVif8AhDdTGRg/6XZf/JFR7Cp2NVi6PWRh3vDFg5BPcmoXViS3VMqdxral8I+M33AeD9TCkDrd2Xb/ALb1H/wh/jXOP+EP1Haeo+12XJ/7/wBUqE+xE8TSe0jIZBtyRnA5qheIoDHOOMAV1beEfGJRl/4Q7U8Ef8/dl/8AH6o3PgfxtKuF8H3+fe8sv/j9WqU+xzyr039o4C8H71DgAZNdX8JDn4s+Euf+Xm4/9I7ikn+G3juRwV8JXmB63tn/APHq6T4Y+APF+m/Ebw7qOq+HriysLOWZ5p5Lq2cKGtpUHCSsxyzqOBW8ISTTaOSrUi4tJn0nRRRXWcQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient has ptosis of the right upper eyelid. Note that the right eye does not elevate well, indicating a superior division third nerve palsy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21431=[""].join("\n");
var outline_f20_59_21431=null;
var title_f20_59_21432="Atorvastatin: Pediatric drug information";
var content_f20_59_21432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atorvastatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"    see \"Atorvastatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/47/6901?source=see_link\">",
"    see \"Atorvastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13842381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lipitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atorvastatin&reg;;",
"     </li>",
"     <li>",
"      Ava-Atorvastatin;",
"     </li>",
"     <li>",
"      CO Atorvastatin;",
"     </li>",
"     <li>",
"      Dom-Atorvastatin;",
"     </li>",
"     <li>",
"      GD-Atorvastatin;",
"     </li>",
"     <li>",
"      Lipitor&reg;;",
"     </li>",
"     <li>",
"      Mylan-Atorvastatin;",
"     </li>",
"     <li>",
"      Novo-Atorvastatin;",
"     </li>",
"     <li>",
"      PMS-Atorvastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Atorvastatin;",
"     </li>",
"     <li>",
"      ratio-Atorvastatin;",
"     </li>",
"     <li>",
"      Sandoz-Atorvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HMG-CoA Reductase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"      see \"Atorvastatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be individualized according to the baseline LDL-C level, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks (adults: 2-4 weeks).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heterozygous familial and nonfamilial hypercholesterolemia:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Begin treatment if after adequate trial of diet, the following are present: LDL-C &ge;190 mg/dL or LDL-C remains &ge;160 mg/dL and positive family history of premature cardiovascular disease or meets NCEP classification (NHLBI 2011). Therapy may be considered for children 8-9 years of age meeting the above criteria or for children with diabetes mellitus and LDL-C &ge;130 mg/dL (Daniels, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-10 years of age (Tanner stage I): Limited data available: Initial: 5 mg once daily; if LDL-C target not achieved after 4 weeks may increase to maximum daily dose:  10 mg/",
"     <b>",
"      day",
"     </b>",
"     ; dosing based on trial which included 13 patients as part of a larger study population (n=45); efficacy and tolerability were similar to a group of children age 10-17 years receiving 10-20 mg/day (Gandelman, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents 10-17 years: Initial: 10 mg once daily; if LDL-C target not achieved after 4 weeks may increase to a maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; doses &gt;20 mg have not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hyperlipidemia:",
"     </b>",
"     Oral: Children and Adolescents 10-17 years  (males and postmenarchal females): Initial: 10 mg once daily; if LDL-C target not achieved after 1-3 months, may increase to a maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; doses &gt;20 mg have not been studied (McCrindle, 2007; NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prevention of graft coronary artery disease:",
"     </b>",
"     Oral: Children and Adolescents: 0.2 mg/kg/day rounded to nearest 2.5 mg increment; not to exceed age-appropriate doses (Chin, 2002; Chin, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypercholesterolemia (heterozygous familial and nonfamilial) and mixed hyperlipidemia (Fredrickson types IIa and IIb):",
"     </b>",
"     Initial: 10-20 mg once daily; patients requiring &gt;45% reduction in LDL-C may be started at 40 mg once daily; range: 10-80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Homozygous familial hypercholesterolemia:",
"     </b>",
"     10-80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for atorvastatin with concomitant medications:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Boceprevir, nelfinavir:",
"     </i>",
"     Use lowest effective atorvastatin dose (not to exceed 40 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Clarithromycin, itraconazole, fosamprenavir, ritonavir (plus darunavir, fosamprenavir, or saquinavir):",
"     </i>",
"     Use lowest effective atorvastatin dose (not to exceed 20 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Children &ge;10 years, Adolescents, and Adults: Because atorvastatin does not undergo significant renal excretion, dose modification is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling; contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lipitor&reg;: 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken without regard to meals or time of day",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); dispense in a tightly closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hyperlipidemia: Adjunct to dietary therapy in pediatric patients with heterozygous familial hypercholesterolemia if LDL-C remains &ge;190 mg/dL, if &ge;160 mg/dL with family history of premature CHD or presence of &ge;2 cardiovascular risk factors (FDA approved in boys and postmenarchal girls 10-17 years). Adjunct to dietary therapy to decrease elevated serum total and low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo-B), and triglyceride levels, and to increase high density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous, familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb) (FDA approved in adults); treatment of homozygous familial hypercholesterolemia (FDA approved in adults); treatment of isolated hypertriglyceridemia (Fredrickson type IV); treatment of primary dysbetalipoproteinemia (Fredrickson Type III) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Primary prevention of cardiovascular disease in high risk patients (FDA approved in adults); risk factors include: Age &ge;55 years, smoking, hypertension, low HDL-C, or family history of early coronary heart disease; secondary prevention of cardiovascular disease to reduce the risk of MI, stroke, revascularization procedures, and angina in patients with evidence of coronary heart disease and to reduce the risk of hospitalization for heart failure. Has also been used in prevention of graft coronary artery disease in heart transplant patients.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F137707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AtorvaSTATin may be confused with atoMOXetine, lovastatin, nystatin, pitavastatin, pravastatin, rosuvastatin, simvastatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lipitor&reg; may be confused with labetalol, Levatol&reg;, lisinopril, Loniten&reg;, Lopid&reg;, Mevacor&reg;, Zocor&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F137705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased (with 80 mg/day dosing)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, limb pain, muscle spasms, musculoskeletal pain, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkaline phosphatase increased, alopecia, amnesia (reversible), anaphylaxis, anemia, angioneurotic edema, anorexia, biliary pain, blood glucose increased, blurred vision, bullous rash, bullous rash, bursitis, cholestasis, cholestatic jaundice, cognitive impairment (reversible), colitis, confusion (reversible), CPK increased, depression, diabetes mellitus (new onset), dizziness, duodenal ulcer, dysphagia, ecchymosis, emotional lability, epistaxis, eructation, erythema multiforme, esophagitis, fatigue, flatulence, gastritis, gastroenteritis, gingival hemorrhage, glossitis, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, hematuria, hepatic failure, hepatitis, hyper-/hypoglycemia, incoordination, jaundice, joint swelling, leg cramps, malaise, melena, memory disturbance (reversible), memory impairment (reversible), metrorrhagia, migraine, muscle fatigue, myasthenia, myopathy, myositis, neck pain, neck rigidity, nephritis, nightmare, pancreatitis, paresthesia, parosmia, peripheral neuropathy, petechiae, photosensitivity, pruritus, rectal hemorrhage, rhabdomyolysis, Stevens-Johnson syndrome, stomatitis, syncope, taste loss, taste perversion, tendinous contracture, tendon rupture, tenesmus, thrombocytopenia, tinnitus, torticollis, toxic epidermal necrolysis, urticaria, vaginal hemorrhage, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional class-related events or case reports (not necessarily reported with atorvastatin therapy): Cataracts, cirrhosis, dermatomyositis, eosinophilia, erectile dysfunction, extraocular muscle movement impaired, fulminant hepatic necrosis, gynecomastia, hemolytic anemia, immune-mediated necrotizing myopathy (IMNM), interstitial lung disease, ophthalmoplegia, peripheral nerve palsy, polymyalgia rheumatica, positive ANA, renal failure (secondary to rhabdomyolysis), systemic lupus erythematosus-like syndrome, thyroid dysfunction, tremor, vasculitis, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atorvastatin or any component; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia. Secondary causes of hyperlipidemia should be ruled out prior to therapy; has not been studied when the primary lipid abnormality is chylomicron elevation (Fredrickson types I and V).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Although rare, reversible cognitive impairment (including confusion, forgetfulness, amnesia, and memory loss) can occur with HMG-CoA reductase inhibitors. These cognitive symptoms have been reported at variable times during therapy (1 day to years after initiation) and are reversible with discontinuation; resolution usually occurs within ~3 weeks. Cases have not been associated with fixed or progressive dementia; nor have they been associated with age, specific HMG-CoA reductase inhibitor, dose, or concomitant medication use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with or without acute renal failure and/or myopathy; patients should be monitored closely; risk is dose-related and is increased with concurrent use of other lipid-lowering medications (eg, fibric acid derivatives or niacin at doses &gt;1 g/day) or during concurrent use with potent CYP3A4 inhibitor or large quantities of grapefruit juice (&gt;1 quart/day). With concurrent use of erythromycin, clarithromycin, itraconazole, and protease inhibitors (eg, lopinavir, ritonavir);  dosage reductions of atorvastatin recommended. Avoid use with cyclosporine, tipranivir plus ritonavir, or telaprevir. Ensure patient is on the lowest effective atorvastatin dose in all circumstances. Discontinue in any patient in which CPK levels are markedly elevated (&gt;10 times ULN) or if myopathy is suspected/diagnosed; monitoring of CPK may be warranted, but may not prevent severe myopathy. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Use caution in patients with renal impairment, inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An autoimmune-mediated myopathy (IMNM), has been reported (rarely) with HMG-CoA reductase inhibitor therapy; presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation; immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment. Patients with a history of hemorrhagic stroke may be at increased risk for another when taking atorvastatin. Tablets contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Postmarketing reports of fatal and nonfatal hepatic failure are rare; if serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart atorvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary. Use with caution in patients with history of heavy alcohol use or a previous history of liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein, SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: AtorvaSTATin may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of AtorvaSTATin. Management: Limit the atorvastatin maximum adult dose to 40 mg daily in patients receiving boceprevir.  Monitor clinical response to ensure that the lowest necessary atorvastatin dose is used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of AtorvaSTATin. Management: Initiate atorvastatin at the lowest starting dose and titrate up slowly as needed while monitoring closely for evidence of atorvastatin adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: AtorvaSTATin may decrease the serum concentration of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: AtorvaSTATin may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: AtorvaSTATin may increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of AtorvaSTATin.  Management: Consider using lower atorvastatin doses when used together with diltiazem.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. Gemfibrozil may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): AtorvaSTATin may enhance the adverse/toxic effect of Ketoconazole (Systemic). Specifically, there is a theoretical potential for additive effects on reducing endogenous steroid concentrations. Ketoconazole (Systemic) may increase the serum concentration of AtorvaSTATin.  Management: Administer ketoconazole with atorvastatin cautiously, and monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities). Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: AtorvaSTATin may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of AtorvaSTATin. Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: AtorvaSTATin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin.  Management: Consider using lower atorvastatin doses when used together with verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of AtorvaSTATin. Management: Monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment, and reduce atorvastatin dose when possible. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1056621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases the maximum concentration (25%) and extent of absorption (9%), but does not affect efficacy. Atorvastatin serum concentration may be increased when taken with large quantities (&gt;1 quart/day) of grapefruit juice; avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1757842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pediatric patients: Baseline: ALT, AST, and creatine phosphokinase levels (CPK); fasting lipid panel (FLP) and repeat ALT and AST should be checked after 4 weeks of therapy; if no myopathy symptoms or laboratory abnormalities, then monitor FLP, ALT , and AST every 3-4 months during the first year and then every 6 months thereafter (NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow-up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Analyze lipid panel at initiation and 2-4 weeks after each titration.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atorvastatin is a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: After 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     LDL reduction: 10 mg/day: 39% (for each doubling of this dose, LDL is lowered approximately 6%)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapidly absorbed; extensive first-pass metabolism in GI mucosa and liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~381 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive metabolism to ortho- and parahydroxylated derivatives and various beta-oxidation products with equivalent",
"     <i>",
"      in vitro",
"     </i>",
"     activity to atorvastatin; plasma concentrations are elevated in patients with chronic alcoholic liver disease and Childs-Pugh class A and B  liver disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute: 14%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 14 hours (half-life of inhibitory activity due to active metabolites is 20-30 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in bile following hepatic and/or extra-hepatic metabolism; does not appear to undergo enterohepatic recirculation; &lt;2% excreted in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis:  Due to the high protein binding, atorvastatin is not expected to be cleared by dialysis (not studied)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/47/6901?source=see_link\">",
"      see \"Atorvastatin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Report severe and unresolved gastric upset, any vision changes, muscle pain and weakness, changes in color of urine or stool, yellowing of skin or eyes, and any unusual bruising. Female patients of childbearing age must be counseled to use two effective forms of contraception simultaneously, unless absolute abstinence is the chosen method; this drug may cause severe fetal defects. May cause dry mouth. This drug does not eliminate the need for prescribed diet or exercise regimen.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Belay B, Belamarich PF, and Tom-Revzon C, \"The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119(2):370-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/59/21432/abstract-text/17272627/pubmed\" id=\"17272627\" target=\"_blank\">",
"        17272627",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chin C, Gamberg P, Miller J, et al, \"Efficacy and Safety of Atorvastatin After Pediatric Heart Transplantation,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2002, 21(11):1213-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/59/21432/abstract-text/12431495/pubmed\" id=\"12431495\" target=\"_blank\">",
"        12431495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chin C, Lukito SS, Shek J, et al, \"Prevention of Pediatric Graft Coronary Artery Disease: Atorvastatin,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2008, 12(4):442-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/59/21432/abstract-text/18466431/pubmed\" id=\"18466431\" target=\"_blank\">",
"        18466431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/59/21432/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Ose L, and Marais AD, &ldquo;Efficacy and Safety of Atorvastatin in Children and Adolescents With Familial Hypercholesterolemia or Severe Hyperlipidemia: A Multicenter, Randomized, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2003, 143(1):74-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/59/21432/abstract-text/12915827/pubmed\" id=\"12915827\" target=\"_blank\">",
"        12915827",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al, \"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(14):1948-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/59/21432/abstract-text/17377073/pubmed\" id=\"17377073\" target=\"_blank\">",
"        17377073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, \"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,\" Clinical Practice Guidelines, 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12908 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21432=[""].join("\n");
var outline_f20_59_21432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842381\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137661\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137662\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056610\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056603\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137639\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137625\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056614\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056606\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056613\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137707\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137705\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056618\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056602\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056601\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137693\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137634\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056621\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137635\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1757842\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056609\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056600\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056616\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056617\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056608\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12908|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=related_link\">",
"      Atorvastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/47/6901?source=related_link\">",
"      Atorvastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_59_21433="MRI insufficiency fracture";
var content_f20_59_21433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    MRI insufficiency fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 533px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The T1 weighted MRI sequence of the pelvis (A, B) reveals bilateral broad dark bands suggesting edema (red arrows). The T2 weighted images (C, D) confirm dark fracture lines (green arrows). These findings are consistent with bilateral insufficiency fractures of the sacral ala.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21433=[""].join("\n");
var outline_f20_59_21433=null;
var title_f20_59_21434="Treatment of unconjugated hyperbilirubinemia in term and late preterm infants";
var content_f20_59_21434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/59/21434/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/59/21434/contributors\">",
"     Ronald J Wong, BA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/59/21434/contributors\">",
"     Vinod K Bhutani, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/59/21434/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/59/21434/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/59/21434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/59/21434/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/59/21434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all newborn infants develop a total serum or plasma bilirubin (TB) value greater than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (17",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    which is the upper limit of normal for adults. As TB increases, it produces neonatal jaundice, the yellowish discoloration of the skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sclerae caused by bilirubin deposition in half of all newborn infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperbilirubinemia in infants &ge;35 weeks gestational age is defined as TB &gt;95th percentile on the hour-specific Bhutani nomogram [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. Hyperbilirubinemia with a TB &gt;25 to 32",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (428 to 547",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    is associated with an increased risk for bilirubin-induced neurologic dysfunction (BIND), which occurs when bilirubin crosses the blood-brain barrier and binds to brain tissue. The term \"acute bilirubin encephalopathy\" (ABE) is used to describe the acute manifestations of BIND. The term \"kernicterus\" is used to describe the chronic and permanent sequelae of BIND. Appropriate intervention is important to consider in every infant with severe hyperbilirubinemia. However, even if these infants are adequately treated, long-term neurologic sequelae (kernicterus) can sometimes develop.",
"   </p>",
"   <p>",
"    The treatment of neonatal unconjugated hyperbilirubinemia is reviewed here. The clinical manifestations, evaluation, pathogenesis, and etiology of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two advances in medical care had a significant impact on the need for treatment and the way in which hyperbilirubinemia is managed. The administration of Rh (D) immunoglobulin to Rh-negative mothers in the late 1960s decreased dramatically the incidence of neonatal Rh isoimmune hemolytic disease. At about the same time, the introduction of phototherapy in the United States reduced significantly the need for exchange transfusions and the risk of severe hyperbilirubinemia. Thus, the risk of kernicterus was significantly reduced from its peak incidence in the 1950s to the 1970s. Nevertheless, isolated cases of kernicterus, a preventable condition, continue to be reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data based upon case reports suggest that kernicterus occurs in term or late preterm infants with hyperbilirubinemia, defined as TB &gt;95th percentile on the hour-specific Bhutani nomogram [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. In order to prevent future cases of kernicterus, the management of unconjugated hyperbilirubinemia focuses on two key elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of hyperbilirubinemia by identifying at risk infants and initiation of preventive therapeutic interventions (eg, phototherapy) as needed",
"     </li>",
"     <li>",
"      Reduction of TB in infants with severe hyperbilirubinemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevention of hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Universal screening of all term and late preterm infants identifies at-risk infants for hyperbilirubinemia. In these patients, phototherapy is initiated to prevent hyperbilirubinemia when TB exceeds a threshold level based upon a nomogram of TB levels adjusted by the infant's age-in-hours [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/3\">",
"     3",
"    </a>",
"    ] and the presence or absence of additional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Phototherapy indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment of severe hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic interventions for infants with hyperbilirubinemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phototherapy",
"     </li>",
"     <li>",
"      Exchange transfusion",
"     </li>",
"     <li>",
"      Improving the frequency and efficacy of breastfeeding or supplementing inadequate breastfeeding with formula",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHOTOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy is the most commonly used intervention to treat and prevent severe hyperbilirubinemia. In term and large preterm infants, phototherapy is safe based upon its extensive use in millions of infants over 30 years and only rare reports of significant toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Phototherapy reduces the risk that TB concentration will reach the level at which exchange transfusion is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. It decreases or blunts the rise of TB in almost all cases of hyperbilirubinemia regardless of the patient's ethnicity or the etiology of hyperbilirubinemia. It is estimated that 5 to 10 infants with TB between 15 and 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (257 to 342",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    must receive phototherapy to prevent one patient from developing a TB &gt;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (342",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Efficacy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Exchange transfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy exposes the infant's skin to light of a specific wavelength, which reduces TB by the following three mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Structural isomerization to lumirubin &ndash; Phototherapy converts bilirubin into lumirubin via structural isomerization that is not reversible [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/6\">",
"       6",
"      </a>",
"      ]. Lumirubin, a more soluble substance than bilirubin, is excreted without conjugation into bile and urine. This is the principal mechanism by which phototherapy reduces TB concentration.",
"     </li>",
"     <li>",
"      Photo-isomerization to a less toxic bilirubin isomer &ndash; Phototherapy converts the stable 4Z,15Z bilirubin isomer to the 4Z,15E isomer, which is more polar and less toxic than the 4Z,15Z form. Like lumirubin, 4Z,15E isomer is excreted into bile without conjugation. Unlike structural isomerization to lumirubin, photoisomerization is reversible, however, clearance of the 4Z,15E isomer is very slow and the photoisomerization is reversible. Thus, some of the 4Z,15E isomer in bile is converted back to the stable 4Z,15Z isomer. As a result, this pathway may have little effect on TB values. In addition, standard laboratory measurements do not distinguish among the isomers, so these measurements do not reflect these changes. Nevertheless, photoisomerization does reduce the amount of potentially toxic bilirubin by rapidly converting 15 percent of it to a non-toxic form.",
"     </li>",
"     <li>",
"      Photo-oxidation to polar molecules &ndash; Photo-oxidation reactions convert bilirubin to colorless, polar compounds that are excreted primarily in the urine. This is a slow process and accounts for a small proportion of bilirubin elimination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of phototherapy, known as irradiance (measured in",
"    <span class=\"nowrap\">",
"     microW/cm",
"     <sup>",
"      2",
"     </sup>",
"     /nm),",
"    </span>",
"    determines its efficacy. Irradiance depends upon the type of the light used, distance between the light and infant (except with light emitting diodes), and the exposed surface area of the infant. Irradiance usually is expressed for a certain wavelength band (spectral irradiance) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/7\">",
"     7",
"    </a>",
"    ]. In conventional phototherapy, the irradiance dosing is typically 6 to 12",
"    <span class=\"nowrap\">",
"     microW/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of body surface area exposed per nm of wavelength (425 to 475 nm) and with intensive phototherapy it is &ge;30",
"    <span class=\"nowrap\">",
"     microW/cm",
"     <sup>",
"      2",
"     </sup>",
"     /nm.",
"    </span>",
"   </p>",
"   <p>",
"    For",
"    TB levels &ge;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (342",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    phototherapy should be administered continuously, until the TB falls below 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (342",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Once this occurs, phototherapy can be interrupted for feeding and parental visits.",
"   </p>",
"   <p>",
"    During phototherapy, the area covered by the diaper should be minimized. The eyes should be shielded with an opaque blindfold and care should be taken to prevent the blindfold from covering the nose. With fluorescent lights, the infant should be placed in an open crib, bassinet, or on a warmer, rather than in an incubator (the top of the incubator prevents the light from being brought sufficiently close to the infant). Lining the sides of the bassinet or warmer with aluminum foil or white material increases the exposed surface area of the infant and the efficiency of phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The use of reflective white curtains around the phototherapy light source has also been shown to increase phototherapy efficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14988413\">",
"    <span class=\"h3\">",
"     Light sources and devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilirubin absorbs light most strongly in the blue region of the spectrum near 460 nm. Several light sources, utilizing different wavelengths of light and varying degrees of irradiance, and devices are available for phototherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluorescent blue light &ndash; Fluorescent special blue light, F20",
"      <span class=\"nowrap\">",
"       T12/BB",
"      </span>",
"      and TL52 tubes (Philips, The Netherlands), should be used. They are the most effective light source in lowering TB because they deliver light in the blue-green spectrum, which penetrates the skin well and is absorbed maximally. Fluorescent special blue light should not be confused with regular blue light or blue light-emitting diodes (LEDs).",
"     </li>",
"     <li>",
"      Halogen white light &ndash; Halogen white lamps are hot and can cause thermal injury. They should be placed at the distance from the patient recommended by the manufacturer.",
"     </li>",
"     <li>",
"      Fiberoptic blankets or pads &ndash; Fiberoptic blankets or pads generate little heat and can be placed close to the infant, providing higher irradiance than do fluorescent lights [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/11\">",
"       11",
"      </a>",
"      ]. However, blankets are small and rarely cover sufficient surface area to be effective when used alone in term infants. They can be used as an adjunct to overhead fluorescent or halogen lights. Fiberoptic blankets also can be used during feedings when overhead fluorescent or halogen lights are discontinued. This is particularly helpful for infants with severe hyperbilirubinemia.",
"     </li>",
"     <li>",
"      Blue LEDs &ndash; LEDs use high-intensity blue gallium nitride and are commercially available as both overhead and underneath devices [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/7,12,13\">",
"       7,12,13",
"      </a>",
"      ]. These devices, which deliver high intensity narrow band light in the absorption spectrum of bilirubin, are as effective as conventional fluorescent blue light [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. The mattress LED device is preferable to the fiberoptic pad because it is large enough to cover the entire surface (in contact with the mattress) of a term infant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For effective (intensive) phototherapy, high levels of irradiance (usually &ge;30",
"    <span class=\"nowrap\">",
"     microW/cm",
"     <sup>",
"      2",
"     </sup>",
"     /nm)",
"    </span>",
"    are delivered to as much of the infant's surface area as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. The necessary irradiance can be achieved with a bank of special blue fluorescent lights placed at a distance of 10 to 30 cm from the infant's body depending on the manufacturer&rsquo;s recommendation and a fiberoptic pad, LED mattress, or special blue lights below the infant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/16\">",
"     16",
"    </a>",
"    ]. LEDs at the distance dictated by the device also provide an irradiance of 30",
"    <span class=\"nowrap\">",
"     microW/cm",
"     <sup>",
"      2",
"     </sup>",
"     /nm.",
"    </span>",
"   </p>",
"   <p>",
"    Although there are no trials comparing the efficacy of phototherapy devices in term and late preterm infants, a trial in extremely low birth weight preterm infants (birth weight &le;1000 g) found that the absolute and relative decrease of TB during the first 24 hours of life was greatest for LEDs, followed by spotlights, bank of lights, and blankets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19400?source=see_link&amp;anchor=H6787702#H6787702\">",
"     \"Hyperbilirubinemia in the premature infant (less than 35 weeks gestation)\", section on 'Light source and devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Home phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an alternative to readmission to the hospital, phototherapy can be administered to term infants at home. Home phototherapy is less disruptive to the family and can be considered for otherwise healthy term infants (&gt;38 weeks gestational age [GA]) without hemolysis or other risk factors who have TB levels 2 to 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (34 to 51",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    below the recommended threshold level for initiation of hospital phototherapy, are feeding well, and can be closely followed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Phototherapy indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sunlight exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although exposure to sunlight provides sufficient irradiance in the 425 to 475 nm band and is known to lower the TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/18\">",
"     18",
"    </a>",
"    ], exposure to sunlight is not recommended to prevent severe hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. The difficulties of avoiding sunburn while exposing a naked infant to sunlight preclude the use of sunlight exposure as a reliable therapeutic option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14988405\">",
"    <span class=\"h3\">",
"     Selection of light source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a wide selection of commercially available phototherapy devices, there are no standardized methods of reporting and measuring phototherapy devices. (See",
"    <a class=\"local\" href=\"#H14988413\">",
"     'Light sources and devices'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In order to help guide clinicians and hospitals to provide the most &ldquo;effective phototherapy,&rdquo; a technical report from the American Academy of Pediatrics (AAP) summarized the key features to consider in the selection of a device to treat neonatal hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/16\">",
"     16",
"    </a>",
"    ]. After review of the available literature, the report concluded that the most effective devices displayed the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emission of light in the blue-to-green range (460 to 490 nm). Lights with broader emission also will work, but not as effectively.",
"     </li>",
"     <li>",
"      Irradiance of at least 30",
"      <span class=\"nowrap\">",
"       microW/cm",
"       <sup>",
"        2",
"       </sup>",
"       /nm",
"      </span>",
"      (confirmed by an appropriate irradiance meter calibrated over the appropriate wavelength range).",
"     </li>",
"     <li>",
"      Ability to illuminate maximal body surface. Blocking the light source or reducing the exposed body surface area should be avoided.",
"     </li>",
"     <li>",
"      Demonstration of a decrease in TB during the first four to six hours of exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Phototherapy indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion on the indications for phototherapy for term and late preterm infants (&ge;35 weeks GA) is based upon the practice guideline developed by the AAP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar guidelines for term infants based on TB and postnatal age have been developed by the United Kingdom&rsquo;s National Institute for Health and Clinical Excellence (",
"    <a class=\"external\" href=\"file://www.nice.org.uk/nicemedia/live/12986/48678/48678.pdf\">",
"     NICE guideline for Neonatal Jaundice",
"    </a>",
"    ). National guidelines have also been developed in Norway, which are based on TB values, birth weight (BW), and postnatal age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initiation of phototherapy is based upon hour-specific TB values [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/3\">",
"     3",
"    </a>",
"    ], GA, and the presence or absence of risk factors that include isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency, asphyxia, lethargy, temperature instability, sepsis, acidosis, or albumin &lt;3.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (if measured) (",
"    <a class=\"graphic graphic_figure graphicRef56490 \" href=\"UTD.htm?27/51/28464\">",
"     figure 1",
"    </a>",
"    ). These are conditions that increase the risk of brain damage because of their negative effects on albumin binding of bilirubin, the blood-brain barrier, and the susceptibility of the brain cells to damage by bilirubin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Risk assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link&amp;anchor=H21#H21\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Bilirubin/albumin ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for severe hyperbilirubinemia and the threshold for intervention based upon the hour-specific bilirubin value may be determined using the newborn hyperbilirubinemia assessment calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). In general, the guidelines for phototherapy are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants at low risk (&ge;38 weeks GA and without risk factors), phototherapy is started at the following TB values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      24 hours of age: &gt;12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (205",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      48 hours of age: &gt;15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (257",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      72 hours of age: &gt;18",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (308",
"      <span class=\"nowrap\">",
"       micromol/L)",
"       <br/>",
"       <br/>",
"       Infants",
"      </span>",
"      in this category who have TB levels 2 to 3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (34 to 51",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      below the recommended levels may be treated with fiberoptic or conventional phototherapy at home.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants at medium risk (&ge;38 weeks GA with risk factors or 35 to 37",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      weeks gestation without risk factors), phototherapy is started at the following TB values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      24 hours of age: &gt;10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (171",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      48 hours of age: &gt;13",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (222",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      72 hours of age: &gt;15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (257",
"      <span class=\"nowrap\">",
"       micromol/L)",
"       <br/>",
"       <br/>",
"       The",
"      </span>",
"      threshold for intervention may be lowered for infants closer to 35 weeks GA and raised for those closer to 37",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      weeks GA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants at high risk (35 to 37",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      weeks GA with risk factors), phototherapy is initiated at the following TB values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      24 hours of age: &gt;8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (137",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      48 hours of age: &gt;11",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (188",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      72 hours of age: &gt;13.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (231",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Special circumstances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with clinical jaundice within the first 24 hours frequently have hemolysis. They require immediate evaluation and close surveillance to assess the need for phototherapy.",
"   </p>",
"   <p>",
"    In infants with other causes of increased bilirubin production, such as cephalohematoma or extensive bruising, or in infants suspected of having genetic disorder of bilirubin conjugation (eg, Crigler-Najjar or Gilbert's syndromes), we start phototherapy when the hour-specific TB concentration is in the high intermediate risk zone (&gt;75th percentile) (",
"    <a class=\"graphic graphic_figure graphicRef70863 \" href=\"UTD.htm?18/51/19263\">",
"     figure 2",
"    </a>",
"    ). The risk for severe hyperbilirubinemia and the threshold for intervention based upon the hour-specific bilirubin value may be determined using the newborn hyperbilirubinemia assessment calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Efficacy of phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no data showing that phototherapy improves neurodevelopmental outcome, phototherapy does reduce the likelihood that TB reaches a level associated with an increased risk of kernicterus or at which exchange transfusion is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intensive phototherapy results in a decline of TB of at least 2 to 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (34 to 51",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    within four to six hours. A decrease in TB can be measured as soon as two hours after initiation of treatment. In infants &ge;35 weeks GA, 24 hours of intensive phototherapy can result in a 30 to 40 percent decrease in the initial TB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/22\">",
"     22",
"    </a>",
"    ]. With conventional phototherapy, a decline of 6 to 20 percent can be expected in the first 18 to 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/11,23,24\">",
"     11,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of phototherapy in preventing a rise in TB to the exchange transfusion was demonstrated in a large retrospective cohort study of 281,898 infants born &ge;35 weeks GA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/25\">",
"     25",
"    </a>",
"    ]. Overall, 23 percent of patients received phototherapy within 8 hours after reaching a TB within 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (51",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    of the AAP phototherapy threshold (",
"    <a class=\"graphic graphic_figure graphicRef56490 \" href=\"UTD.htm?27/51/28464\">",
"     figure 1",
"    </a>",
"    ). Only 1.6 percent (354 infants) ever exceeded the AAP exchange threshold (",
"    <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"     figure 3",
"    </a>",
"    ) and only three received exchange transfusions. Multivariate analysis demonstrated that lower GA and birth weight, younger age at the time TB level reached the phototherapy threshold, and a positive direct antiglobulin test (DAT) were associated with an increased risk in reaching the AAP exchange transfusion threshold. Based upon these results, phototherapy was found to be highly effective in preventing TB from rising to the AAP exchange transfusion threshold, especially in full-term infants who are appropriate size for GA, older than 48 hours at the time TB level reached the phototherapy threshold, and are not DAT positive.",
"   </p>",
"   <p>",
"    The rate of decline of TB during phototherapy is affected by a number of factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased irradiance increases the rate of TB decline.",
"     </li>",
"     <li>",
"      Greater surface area exposure to phototherapy increases the rate of TB reduction.",
"     </li>",
"     <li>",
"      The higher the initial TB, the more rapid is the rate of decline (as much as 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [171",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      within a few hours).",
"     </li>",
"     <li>",
"      Phototherapy is less effective in infants whose hyperbilirubinemia is due to cholestasis or hemolysis with a DAT than in infants with other causes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;During phototherapy, the dose of phototherapy (irradiance) and the infant's temperature, hydration status, time of exposure, and TB are monitored. Phototherapy may increase both the body and environmental temperature resulting in increased insensible fluid loss. LED-based devices emit low levels of heat, and thus fluid loss is less of a concern with these devices [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Hydration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The frequency of TB measurements depends upon the initial TB value. When infants are discharged and readmitted with TB values exceeding the 95th percentile for hour-specific TB levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/3\">",
"     3",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef70863 \" href=\"UTD.htm?18/51/19263\">",
"     figure 2",
"    </a>",
"    ), the TB measurement should be repeated two to three hours after initiation of phototherapy to assess the response. When phototherapy is started for a rising TB, which should be always at a lower initial TB values, TB should be measured after 4 to 6 hours and then within 8 to 12 hours, if TB continues to fall.",
"   </p>",
"   <p>",
"    If, despite intensive phototherapy, the TB is at or approaches the threshold for exchange transfusion, blood should be sent for immediate type and cross-match. In addition, if exchange transfusion is being considered, the serum albumin level should be measured so that the serum",
"    <span class=\"nowrap\">",
"     bilirubin/albumin",
"    </span>",
"    <span class=\"nowrap\">",
"     (B/A)",
"    </span>",
"    ratio can be used in conjunction with the TB level and other factors to determine the need for exchange transfusion. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Exchange transfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to maintain adequate hydration and urine output during phototherapy since urinary excretion of lumirubin is the principal mechanism by which phototherapy reduces TB. Thus, during phototherapy, infants should continue oral feedings by breast or bottle. For TB levels that approach the exchange transfusion level, phototherapy should be continuous until the TB has declined to about 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (342",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Thereafter phototherapy can be interrupted for feeding. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Technique'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Intravenous hydration may be necessary to correct hypovolemia in infants with significant volume depletion whose oral intake is inadequate; otherwise, intravenous fluid is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfed infants whose intake is inadequate, with excessive weight loss (&gt;12 percent of BW), or who have evidence of hypovolemia, should receive supplementation with expressed breast milk or formula [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. The temporary interruption of breastfeeding with the substitution of formula may enhance the efficacy of phototherapy by decreasing the enterohepatic circulation of bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/4,26,27\">",
"     4,26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\", section on 'Breastfeeding failure jaundice'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Breastfed infants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If breastfeeding is interrupted, it should be resumed as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants who have been readmitted for phototherapy, we discontinue the phototherapy when the TB has reached 12 to 14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (205 to 239",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    For those who required phototherapy during the birth hospitalization, phototherapy is started at a significantly lower level and, therefore, is stopped at a lower level. For these infants, we generally discontinue phototherapy when the TB has fallen to, or below, the level at which phototherapy was initiated because, by this time, the infant is significantly older and the level for initiation of phototherapy has, consequently, increased.",
"   </p>",
"   <p>",
"    TB is measured 18 to 24 hours after phototherapy is terminated. This is important in infants who need phototherapy during their birth hospitalization but might not be necessary in those who have been readmitted where the risk of rebound is much lower. The readmitted infant should not be kept in the hospital pending measurement of rebound. If necessary, this can be done as an outpatient.",
"   </p>",
"   <p>",
"    Although the value following discontinuation is known as the rebound bilirubin, typically it is lower than the TB value before the initiation of phototherapy.",
"   </p>",
"   <p>",
"    In one study of 161 infants with BW &gt;1800 g, TB was significantly lower 17 hours after termination of phototherapy compared to TB at the time of termination (11.5 versus 12.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [197 versus 209",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in another study of 226 infants, which included 110 neonates with a positive DAT (Coombs test), 13 percent had rebound TB levels &gt;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (257",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/29\">",
"     29",
"    </a>",
"    ]. Risk factors for significant rebound (TB levels &gt;15",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    were initial phototherapy beginning &lt;72 hours of age (odds ratio [OR] 3.61, 95% CI 1.21-10.77), GA &lt;37 weeks (OR 3.21, 95% CI 1.29-7.96), and a positive DAT test (OR 2.44, 95% CI 1.25-4.74).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy is considered safe. Side effects include transient erythematous rashes, loose stools, and hyperthermia. Increased insensible water loss may lead to dehydration. Phototherapy is not associated with an increase in nevus count [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Hydration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The \"bronze baby syndrome\" is an uncommon complication of phototherapy that occurs in some infants with cholestatic jaundice. It is manifested by a dark, grayish-brown discoloration of the skin, serum, and urine [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/31\">",
"     31",
"    </a>",
"    ]. Although the etiology of the bronze appearance remains unknown, it is proposed that the color is a result of impaired biliary excretion of bile pigment photoproducts due to cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The condition gradually resolves without sequelae within several weeks after discontinuation of phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/33\">",
"     33",
"    </a>",
"    ]. It remains controversial whether the bronze pigments have potential neurotoxic consequences.",
"   </p>",
"   <p>",
"    Although the effect of phototherapy on the eyes of infants is not known, animal studies indicate that retinal degeneration may occur after 24 hours of continuous exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/34\">",
"     34",
"    </a>",
"    ]. As a result, it is essential that the eyes of all neonates treated with phototherapy are sufficiently covered to eliminate any potential eye exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     EXCHANGE TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exchange transfusion is used to remove bilirubin from the circulation when intensive phototherapy fails or in infants with signs of bilirubin-induced neurologic dysfunction (BIND). The term ABE, or \"acute bilirubin encephalopathy,\" is used to describe the acute manifestations of overt BIND. The term \"kernicterus\" is used to describe the chronic and permanent sequelae of overt BIND and differentiate these from the subtle signs observed in the syndrome of BIND [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/35\">",
"     35",
"    </a>",
"    ]. Exchange transfusion is especially useful for infants with increased bilirubin production resulting from isoimmune hemolysis because circulating antibodies and sensitized red blood cells also are removed.",
"   </p>",
"   <p>",
"    Although exchange transfusion is both expensive and time consuming, it is the most effective method for removing bilirubin rapidly. Exchange transfusion is indicated when intensive phototherapy cannot prevent a continued rise in the TB or in infants who already display signs indicative of BIND. Exchange transfusions should be performed only by trained personnel in a neonatal or pediatric intensive care unit equipped with full monitoring and resuscitation capabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Neurologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for exchange transfusions has decreased with the prevention of Rh isoimmune hemolytic disease and the systemic application of the AAP guideline for identification and treatment of infants at risk for severe hyperbilirubinemia with phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was best illustrated in a study from a large Northern California health maintenance organization of over 18,000 neonates with a gestational age &ge;35 weeks born between 2005 and 2007 following the initiation of universal screening. In this cohort, only 22 patients (0.1 percent) had a TB level that exceeded the AAP recommended threshold for exchange transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/38\">",
"     38",
"    </a>",
"    ]. Fourteen of these infants were &lt;38 weeks gestation. Only one exchange transfusion was performed and there were no reported sequelae.",
"   </p>",
"   <p>",
"    A similar incidence was reported from a single institution with an exchange transfusion rate of 0.015 percent (8 of 55,128 inborn infants) between 1988 and 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Systematic approach'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Phototherapy indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because exchange transfusions are rarely performed, it is difficult to assess the current risks of morbidity and mortality associated with this procedure. Studies published in 1985 reported mortality rates of 0.3 percent associated with the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] and a significant complication rate of 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/40\">",
"     40",
"    </a>",
"    ]. More recent studies are limited by the number of patients due to the infrequency of the procedure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously mentioned retrospective 21-year review, five of the 141 patients died within seven days of the exchange transfusion; however, none of the deaths appeared to be related to the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/37\">",
"       37",
"      </a>",
"      ]. In this study, the most common complications were thrombocytopenia (38 percent of patients) and hypocalcemia (38 percent).",
"     </li>",
"     <li>",
"      In a retrospective study of 55 infants cared for at two neonatal intensive care units between 1992 and 2002, there was only one death, which was a critically ill preterm infant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/41\">",
"       41",
"      </a>",
"      ]. There was a high rate of complications including thrombocytopenia (44 percent), hypocalcemia (29 percent), and metabolic acidosis (24 percent).",
"     </li>",
"     <li>",
"      In another retrospective study published in 1997, which reviewed 106 patients who underwent exchange transfusion over 15 years from two NICUs, two patients died because of complications attributed to exchange transfusions. These two deaths occurred in patients classified as \"ill,\" having other existing co-morbidities [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infant's circulating blood volume is approximately 80 to 90",
"    <span class=\"nowrap\">",
"     mL/kg.",
"    </span>",
"    A double-volume exchange transfusion (160 to 180",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    replaces approximately 85 percent of the infant's circulating red blood cells with appropriately cross-matched reconstituted (from packed red blood cells and fresh frozen plasma) blood.",
"   </p>",
"   <p>",
"    Irradiated blood products should be used to reduce the risk of graft versus host disease. In infants born to cytomegalovirus (CMV) seronegative mothers, CMV-safe blood products should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The procedure involves placement of at least a central catheter and removing and replacing blood in aliquots that are approximately 10 percent or less of the infant's blood volume. Exchange transfusion usually reduces TB by approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/43\">",
"     43",
"    </a>",
"    ]. Infusion of albumin (1",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    one to two hours before the procedure shifts more extravascular bilirubin into the circulation, allowing removal of more bilirubin, although this has not been shown to decrease the need for repeat exchange transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion on the indications for exchange transfusions for term and late preterm infants (&ge;35 weeks gestational age [GA]) is based upon the clinical practice guideline developed by the AAP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar guidelines for term infants based on TB and postnatal age have been developed by the United Kingdom&rsquo;s National Institute for Health and Clinical Excellence (",
"    <a class=\"external\" href=\"file://www.nice.org.uk/nicemedia/live/12986/48678/48678.pdf\">",
"     NICE guideline for Neonatal Jaundice",
"    </a>",
"    ). National guidelines have also been developed in Norway, which are based on TB values, birth weight (BW), and postnatal age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exchange transfusions are indicated in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jaundiced infants with signs of ABE, such as significant lethargy, hypotonia, poor sucking, or high-pitched cry, irrespective of the TB level. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Acute bilirubin encephalopathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     or",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with a TB greater than threshold values established by the AAP (",
"      <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Infants who have not yet been discharged from the birth hospital, exchange transfusion is recommended if the TB reaches the threshold level despite intensive phototherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infants who have been discharged from the nursery to home and have TB concentrations that are approaching or exceed threshold values for exchange transfusion are initially treated with phototherapy. If TB remains above the threshold TB after about six hours of phototherapy, then exchange transfusion is indicated. This approach reduces the number of infants requiring an invasive therapy that has significant morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk for severe hyperbilirubinemia and the threshold for intervention based upon the hour-specific bilirubin value may be determined using the newborn hyperbilirubinemia assessment calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The following are general age-in-hours specific TB threshold values for exchange transfusion recommended by the AAP based upon gestational age and the presence or absence of risk factors (isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase [G6PD] deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin &lt;3.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [if measured]) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants at low risk (&ge;38 weeks GA and without risk factors), exchange transfusion is indicated for the following TB values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      24 hours of age: &gt;19",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (325",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      48 hours of age: &gt;22",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (376",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      72 hours of age: &gt;24",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (410",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Any age greater than 72 hours: &ge;25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (428",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants at medium risk (&ge;38 weeks GA with risk factors or 35 to 37",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      weeks GA without risk factors), exchange transfusion is indicated for the following TB values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      24 hours of age: &gt;16.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (282",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      48 hours of age: &gt;19",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (325",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      &ge;72 hours of age: &gt;21",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (359",
"      <span class=\"nowrap\">",
"       micromol/L)",
"       <br/>",
"       <br/>",
"       The",
"      </span>",
"      threshold for intervention may be lowered for infants closer to 35 weeks GA and raised for those closer to 37",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      weeks GA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants at high risk (35 to 37",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      weeks GA with risk factors), exchange transfusion is indicated for the following TB values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      24 hours of age: &gt;15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (257",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      48 hours of age: &gt;17",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (291",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      &ge;72 hours of age: &gt;18.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (316",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants who are close or meet the criteria for exchange transfusion should be directly admitted or transferred to the neonatal or pediatric intensive care unit. Referral should not be through an emergency department, because this delays the initiation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/44\">",
"     44",
"    </a>",
"    ]. Upon admission, a type and cross-match and placement of umbilical catheter are performed promptly, so that exchange transfusion can be started as quickly as possible. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Technique'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Special circumstances",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with isoimmune hemolytic disease and rising TB despite intensive phototherapy, administration of intravenous immunoglobulin (IVIG) is recommended since it may avoid the need for exchange transfusion. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Intravenous immunoglobulin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Exchange transfusion should be considered in infants receiving phototherapy who develop the \"bronze baby\" syndrome, if phototherapy has been ineffective in reducing TB below the threshold range for intensive phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Bilirubin/albumin ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     bilirubin/albumin",
"    </span>",
"    <span class=\"nowrap\">",
"     (B/A)",
"    </span>",
"    ratio can be used as an additional factor in determining the need for exchange transfusion; it should not be used alone but in conjunction with TB values [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2,45\">",
"     2,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link&amp;anchor=H21#H21\">",
"     \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Bilirubin/albumin ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants &ge;38 weeks gestation, consider exchange transfusion when TB",
"      <span class=\"nowrap\">",
"       (mg/dL)/albumin",
"      </span>",
"      <span class=\"nowrap\">",
"       (g/dL)",
"      </span>",
"      ratio is &gt;8.0 or TB",
"      <span class=\"nowrap\">",
"       (micromol/L)/albumin",
"      </span>",
"      <span class=\"nowrap\">",
"       (micromol/L)",
"      </span>",
"      is &gt;0.94.",
"     </li>",
"     <li>",
"      For infants 35 to 37",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      weeks and well or &ge;38 weeks with high risk (eg, isoimmune hemolytic disease or G6PD deficiency), consider exchange transfusion when TB",
"      <span class=\"nowrap\">",
"       (mg/dL)/albumin",
"      </span>",
"      <span class=\"nowrap\">",
"       (g/dL)",
"      </span>",
"      ratio is &gt;7.2 or TB",
"      <span class=\"nowrap\">",
"       (micromol/L)/albumin",
"      </span>",
"      <span class=\"nowrap\">",
"       (micromol/L)",
"      </span>",
"      is &gt;0.84.",
"     </li>",
"     <li>",
"      For infants 35 to 37",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      weeks with high risk (eg, isoimmune hemolytic disease or G6PD deficiency), consider exchange transfusion when TB",
"      <span class=\"nowrap\">",
"       (mg/dL)/albumin",
"      </span>",
"      <span class=\"nowrap\">",
"       (g/dL)",
"      </span>",
"      ratio is &gt;6.8 or TB",
"      <span class=\"nowrap\">",
"       (micromol/L)/albumin",
"      </span>",
"      <span class=\"nowrap\">",
"       (micromol/L)",
"      </span>",
"      is &gt;0.80.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a successful procedure, TB typically falls to approximately one-half of the pre-exchange value, then increases to approximately two-thirds of that of the pre-exchange concentration because there is re-equilibration between extravascular and vascular bilirubin.",
"   </p>",
"   <p>",
"    Observational studies report that exchange transfusions decreased the risk for prominent neurologic abnormalities in term infants with TB &gt;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (342",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/46\">",
"     46",
"    </a>",
"    ] and improved abnormal brainstem auditory evoked response (BAER) in infants with severe hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks of exchange transfusion result from the use of blood products and from the procedure itself. Complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood-borne infection",
"     </li>",
"     <li>",
"      Thrombocytopenia and coagulopathy",
"     </li>",
"     <li>",
"      Graft-versus-host disease",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis",
"     </li>",
"     <li>",
"      Portal vein thrombosis",
"     </li>",
"     <li>",
"      Electrolyte abnormalities (eg, hypocalcemia and hyperkalemia)",
"     </li>",
"     <li>",
"      Cardiac arrhythmias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=see_link\">",
"     \"Administration and complications of red cell transfusion in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As previously mentioned, the current morbidity and mortality rates associated with exchange transfusions are not known because the procedure is rarely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/36\">",
"     36",
"    </a>",
"    ]. Studies published in 1985 reported mortality rates of 0.3 percent associated with exchange transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] and a significant complication rate of 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/40\">",
"     40",
"    </a>",
"    ]. In a retrospective review of 15 years experience from 1981 to 1995 at two academic medical centers, 1 of 81 healthy infants developed necrotizing enterocolitis after exchange transfusion and none died [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic agents, including IVIG,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    , and metalloporphyrins can be used to inhibit hemolysis, increase conjugation and excretion of bilirubin, increase bile flow, or inhibit the formation of bilirubin, respectively. However, currently only IVIG is used to treat unconjugated hyperbilirubinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVIG can reduce the need for exchange transfusion in infants with hemolytic disease caused by Rh or ABO incompatibility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Several systematic reviews and meta-analyses have shown that infants who received IVIG compared with the control group had a lower rate of exchange transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. Avoiding exchange transfusion reduces the risk of any of its potential adverse effects; as a result, the administration of IVIG should be considered based on the relative benefits and risks of the two interventions.",
"   </p>",
"   <p>",
"    IVIG (dose 0.5 to 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    over two hours) is recommended in infants with isoimmune hemolytic disease if the TB is rising despite intensive phototherapy or is within 2 or 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (34 to 51",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    of the threshold for exchange transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2,55\">",
"     2,55",
"    </a>",
"    ]. The dose may be repeated in 12 hours if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Exchange transfusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The mechanism is uncertain, but IVIG is thought to inhibit hemolysis by blocking antibody receptors on red blood cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Phenobarbital",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    increases the conjugation and excretion of bilirubin and decreases postnatal TB levels when given to pregnant women or infants. However, prenatal administration of phenobarbital may adversely affect cognitive development and reproduction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. As a result, phenobarbital is",
"    <strong>",
"     not",
"    </strong>",
"    routinely used to treat indirect neonatal hyperbilirubinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/19/13621?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    increases bile flow and helps to lower TB levels. It is also useful in the treatment of cholestatic jaundice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Metalloporphyrins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic metalloporphyrins, such as tin mesoporphyrin (SnMP), reduce bilirubin production by competitive inhibition of heme oxygenase [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/59-66\">",
"     59-66",
"    </a>",
"    ]. There are limited data upon the safety of SnMP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/66\">",
"     66",
"    </a>",
"    ], and SnMP is not available for general use.",
"   </p>",
"   <p>",
"    In one report, term infants with G6PD deficiency given SnMP at approximately 27 hours-of-age had lower and earlier peak TB values than did control infants with and without G6PD deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/59\">",
"     59",
"    </a>",
"    ]. No treated infant required phototherapy, compared to 31 and 15 percent in the controls with and without G6PD deficiency, respectively.",
"   </p>",
"   <p>",
"    In a systematic review of three randomized trials including 170 infants, short-term benefits of metalloporphyrin therapy included lower maximum TB, lower frequency of severe hyperbilirubinemia, decreased need for phototherapy, and shorter duration of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/60,61,65\">",
"     60,61,65",
"    </a>",
"    ]. None of the enrolled infants required exchange transfusion. None of the studies reported on kernicterus, death, or long-term neurodevelopmental outcome.",
"   </p>",
"   <p>",
"    SnMP is not approved for use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;When infants with hyperbilirubinemia are identified and treated appropriately, the outcome is excellent with minimal or no additional risk for adverse neurodevelopmental sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. This was illustrated in a prospective cohort control study of 140 infants with TB levels &ge;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (428",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    identified from a cohort of 106,627 term or late preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/67\">",
"     67",
"    </a>",
"    ]. The study group also included 10 infants with TB &ge;30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (513",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Treatment of hyperbilirubinemia included phototherapy in 136 cases and exchange transfusions in five cases. The hyperbilirubinemic infants compared with the control group had a greater proportion of infants who were born &lt;38 weeks gestational age, Asian, and were exclusively breastfed during birth hospitalization. At two-year follow-up, results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no reports of kernicterus in either the hyperbilirubinemic or control group.",
"     </li>",
"     <li>",
"      Formal cognitive testing was performed in 82 children with neonatal hyperbilirubinemia and 168 control children at 2 and 6 years of age. There was no difference between patients with hyperbilirubinemia and matched controls in cognitive testing, reported behavioral problems and frequency of parental concerns.",
"     </li>",
"     <li>",
"      On physical examination, patients with hyperbilirubinemia compared to control patients had a lower prevalence of abnormal neurologic findings (14 versus 29 percent). The degree and duration of hyperbilirubinemia had no effect on these outcomes.",
"     </li>",
"     <li>",
"      In a subset analysis, nine patients with hyperbilirubinemia and a positive direct antiglobulin test (DAT, Coombs test) had lower scores on cognitive testing than other patients with hyperbilirubinemia with a negative DAT. There was no difference between these two hyperbilirubinemic groups regarding the presence of an abnormal neurologic finding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a follow-up study from the Collaborative Perinatal Project of children (n = 46,872) at seven and eight years of age who were born &ge;36 weeks gestation with a birth weight &ge;2000 g between 1959 and 1966 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/68\">",
"     68",
"    </a>",
"    ]. Results showed an adverse effect on cognitive testing was only seen in children who had a TB &ge;25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (428",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and a positive DAT result as neonates. TB in the absence of a positive DAT had no effect on cognitive testing.",
"   </p>",
"   <p>",
"    Population-based studies have also reported observing no or limited chronic neurologic effects of severe hyperbilirubinemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of all live-born births in Denmark from 2004 to 2007, results based on parental survey demonstrated no difference in development at one to five years of age between infants with at least one neonatal measurement of TB &ge;25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (428",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      from controls matched by gender, age, gestational age, and municipality of residency [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from Nova Scotia of 61,238 infants born between 1994 and 2000, there were no reported cases of kernicterus after implementation of treatment guidelines for hyperbilirubinemia in term and late preterm infants [",
"      <a class=\"abstract\" href=\"UTD.htm?20/59/21434/abstract/69\">",
"       69",
"      </a>",
"      ]. There were no differences in the overall neurologic composite outcome (cerebral palsy, developmental delay, hearing and vision abnormalities, attention-deficit disorder, and autism) in infants with severe (TB &ge;19",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      325",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or moderate (TB &ge;19",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      325",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      hyperbilirubinemia compared to those without hyperbilirubinemia. However, subset analysis for each neurologic outcome suggested that some neurologic impairment might be associated with hyperbilirubinemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Neurologic dysfunction'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results support the AAP treatment guidelines for the management of hyperbilirubinemia in term and late preterm infants, especially the use of lower threshold values for intervention in infants with a positive DAT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"       \"Patient information: Jaundice in babies (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=see_link\">",
"       \"Patient information: Jaundice in newborn infants (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A list of frequently asked questions and answers for parents is available through the American Academy of Pediatrics (AAP):",
"    <a class=\"external\" href=\"file://www.healthychildren.org/English/news/Pages/Jaundice-in-Newborns.aspx\">",
"     file://www.healthychildren.org/English/news/Pages/Jaundice-in-Newborns.aspx",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of neonatal hyperbilirubinemia is focused upon prevention of severe hyperbilirubinemia in identified high-risk infants and reduction of total serum or plasma bilirubin (TB) in infants with severe hyperbilirubinemia. The risk for severe hyperbilirubinemia and the threshold for intervention based upon the hour-specific bilirubin value may be determined using the newborn hyperbilirubinemia assessment calculator (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=see_link\">",
"       \"Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phototherapy is the most commonly used intervention to treat and prevent severe hyperbilirubinemia. It is a safe and effective method to reduce the toxicity of bilirubin and increase its elimination. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phototherapy has been shown to reduce the risk of TB values reaching a level associated with kernicterus and reduces the number of infants who reach a TB threshold for exchange transfusions. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Efficacy of phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend phototherapy as the initial therapy to treat hyperbilirubinemia in term and late preterm infants (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In our practice, we initiate phototherapy based upon the guidelines developed by the American Academy of Pediatrics (AAP). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants with hyperbilirubinemia due to isoimmune hemolytic disease, we recommend the administration of intravenous immunoglobulin (IVIG) if TB is rising in spite of intensive phototherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). IVIG administration may avoid the need of exchange transfusion in these patients. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Intravenous immunoglobulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exchange transfusion is the most effective method to lower TB. Although it is difficult to ascertain the current risk of morbidity and mortality, there are reported serious complications and deaths associated with the procedure.",
"     </li>",
"     <li>",
"      We recommend exchange transfusions in infants who exhibit clinical findings of bilirubin-induced neurologic dysfunction (BIND) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest exchange transfusion for infants with TB that exceed threshold TB values based upon the guideline developed by the AAP who have failed initial intensive phototherapy (",
"      <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"       figure 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Exchange transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When infants with hyperbilirubinemia are identified and treated appropriately, the outcome is excellent with minimal or no additional risk for adverse neurodevelopmental sequelae. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/1\">",
"      Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001; 344:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/2\">",
"      American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/3\">",
"      Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/4\">",
"      Martinez JC, Maisels MJ, Otheguy L, et al. Hyperbilirubinemia in the breast-fed newborn: a controlled trial of four interventions. Pediatrics 1993; 91:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/5\">",
"      Brown AK, Kim MH, Wu PY, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics 1985; 75:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/6\">",
"      Ennever JF, Costarino AT, Polin RA, Speck WT. Rapid clearance of a structural isomer of bilirubin during phototherapy. J Clin Invest 1987; 79:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/7\">",
"      Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current methods and future directions. Semin Perinatol 2004; 28:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/8\">",
"      Eggert P, Stick C, Schr&ouml;der H. On the distribution of irradiation intensity in phototherapy. Measurements of effective irradiance in an incubator. Eur J Pediatr 1984; 142:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/9\">",
"      Maisels MJ. Why use homeopathic doses of phototherapy? Pediatrics 1996; 98:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/10\">",
"      Djokomuljanto S, Quah BS, Surini Y, et al. Efficacy of phototherapy for neonatal jaundice is increased by the use of low-cost white reflecting curtains. Arch Dis Child Fetal Neonatal Ed 2006; 91:F439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/11\">",
"      Holtrop PC, Madison K, Maisels MJ. A clinical trial of fiberoptic phototherapy vs conventional phototherapy. Am J Dis Child 1992; 146:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/12\">",
"      Vreman HJ, Wong RJ, Stevenson DK, et al. Light-emitting diodes: a novel light source for phototherapy. Pediatr Res 1998; 44:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/13\">",
"      Seidman DS, Moise J, Ergaz Z, et al. A new blue light-emitting phototherapy device: a prospective randomized controlled study. J Pediatr 2000; 136:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/14\">",
"      Kumar P, Chawla D, Deorari A. Light-emitting diode phototherapy for unconjugated hyperbilirubinaemia in neonates. Cochrane Database Syst Rev 2011; :CD007969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/15\">",
"      Tridente A, De Luca D. Efficacy of light-emitting diode versus other light sources for treatment of neonatal hyperbilirubinemia: a systematic review and meta-analysis. Acta Paediatr 2012; 101:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/16\">",
"      Bhutani VK, Committee on Fetus and Newborn, American Academy of Pediatrics. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2011; 128:e1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/17\">",
"      Morris BH, Tyson JE, Stevenson DK, et al. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study. J Perinatol 2013; 33:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/18\">",
"      CREMER RJ, PERRYMAN PW, RICHARDS DH. Influence of light on the hyperbilirubinaemia of infants. Lancet 1958; 1:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/19\">",
"      Bratlid D, Nakstad B, Hansen TW. National guidelines for treatment of jaundice in the newborn. Acta Paediatr 2011; 100:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/20\">",
"      Ip S, Chung M, Kulig J, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004; 114:e130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/21\">",
"      John E. Phototherapy in neonatal hyperbilirubinaemia. Aust Paediatr J 1975; 11:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/22\">",
"      Maisels MJ, Kring E. Rebound in serum bilirubin level following intensive phototherapy. Arch Pediatr Adolesc Med 2002; 156:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/23\">",
"      Garg AK, Prasad RS, Hifzi IA. A controlled trial of high-intensity double-surface phototherapy on a fluid bed versus conventional phototherapy in neonatal jaundice. Pediatrics 1995; 95:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/24\">",
"      Tan KL. Comparison of the efficacy of fiberoptic and conventional phototherapy for neonatal hyperbilirubinemia. J Pediatr 1994; 125:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/25\">",
"      Newman TB, Kuzniewicz MW, Liljestrand P, et al. Numbers needed to treat with phototherapy according to American Academy of Pediatrics guidelines. Pediatrics 2009; 123:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/26\">",
"      Osborn LM, Bolus R. Breast feeding and jaundice in the first week of life. J Fam Pract 1985; 20:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/27\">",
"      Amato M, Howald H, von Muralt G. Interruption of breast-feeding versus phototherapy as treatment of hyperbilirubinemia in full-term infants. Helv Paediatr Acta 1985; 40:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/28\">",
"      Yetman RJ, Parks DK, Huseby V, et al. Rebound bilirubin levels in infants receiving phototherapy. J Pediatr 1998; 133:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/29\">",
"      Kaplan M, Kaplan E, Hammerman C, et al. Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia. Arch Dis Child 2006; 91:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/30\">",
"      Mah&eacute; E, Beauchet A, Aegerter P, Saiag P. Neonatal blue-light phototherapy does not increase nevus count in 9-year-old children. Pediatrics 2009; 123:e896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/31\">",
"      Rubaltelli FF, Da Riol R, D'Amore ES, Jori G. The bronze baby syndrome: evidence of increased tissue concentration of copper porphyrins. Acta Paediatr 1996; 85:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/32\">",
"      McDonagh AF. Bilirubin, copper-porphyrins, and the bronze-baby syndrome. J Pediatr 2011; 158:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/33\">",
"      Tan KL, Jacob E. The bronze baby syndrome. Acta Paediatr Scand 1982; 71:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/34\">",
"      Messner KH, Maisels MJ, Leure-DuPree AE. Phototoxicity to the newborn primate retina. Invest Ophthalmol Vis Sci 1978; 17:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/35\">",
"      Johnson L, Bhutani VK. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol 2011; 35:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/36\">",
"      McDonagh AF, Maisels MJ. Bilirubin unbound: d&eacute;j&agrave; vu all over again? Pediatrics 2006; 117:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/37\">",
"      Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics 2007; 120:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/38\">",
"      Flaherman VJ, Kuzniewicz MW, Escobar GJ, Newman TB. Total serum bilirubin exceeding exchange transfusion thresholds in the setting of universal screening. J Pediatr 2012; 160:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/39\">",
"      Keenan WJ, Novak KK, Sutherland JM, et al. Morbidity and mortality associated with exchange transfusion. Pediatrics 1985; 75:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/40\">",
"      Hovi L, Siimes MA. Exchange transfusion with fresh heparinized blood is a safe procedure. Experiences from 1 069 newborns. Acta Paediatr Scand 1985; 74:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/41\">",
"      Patra K, Storfer-Isser A, Siner B, et al. Adverse events associated with neonatal exchange transfusion in the 1990s. J Pediatr 2004; 144:626.",
"     </a>",
"    </li>",
"    <li>",
"     Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 1997; 99:e7 www.pediatrics.org/cgi/content/full/99/5/e7 (Accessed on July 14, 2007).",
"    </li>",
"    <li>",
"     Wong RJ, DeSandre GH, Sibley E, Stevenson DK. Neonatal jaundice and liver disease. In: Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant, 8th ed, Martin RJ, Klaus MH, Fanaroff AA, Walsh MC (Eds), Mosby and Elsevier, Philadelphia 2006. p.1446.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/44\">",
"      Garland JS, Alex C, Deacon JS, Raab K. Treatment of infants with indirect hyperbilirubinemia. Readmission to birth hospital vs nonbirth hospital. Arch Pediatr Adolesc Med 1994; 148:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/45\">",
"      Ahlfors CE. Criteria for exchange transfusion in jaundiced newborns. Pediatrics 1994; 93:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/46\">",
"      Ozmert E, Erdem G, Top&ccedil;u M, et al. Long-term follow-up of indirect hyperbilirubinemia in full-term Turkish infants. Acta Paediatr 1996; 85:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/47\">",
"      Funato M, Teraoka S, Tamai H, Shimida S. Follow-up study of auditory brainstem responses in hyperbilirubinemic newborns treated with exchange transfusion. Acta Paediatr Jpn 1996; 38:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/48\">",
"      Hung KL. Auditory brainstem responses in patients with neonatal hyperbilirubinemia and bilirubin encephalopathy. Brain Dev 1989; 11:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/49\">",
"      Kuriyama M, Tomiwa K, Konishi Y, Mikawa H. Improvement in auditory brainstem response of hyperbilirubinemic infants after exchange transfusions. Pediatr Neurol 1986; 2:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/50\">",
"      Nwaesei CG, Van Aerde J, Boyden M, Perlman M. Changes in auditory brainstem responses in hyperbilirubinemic infants before and after exchange transfusion. Pediatrics 1984; 74:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/51\">",
"      Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 1997; 99:E7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/52\">",
"      Alpay F, Sarici SU, Okutan V, et al. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 1999; 88:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/53\">",
"      Da��o��lu T, Ovali F, Samanci N, Bengisu E. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res 1995; 23:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/54\">",
"      Hammerman C, Kaplan M, Vreman HJ, Stevenson DK. Intravenous immune globulin in neonatal ABO isoimmunization: factors associated with clinical efficacy. Biol Neonate 1996; 70:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/55\">",
"      Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2003; 88:F6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/56\">",
"      Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002; :CD003313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/57\">",
"      Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995; 274:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/58\">",
"      Yaffe SJ, Dorn LD. Effects of prenatal treatment with phenobarbital. Dev Pharmacol Ther 1990; 15:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/59\">",
"      Kappas A, Drummond GS, Valaes T. A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns. Pediatrics 2001; 108:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/60\">",
"      Kappas A, Drummond GS, Henschke C, Valaes T. Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns. Pediatrics 1995; 95:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/61\">",
"      Martinez JC, Garcia HO, Otheguy LE, et al. Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. Pediatrics 1999; 103:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/62\">",
"      Kappas A, Drummond GS. Control of heme metabolism with synthetic metalloporphyrins. J Clin Invest 1986; 77:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/63\">",
"      Reddy P, Najundaswamy S, Mehta R, et al. Tin-mesoporphyrin in the treatment of severe hyperbilirubinemia in a very-low-birth-weight infant. J Perinatol 2003; 23:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/64\">",
"      Valaes T, Petmezaki S, Henschke C, et al. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin. Pediatrics 1994; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/65\">",
"      Suresh GK, Martin CL, Soll RF. Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates. Cochrane Database Syst Rev 2003; :CD004207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/66\">",
"      Wong RJ, Bhutani VK, Vreman HJ, et al. Tin mesoporphyrin for the prevention of severe neonatal hyperbilirubinemia. NeoReviews 2007; 8:e77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/67\">",
"      Newman TB, Liljestrand P, Jeremy RJ, et al. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med 2006; 354:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/68\">",
"      Kuzniewicz M, Newman TB. Interaction of hemolysis and hyperbilirubinemia on neurodevelopmental outcomes in the collaborative perinatal project. Pediatrics 2009; 123:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/69\">",
"      Jangaard KA, Fell DB, Dodds L, Allen AC. Outcomes in a population of healthy term and near-term infants with serum bilirubin levels of &gt;or=325 micromol/L (&gt;or=19 mg/dL) who were born in Nova Scotia, Canada, between 1994 and 2000. Pediatrics 2008; 122:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/59/21434/abstract/70\">",
"      Vandborg PK, Hansen BM, Greisen G, et al. Follow-up of neonates with total serum bilirubin levels &ge; 25 mg/dL: a Danish population-based study. Pediatrics 2012; 130:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5063 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21434=[""].join("\n");
var outline_f20_59_21434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevention of hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment of severe hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHOTOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14988413\">",
"      - Light sources and devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Home phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sunlight exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14988405\">",
"      - Selection of light source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Phototherapy indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy of phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      EXCHANGE TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Bilirubin/albumin ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PHARMACOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Phenobarbital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Metalloporphyrins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5063|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28464\" title=\"figure 1\">",
"      TSB guideline phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/51/19263\" title=\"figure 2\">",
"      Nomogram of hour-specific total bilirubin in term infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/44/21184\" title=\"figure 3\">",
"      TSB guide exchange transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/63/5109?source=related_link\" title=\"calculator 1\">",
"      Calculator: Newborn hyperbilirubinemia assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11672?source=related_link\">",
"      Administration and complications of red cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11898?source=related_link\">",
"      Evaluation of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19400?source=related_link\">",
"      Hyperbilirubinemia in the premature infant (less than 35 weeks gestation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=related_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=related_link\">",
"      Patient information: Jaundice in newborn infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_59_21435="Hypothermia PI";
var content_f20_59_21435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypothermia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Body temperature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        98.6&deg;F (37&deg;C)",
"       </td>",
"       <td>",
"        (Normal body temperature)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90 to 95&deg;F (32 to 35&deg;C)",
"       </td>",
"       <td>",
"        Mild hypothermia",
"       </td>",
"       <td>",
"        Shivering, goose bumps, bluish skin, confusion, trouble speaking, memory problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        82 to 90&deg;F (28 to 32&deg;C)",
"       </td>",
"       <td>",
"        Moderate hypothermia",
"       </td>",
"       <td>",
"        Shivering stops, feeling very sleepy, seeing things that are not there (hallucinations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less than 82&deg;F (28&deg;C)",
"       </td>",
"       <td>",
"        Severe hypothermia",
"       </td>",
"       <td>",
"        Stiffness, passing out, coma, breathing stops, heart stops",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal body temperature is around 98.6&deg;F (37&deg;C). Hypothermia is when body temperature drops below 95&deg;F (35&deg;C). This table shows the temperatures at which hypothermia is called mild, moderate, and severe, and lists some of the symptoms that happen with each stage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21435=[""].join("\n");
var outline_f20_59_21435=null;
var title_f20_59_21436="Cairo-Bishop TLS grading";
var content_f20_59_21436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cairo-Bishop clinical tumor lysis syndrome definition* and grading",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Complication",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"6\">",
"       Grade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       0",
"      </td>",
"      <td class=\"subtitle2\">",
"       1",
"      </td>",
"      <td class=\"subtitle2\">",
"       2",
"      </td>",
"      <td class=\"subtitle2\">",
"       3",
"      </td>",
"      <td class=\"subtitle2\">",
"       4",
"      </td>",
"      <td class=\"subtitle2\">",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Creatinine&bull;&Delta;",
"      </td>",
"      <td>",
"       &le;1.5 x ULN",
"      </td>",
"      <td>",
"       1.5 x ULN",
"      </td>",
"      <td>",
"       &gt;1.5-3.0 x ULN",
"      </td>",
"      <td>",
"       &gt;3.0-6.0 x ULN",
"      </td>",
"      <td>",
"       &gt;6.0 x ULN",
"      </td>",
"      <td>",
"       Death",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cardiac arrhythmia&bull;",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       Intervention not indicated",
"      </td>",
"      <td>",
"       Nonurgent medical intervention indicated",
"      </td>",
"      <td>",
"       Symptomatic and incompletely controlled medically or controlled with device (eg, defibrillator)",
"      </td>",
"      <td>",
"       Life-threatening (eg, arrhythmia associated with HF, hypotension, syncope, shock)",
"      </td>",
"      <td>",
"       Death",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seizure&bull;",
"      </td>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       One brief, generalized seizure; seizure(s) well controlled by anticonvulsants or infrequent focal motor seizures not interfering with ADL",
"      </td>",
"      <td>",
"       Seizure in which consciousness is altered; poorly controlled seizure disorder; with breakthrough generalized seizures despite medical intervention",
"      </td>",
"      <td>",
"       Seizure of any kind which are prolonged, repetitive or difficult to control (eg, status epilepticus, intractable epilepsy)",
"      </td>",
"      <td>",
"       Death",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ULN: upper limit of normal; HF: heart failure; ADL: activities of daily living.",
"     <br>",
"      * Clinical tumor lysis syndrome defined as laboratory tumor lysis syndrome plus at least one clinical complication",
"      <br>",
"       &bull; Not directly or probably attributable to therapeutic agent.",
"       <br>",
"        &Delta; If no institutional ULN is specified, age/sex ULN creatinine may be defined as follows: &gt;1 to &lt;12 years of age, both male and female, 61.6 mmol/L; &ge;12 to &lt;16 years, both male and female, 88 mmol/L; &ge;16 years, female 105.6 mmol/L, male 114.4 mmol/L.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008; 26:2767. Copyright &copy; 2008 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21436=[""].join("\n");
var outline_f20_59_21436=null;
var title_f20_59_21437="Valt equation";
var content_f20_59_21437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Equation for calculating voltage difference of alternation (V alt)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 92px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21437=[""].join("\n");
var outline_f20_59_21437=null;
var title_f20_59_21438="HP caused by Cladosporium";
var content_f20_59_21438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypersensitivity pneumonitis caused by Cladosporium in an enclosed hot-tub",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 344px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spirometry from a 48-year-old woman with an 18-month history of malaise and chronic cough, intermittent episodes of fever, chills, and pneumonic infiltrates. Removal of the patient from the home environment led to a resolution of symptoms within&nbsp;one week. Within&nbsp;four hours of reexposure to the hot-tub room, symptoms and signs and changes in leukocyte count and spirometric values again occurred. Bronchial provocation with a commercial extract of C. cladosporioides led to a similar pattern&nbsp;five hours after the initial challenge.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Jacobs RL, Thorner RE, Holcomb JR, et al. Ann Intern Med 1986; 105:204.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21438=[""].join("\n");
var outline_f20_59_21438=null;
var title_f20_59_21439="Scoliosis PI";
var content_f20_59_21439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scoliosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 406px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGWAQoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlVTjP+e9PA4p+2nBa5CRgXjoKeBkYp6rS7aQiJvl+lU5pBnDZzjr6VanPy9cA8VkzPtLuTnPb2qZMqJla9cNuEbEhQM8f/rrk558lseuM4rb1d9ztJIfvcBfasMw7kbZ3OacTZRKBKsCGzn61AVwWIB6Vc+zNkgmhodikk8CtFKw7FezhNw2DyFGfSr7K8QBPU8Yz0qC0+WQOmcVfuZAYScZPpQ3cpIbG5MWFJ3Dvmm+f5UbM4z9Saba5dMqeccj3pt1H5wUDqTUNahYcdRmHly7zn+EelW4rySUS7y+7GetZqRNvCuOBjIrSgQrcELwSOPpUuKJZNbgXUUYUkMOgJ6VYjsIom8yZt0gIIAJxVW1iaNzIjZw2GWujWeH7MC0asT+dZSk0My5opb6YNM+FB7twBWRfRCK5dEOQh3KfWtq6kSWQIg2f1rF1Zm+1hSpzjHFOne4jdsXE8CSeowasBQDkVkaBLtZ4W/CtvGRVS0MupYt2C4buK6ezYPbq3f8AGuVt1y4HrXUWAxCq1UWQyfbnkEg+tG04Gck1Nt7Um2qJICvPemlanxzSbeaBlcrTGWrLAVGVpgVivtTHTirLCo2FMCqy4U49KRl+Y896nZeDn0pjY3H60XGXQvNPC8VIE4/z708LUiIlXmlIFTBKZNhSCKQzPuRubbjgHNY86fugxGCMjH41tTqxlJBrKvFAWQA4A5+tZtlROS1QeZJjsKyicPg9BVzVJX81yvQVlu+TnvWsdjoWwssucgHimzyAAIPmGKiO7J7GkiQzTIAO/NUJlqOQWwiYgfOORUV1LvUYHQ/nRfurXGwEYHy/SnSoGtI2iOWQ4P09aXW4XEsQyksmcg54NaNs0NzuinQZPzKw4wfQ1kxStC+5flHv3q2k6STI6gIP4gehpT7gacduJE8sqwkHGRyDVgWkhjDiNyVG0/KenrVm2024uFFxY/OAMkIwH860bWa5A2eZIhxh0I/r0rmlJgcbeTyW9yJYzyflIPepV1NyOMBfT0rW1az8x9sm0MR8jYwCPSuZuIXgcrIu1h+tbQamgNeC7jldQ/AJ+9TvEUTJBG6HIzw3esVC24N0+tbl9J59lHGclgASe1DVmBh2V1JFcKxOCDXb2s3nxqxHLVxKQZulVgSc9q7yxgMcSqRjAoqtGciWEbWBIroNLfecVjhCOta+jr+9xUxZkzYK9aTbVgpSbK0IKxWmlas7OaRkGKAKpWkKirJTjpTSlMCmy+lRspq4U56VGye1Aymy1C6/O3Perxj9qhdfnbjvQO5fC8Y704LxUgXmnBaQhm04461VuvlwSKv49KqXCfIfzqWUU502oV/Gue1SVVXrye1dLJkRZAy2ORXI6uNzFyQBngY61BcTl9Qx8ykY96ySvzDB6Vq6jneSf4u1Zzj5sDrWsNjdEMp5FSWBwXkI9vpSOhJGOtWo0S3iIPLGre1kIpSATTBQQGPygmlUPZzFJ1Oc8+hFRXK7JQRzmtWzZdRQWl2QsqD91J6+1JuyEXodN0/VLc/ZbhoZgOEk6ZrMm0+S1doLgYbsexqMxSW8pXcEdGwa2YrsatprRykC6gzgnqwrLVPXYZk2F7NZMUErBDxwxrTtL6SfdukbcnK89aw7kcgngkcn0NPtOHbBPTORWnJGSuB2/n2t3p4W5HUcH+61c9dlgrQTATAcqx6ge1QwSy+UUY7gOafHNypbkA4HtWcY8rBoht9PDnzEYFQcFWPNaKRh4jGV+bp14ouQIo1uIP8AVn73samtAuY0U5LHOaTfUCtotgxuDI4+WNsV2Kxjrn8Kis7ZUjGAPm5q8IxnNQ5XMJy1I0jyQMVq6Wm2fkVThQBxmte2jAkXbTiQaRFJtqZFBFOCVqIrlRSFOKnZfSm43LkHIoAgK00pmrG3IpNoFAFVk9qYye1WitMK0DKbpwc1A6fO31q+yjmoHA3t9aYi1jn/AD70oHNP2/5/OlC0MBmKinQtnPYVaC5OKilXk4NQUZc+NrLnBArl9XjDTyccRrn8a6qRdpcMPmfjPpXMeIWRLqRUOSy8/lUlxOIvmLEv79KpuwOxh3q0/wC8MqHtVIED9337VpE3Q8sAxPbtUMjsSw9elNQMQ6MM80qA7AAeBWlxPcgZST15qwdwjUDICcgj1qURZIb+E1dlt9tqxA56/hScirGeLkysGlGX6E+vvUls3lXXmJwaVLVnKsoyMUvkskoyOvNJtPQLD7qHexZPuk7j+NV4wUbZ3Hf2rTsHBlKSAelK1oFu9rHIJxmoU7aCZTtrgLOVznJx+FWp4TF5h6fxCsq4iNteSgHIVuK2LedJ7OTd1Vc5qpLRMFsTaRchspIA0MoIIPY1aihNnKFcbgDmNvUGsHTZHSQK3+8prrrCWO6jiEi5CtyPQ+1ZT0EdDbIPLQ46qKnCcc1WtblGujbKS0ijJOOAKvbazOWW5GBgg4ra04hyCaygtXbFzGRTixG4g+YipMetMt23jNT7a1vcZEVFM244A4qwV4ppWgZDtpjLVjbTCtAEBWmFeeasFTmmleeaoCsyg5qu6fO31q6VqFo2LEgcGgCbHH+felC05Rx/n3p4FAEe2myA8YAOanAxUMgK4yCR1qQKVwoEjE8AKT7V5vq9wZruaTPDfKv0Fd/rokktOBsVjjHc15lrL5lYJjCipW5rTWpmja9wQCAap6rbtFMJVBwRziqsszK5I4J5rXsZFvo/KZtrY6GtPh1NjLgP75sYy4zzTo2Ec2HAKHvRcWslrOyOCCrd6uC0M8e4EdORV3QkS26K0gCnKk8CtB4N1tIn8aHcP9oelZVorxy7DwR+FWBeva3yljvXPNS0UT6UAwIbqpyR7U2a3zMjLyDkfhmorW48rUGK42kEH8atXDFIA5/gYCkwM7JttUeInjqKuXLY8th1DA1W8QLt1GGVRjfGDn1qYsJLSMn72cYpTjZXAz9UXzpSyjneAaWHMVvIBxkfpU7mMX/zcAkEj0wKjutpXIJGF6VSbehBVt3BZOc4PNdNYt5c22M8OOme9crD2I6nr7VsWMx8xCT0IApVVoI7rSo3EoLoqsRjI/iraRcgGqlkqva2koGWLYP0rcihCnA5wTXMZTjcoBPY/lUiKwbhTx7VtWyLkcCtCNFBJIX8qERymZaSBVAYgVoK6kdRUklvHJwyD8Bism8tZLclomJjHOPStE7BaxqgZ6U0rzWTa3zqRvORWvE4lQFT+FNSAaV4ppXipscU0jimBARxTCtWCtMIpgV2U01V+UVMwoUHaOaAGAf5/OngUq4/z9acAKAEApHUMDmpVHFLgcZpAYevYSweQ/dTBPtzXlN1bPLaS3W3gg4U9RXqvjI7NCnIXO9ghHtuFcZJZNC0lq/IdG2nHc4/nx+VC3NIHmMykjLfhT4XeORWTg46itV9NYbuD7ZFPt9MI3GUAbRux7Vtzq1jaIl3dG6t1kkQ71+Uk0afexRErJhQR371cvoootPfYyn5hkfhXOxqJWYDt0z3pRV9CjUvZo/MDwE47g1UunWVAy8etRB1RGDrhsURruhJwR6U7WAkhctKr/xYCn3rcuAXtbgHgh1A/HFZmlQbrkO/QfMR9Oavq5mkiiPAMhlb+gqWIp63J5ktqp6xx7KWAEW6ccg5pgie71RkHIB2j8605rcRW87/AMKLs/pmlN6WGYlj++u2Ljq23PpUurEW5wO52D6etT2No6sqAZPA/Op9d0K8S3Se4U4J2jHammuZEtaGHEcPt9ea0rbKgH34rNWMqVY+laFhIWUBhxnrRUelyYnp/h87YSknRSGGfTaTXXaciy2yuQDvGc1yeiJFI8vl3sZXAUrKMc4rci1O3hiEIRZpEGMwNuC/QCvMk5XuaciZfT5WYqOhxTprny0ZycADNVLG9tzanyS+4kswlBGT3P5VB5c1/bRys8AgMhwAckitYTMp02tje0y4NzbCVxye1TSgPwcFTwRWRPfw2kQG8Iq8DBqa2vJprcP5ZjQ9GPetovuZszriMRysi9AeKtaZKVm2seD0p2px+VMvOSygmqkTFJVb0NGzM3udFimkc0+Mho1I9KQ9a0GRsKjIqZhUbCgCJhSKvyj6U4jmlUfKKYDAP8/jThgEA9TQo/z+NPA6ZFACjGKXFAHFPRT+FICjq+n/ANo6bPaA4ZxlD6MOR+oFclNIl1YOlyoS6VVjdDwySpxn6MM13pBxkDPeuR8Xva3E32cQpLdgDMinaVz05HWgqOuiPPfE9qbJiYLlJE7AdRWTcakLi1jCkAquxitdidEUX6JPEWZk6M+4A9z+VY/iPQ4opFFoweRjgqowAKalFbnWqbS1OR84sSD0A5ye9RPbzCMTIpG4V0Vj4XuX+acEDOcV0NvozBArgMPcVbqpbCscFBD5x3XJ+UDpVuNBOVjiUrEv6V2l74WS7hHkkRyj16NWdbeENTVyuYVH94NU+1TAxpTHbIVh5yMEjrmo1Jgt2diTIwwPaujufC91ZQ+fLbfbNvJSN+n4d65qeS5nnO6MRrnARR0+tNSTGXdAgI3k/fI+ZvQetX9QwYIYI/vyOGOBnIHQe9UreVbeEqcrzknpn2rU0a8sYjJc3UTzXCH5ADwoHTFRa8gH+G0jeWSO6Rd75Yq/GMdvrWx42ItdIKcKjFTGM5J5HWuak1Rby+nnkH7yRseWBgbRznP96tHWFuNYs7Zo5keG3XYqMcMPc+p7VGz1EcTMDlR1IHT8a6vwrpSO1v8AaEO0uHcEdvSo9H8NTXVyF2s7Z57AfjXp/h3w7FYv5kmZJQPwFFWelkKxpaPoFgtoDPaIWf5iM42+38q0oNOgthi3VUXuABVtCR09OakG09+a42mMozWsUqFZYonUjoy8VmXulRNFsiL2/HWE4H4rXQMntUE0YIqRanG22g+Vf+fPcG4UDID9jWjJMJLpY92dpyfb2q7cqYmyORUB2MQ4A3d+K0jV6MzcbkF/L505/wBkYqr0p7ZMzE9zQRzW6kc73NW1nBjCk1bBBPBrAVynP6VftrgE4Jq1IZoMKiapQdwpjirGQnrQo+UU4jmgA4FMQwdR/nvTx7U0Y/z9TTwvNADlUn6VctIDM53H5B+tVl4FT3WoRWdpwQR0z6n0pbasa8jJ8XXslrbwiD93G8mxivXiuPuPtVxeRz2qRx46hhk/jW/cNLqEgab/AFS/dX096nitlHQVhObk9DrptwWxzg0ee6uFnuJW8wD+E4FaUOioDnAya3YYh0wKsrHgVNxuUmYyaYgzxT/7OGOn6VtKgx05qRY80XEc81iUYEU4Wx5JHFb0sAxzUHk9cVNxmSYmVeOnpWZqGg2V7Jvlt1D4+8vHP4V1TQ/L0qJ4BnOKpTa0A4ifwvbRIfKg82MjJXPzqfUZ4rFt/C73Fy21JUiB6txXpTRYPHBpdpAx1FUpO24HJ2/gewIUmeZT/EF4z+Nbdh4d0yzGIbUF/wC/JyTWtGnHSpdnFCk+oEFvapCcRoqZ7AVowoQpJ602Fc5OOtW0UAc1LERqSPpT1bmh/TFRZ+aoYFpDnrTXXOe1NiapWxipAy7xPlweRWIZNkhGMV0F4Pl4rmNSyshNZNEMkkYbgexobjFUDMGjHt3q1bSeZFg/eFb05dGY1I9UPPWlDbeaKStTE1rCbemDVpuax7OXZJgnANbHVRitIspETDmlUfKPpSng0L90VoMjX/P5mpFFNA/z+NTRIzuFA5oYCqpIdv4UBLH0GOa5ySY3lyXGRCpwi+3r9a6LxNJ9j0VoogAznbnuK5yyUBQB7VnVdlY2pRu7mhbx4XpU4B6UyM4NP3ZOKwNiWEYqwAMCqyMO9WVw+0n7w6UhkirmplXApq4yakUcUwGP0qMDrmpnGFNRd8UmAuABzTXTPQU/aDyRkjoaXenmeXuG/GdvegCs0J60wwnvV8JQycUAUFiwQKlSL1qdk7ilIxjFADIwM8VPUYGDUgoARqrsetWGqBxTASN8dan8zABqqDjmnPINtFgEuTkE1zmqKG3GteabqDWZdKGQ4HOKzcSGcxFcYnkizyOcVo2shTa2e/Nc3qcn2TxBEc4SVcVvooAK+pqraCtc1zzz7ZFNNR2khkgyeqnFS1aZytWY3OOR1FbVpJ5kCk9axT1q9pTkMUPStIsRotyaFA2ig9cUi9BWyKEX/P51paeqJG87MMgZPtWanQf57mpVOAQCcHigZmeK5jJFCW/imI/DFZ9qcEVN4rk/48l9Wdv5f41WtW4rKpudNPY00bnNP5B4qFDwKk3DFZSNCeM8Y71ai4FUY29KtxNUAW0zUw6c1XRuKnTkYpgKw4qMrzU5HGKYRSYDQPenhRuLkDeRgnFJjmnY4oAcOlGKBSmmAmBTQOuacKD0pCGNjPFKBSd6eBxTAjao+w9amIPpxUbCmBC6ggg9DUbDHC1MRTWWqGZ04H41VkGelaM0ZPI4NUplwDu5qJESOB8dwFVtrhRyjEH+lXtLuBcWMT9WA2n61a8XQ+fpVwAPugMv4VzfhG6JWWBjwfnWnutBROt099s0iH+LpV496xd/lzxuD0PNbJbIyOh5FOJz1I2dxG6HFTWT7Lhc9CMVATQjBXBq0Zo6I9aaOgpsTbo1OeTTh0FbIsRf8/nTweKjX/P51IAcU2Bz3io/6XYL6I5/lUVsMAVL4pH+m2R7FH/mKbbYNYTOql8JejIxTJZADSrxjFU9TcpGCPWs2aF2GQ5q7C/rWTbSZQHPWr0bcVIGnG2RxVqI8VnW79OavxHIFMRZXpzSNinA8UxqLABpc000q1Ix1GKWgGmIXtSUpPFIaYhMc0o6UL1p3FMBppjKac1NzVARsOajOM1K/Wq8gI5FSAyTAqnN1PFWnb86pzHGaTEYGtputZVz1Q15zoMnkapFk8ZKmvR9WJ8l/wDdNeXQv5d4H6Ykz+tXS6kLc72Y53A+uK0dNm822AP3oxt/D1rKmbjPqAaSyuPInDE/KxwwpLRiqRujebqPzpD60pxngdajYkfSqOQ3NPk324PpVpfuj6Vk6RJklM/StZWG0VtHYtDB/n86kyccVEP6/wBTTweKoZieLUwLOUdnZPzGarWhyvWtHxOm/SGcDmORW/Mgf1rJs2ygxWUzqo7Gsn3RiqupJvgI9BVqEjZnuKScBkIIrJmxjadNmML3ziteF+gNYEi/Z7vj7rGte0kDd6kTNm3FaEXAFZ1ue/atCM5xigRaHSh+BTA/y00k9TQA/nvT19ajj+bk1L04qQFpcUClFMQ0ig0MwBpgOWpoQ9aWmjrTqsBpppBzTyabnNAiN6iapn6VC/AoAqzDkmqNyTzV2U8mqFw/WoAw9VY+U+fQ15ef9Y3sSf1r0fW5NsUnP8Jrzc9z65rWn1IW52u/dBG2eqj+VU7ibYCQeRToXzZxf7oqhdScHP0pNFvY7i3ffbxMe6g/pQzdaSEbIIQeyKP0oag4XuW9KJ+1Ct4YwKxNIUmYtjjitoDgVrDYpEef5/1NPUiowf5n+tOFWwGXkX2iyuIcZ3owH1xXJ6U58pQeuAPy4rs1OCCeg5P0rjNn2bVLuHoFlJH04I/Q1E9jooSN2HpT5BkH0qvbyD1qxnPFZHSZGpRhgSB+NJp02VAz7VYvV4OaxYZjFPt7ZokhM7G2bIFX43AXrWDZTgrxVx7pYly3XsPWshGoZlRctToDJN8x4X0rOska4ffNnH8K+lbUYwvT/wCtSGyRBtXApxPtTNwA60oOaYh1ITS9qYTg0xDHaljB6mopD0+uKljPy+1CAkHWnCmr1pxPFWIa1N6UE4NMZqAGueajZqaz5JFRu3BoEQTnknNZl2+Aauzv19KyLt/vYpMDnPEc2yCUkj7tcIGGB9K7PWba51BZIbTaXVdxB7jNcZPBNbNtuIniI4wy4FaQtYzTVzpEkIsov9yoLGI3uqQwrnarBnPoBzUEcrS28SRDe+MALzzXWaJp40+1/ec3MnMjf0oYVJaWRok8nHAzn+lJ1YD1pEVnOFGa0LC0/icVCOcv6dH5UQ45NXFPyj6UxRgYFOUHaPpW8dhkQP8AP/GlB5pg/wA/macOtVIRJniuX8RL5Ou7xwJowx+oOD/SunBzx3PFc34ukX7ZZAH5tjE/QnioexpS+IktXGM1b8w4rLtX4q4H+XrWR2jbo5zXP3XyXaA8ZrauWznFYGpDzCB3yOatK6sBtQXPkxZPPpWhp8TzuJpsl+w9Kx7CB3lVZeqjIrqbUBEGMYrGStoK5pQDaPoKmaYbeDWZLfLHhR8zn+FasW8MkxEkvy56KKnYGXYyXI9KsgYx602NcAcdKexp2JEPSoZGIBI5NPc8VWlbGc0ARs+4qDxVqMfLVGI7n/GrydaEBIvWnMcimUjHirENJ55NRsfShyc1GSc0ANYgVBI3X0p8hPNVZZOcGgRWuHOMCsa9kIVj3xxWlcvjPNc9qVxtRuaNyZC6V8zXM3PzMEH0H/16vSKkoKzIjqezDd/Oq1goSzjC9xuP1qxmj4Tlk9dBkNvBbjMMKIfZRTi2Tz1PUmhjxTUBZwMUt2JXe5p6XCGyxFaeAgwtQ2cPlRD1qZq0SLFU1IrfKKjWlCnA5rRCIlP+fxpwNRKf8/jTlyeauQiVTyPrXHeK5M66VB4jRQPyNdeD0ri/FiFdbZudrxoQfwNQ9jSluS2knHWrqucVjWcmMAmtASDbx1rI7UPnfrWPctlyauzOT0qq0YldULbd/BOO1aREzT06ZY4Vd2OccH1rShe6vTtj/cx+vc1W0zTIwwChii8KG5/GuotbdVXkfl2rCerEmiLTrCOFcgZfux5rZiTAFRxIAKsAcVKQmx3QUxjxTzjbUb88CrERsfWqV0+M4q3KcCs26YlsCokMmsgTkmrwqvaLtQetWR0oiAoNNdhiimNWgiNic1ETjNSv0NVpGpANkbrVKduallfANZ88hx1pCK19LhSc1yuoXEYnUSqWQnkA1r6lOVBya5oRteXaRqcs7bAPc1cEZTeh0ulq72ztHl4I8Hd6A9Ks5FdJpFjDayQ2KjENxamNhj+NTnP5A1z13A1rcSQPnMbYB9vWqnHqYETVNZ4NwuelQZpY3Mcm70rMDqVXauB6U09ajtJvNgDVIcH6VqhiA4NPU/KKjJYHjkelNFwoGDnI9jVoCMEZ/wA+ppwY1F6/59acCcVbESqeRngetc/4ygLw212ByhMbewJ4P54H41vA8Uy6hS6tZbd+ElQqfY9j+dQOLscJbvg59atrJxWcFe3mkgl+WWI7TnuPWpRJgdcVnbU7oO6uWJJK09LsS7CSXk9h6VW0mza4l8yT7nb3rrLK3CjGOlZylbQGye0hAA4xitKJcD2qGBMdauIvy1CEOUcU/PFJwF96TmrELmmsaQ5xSkcZNAEEx4Oaz0/eXAHWrt221T9Kr2CDeWNQxo0YkAHtUm0URjjilNWkIjYVGetSmmMKYEL9DVOYHFXHqrL3pDM6c4BrJu5CM1rXOOaxNQ4XmpJZgarK2045PYetavgDSybuS+uUOYV2pnpk96yXWSRnkT/lmcD3J7V3NjEbHR7SwRi1wy+ZIT1XNdVKJy1HdkWvyXo1PSjp5QyRy8hzgOD1X8RkVo+JbNby2F5D/ro13Mg7L6e+DVK9ULJCxOTHMhHvyK3P9XM0jbQEfnPQjkEfmaqXYhHCZpCataxHBBqMyWrboc5Ug5BzVEtmudoDV0q62PsJ4razuAIrk4SRICveultGPkDPXFVEZKxx1JH0qJiSxIDHNS5GeDzQDwOTWqGVSf5D+tODcVEDk/596dQxEoPFOB4qHNOBqRmTr+jfbz9ot9qXSrg56OPSuagtJXu1gmjeNlHIYdPoa7zPNUbmTz70jBOzjJpT2NqU3sS2EO1FAHFbUEfymqVqvygYrSiXGK52bk0a8VYQHpUcYqdRQA08Uh9qcwpoqhDuMe9Nc44p1Ry+1ICldMTmprNcRgYwajdMv0q1EuAKlATLkCmk07PFNPNWA0nmmseOOtOpjD0oAifpVWU8GrLe9VZTzSGULjrXP6qSEbHeuguehrm9WOFOfSktyJHPWutJHfw2KW4eVp1xJnpzXp8ePmMXzSMclz1NeU6FbCbxLYOcHM3Ir1mElY0YLxnH+fzrugvdOSW5meIJng05pFC+bGVI+u4VJrWstFPPbtBG+9cM2e55qn4lx9lgVjgTXKJz/vCqGuArqUgJBJCnj6Uqu1xFMcKAO3GKTdzimk0ZwPeucRtafah4VYitYAKMCq2lH/Qkqy1aJFCfxCnA8Co8/MKUHgVaAqj/AA/rRmmBun+fWkJ5pSAkDU4NUOaUH8agZK8gjRmOeATVDTwXzI2csc81Z1O3mTSUnUBo5JBH8vJByO1FrA8R2SgoVA+Vhg1nUehvSRq268Cr0XIFUrYYzV6MjFZGxZQVKtQowxxUitTAVqaDSFuBSAnuaBDi1RyGlJ4qOQ8UgEHWpkNVx1FSqQKBk2eaXPtUYOaMgd6YhTUZJFKWyaYxzTuBHJmqsverLmqs3epGULk8Gua1tgEY+gNdHc5+auT8QOfIcLkkqcYqo6tGc9jL8Jnd4gsc4CiTdmvT9/kQr8/fPNeU+EI2bVbQM2SH+7616fHACpMgMjdhnp1rvgrHIzF12cXT23lKJEtpo3kHbrjP61S1RmN9Jv4OBgVv2GkRz6drcYbEssXlqF7H7wP6VzF5KJpzKCTuVWPsSBkfnms6j90RGTkUHOaZmlB5FYAdZp3FnH7ipyeahsv+PaLHTbUhNbLYoQnHSkDgDBPIpGNQsTuP1qgIvT/PrSE800N0/wA+tNZuamQIeTSg45NRbvelzkYqCjpdFkVrCKIKGbzc8jp3qPWJ0uL4tH82wBCx6kiqmjbzFPlipXJU54xjFVomG7g5Pc+vvUVNjemaEOM5q3GRxVGE9M8VbjOMVibFxAOKfnFQqcAU/dmmIcSKM0w9KTmkA8njpUbEZpxPFNI9aQDV96XmlGKeozSuhjc4HNKDTtuOtGCe3FPmEJk96Y3FSMBio2OOnWgCEnGarzN1zUziTzwysohA+7jnNV5GznPQ0AULv7pzXN3WFvYywyGBQj6jH9a6S475rmdZyFLLww5Bq4boynszK8KRGDxPaxsMFXZST+OK9Hy0WQpwRzk9+tcpYadFfXVjdIzJMpDFh0NdTJBK7KJMqBxj/wCvXcpXRyFjw84R55O8zHJPcDj+Wa4bVLb7Hqd1bYxslbHPYnI/n+ldtHItvDEY+VjOc+vNYvjm2b7Rb36gmOZRGz7cAkdPzqKi0Gc0TxQDkimE8U6Ll1FYiOr0+Tfax47DFTkms3SpPLZoj0xkVoE1rEYhNROfmP1p7HrVd2+dvrVBcjB4/wA+9Rsfmpw7H/PemOeamRSDdir2l2f2tyz5WBRyw7mqEKPNKFiGWwT1xx9a1Ib9bSCO1lkErvIEVY16E+prMo2L021rZIkcqw71wHxk+9ULWyEjEW8iy4GemKqX7Lc6ltBXZGME9AAOTj8q2orqP7NGkChEPAIHOKEubc1vyrQdb6dISA7xp9TzV6PTBnmcn2WobfFxGSDuIOzmpkhVQN7YI6gmqUIk+0ZN/ZqjH7x/0qRdNXnEjcfSsrUbG2u9xVWV8dQTg/rVnSbYWNkqElpieSOf1p8kQ9oy79gXGfMP5Uv9nf8ATX8xUcjl0A+YEds0Rx70PzsCPel7NB7Rjm01z92QflSNpsv99TSyyFExvIPrTIp1UEvMxPpR7KI/aANNlHdKVdPmHUxj8ac0hYfKzYPcVJEWx8x4/Wl7GIe0Y0WEmPvJmgWD4ILjjjpT5HCITlyQM4HWufvvElpavh4ZFPTljyc4o9khe0ZuNp74J3qfwqvJp8uPlKGmW00d5AHR5oz32t0p4MqdJ5sepOafskHtGUp7G6Tny8/RhVCdJIyfMjdcf3lIrod84DKk24kcb1yKwj4mt47kW1+qxyZ27kXcv4+lL2KD2pl3EgycDmuf1VgY2BGeCOnSu8vEsbqMtIi7P768EenSuP1jQppWH2O4hmjPUs4Dr/jSVKzE6iaMzwZqBkuI7PJDKdy+4HWuwv7uRLuHYm6A55zyPwrhvh/ALbxFNBdSBLiLfEoI4Zu/P0Nd/KiKwLHIzz7VulY52VLSdJLe4jcjdFIysD+oqF5ftOl32nztloSHjaRuAvWs5YSuqX8wZtplBb0561F4qjIuYpRkb12t7kUT2BGKDwM4z7UqkhgajzhsY4xxignisRnQop/cSp3GDWpnIB7YrN0hvNtAD1FaB6YrRCEY9arv99vrUpJGagcne31pgRBuMf571E7Ypx7n6f1qBzzUSNEXFBisBKCVaViBjrt71StpUXV7Tf8AKsavMSPZTWzHbf2na2yxSFGjUqQR096wL2FIdXazSVZbqbHm7fuwxDnH1OO1QzRG7bQ50y4uJ+TIAxHcZPFals6BQGVQVAH6VBOyxafNheMKBn6gCoL2aK2hluJfu9h69KuImb+nsMHaPlJyDjvViIh5mD4Lds1nWci/YIpNxVSu7im2mpRXiEAfMpxnPWmI2UKsdhAB9qlTy04zg5xWeu5QxzyMY9asAgHc65JHT3pgSsyEsVyT0qpqd6sFiZM4kxhe341eRPmzgBSOlZWsWUd6jRnlsYAzjI9KoUiPRtSj1C0CMy+ap9c7q0zbqS7HAyKxPDFglmHGzZtOBnsa3nkIxuI56GgUdRiSlFRI0Oe5qQF3Ztp+YDpUEjSIQzHAPAA71PHkMDuIYjmgoa28Mu5Rk9Oap6jolrdzLLLweygdD61pead/KZPr6U2SRVfd98ngD0oEVbCxhty6oZAcY5NTCTYWDnPpmlLPJJlwFVe+ajOTO3y5XtmgBrSSMmEHPcjtWBqOlwTF2liILHqvc1sFnWVwMle6g4qIx/uS2ec/IM5xVIiRllWgk2oSEVQAoOO3WsrXInubTbHbo1x/DJjay89ciujuIMsrlvmPUVkarqsGnBNgMkznAUDPei5Bw/iKC40/XYrqQ4lnUNuU8swwCfavQVdLqCGSElg6j5j3OOf1rzrxWl0fFcUOrTHbME2kDhFbqB+lemWsEUNtHFB/q0X5T16Cgp7GdGmW1AYwd6/qKqeK136dA46rIfxHSrFpI0011Hg7vNUFvXApfEcZmszEgzt5wKl7CRxf8+lGfWm9MD8aTNYlG94fk5dPyrXJ5NcvpM3l3XXg8V0rHkYq4iBj1qBz87fWnsc5qB2G9vrViIyfk/L+tV5D7A1IW+X/AD71BIazmaRFSV0Pyuyn1Vqh8Ox7p725bks23Pcn1pzYWKR89FJ/Sk0FWCRDJAbLfWsjRHUakqnTxnJyyH8Qw/rWB4tM8tnGI+GVsH0Oe9dHdo0mlSxlgrFCAeuOKzJWS+g5+4x8zA4xwK0iBqKsyaPGkSEt5S9Oa53RYriHVwtxISAwYADAx7V1mnySLbx5XC4x8p7VJPDbGYXIQeagxx+XNaIhmhBIGdSMfNljz0qwcNLgcjvWfaZ8xSEwCPWjUL9NOtvM4LM2AT2FAGhMWeRFUkLntSSvGDjALA9aq2s6yBZQ2UPp0FWGQeU2ADznNACSoXkc5AwM5Hekdj5Chh06YpI3D7gOSRipoQVTDHiqArNPE0kcUjbXPPNT+ed20DnoK4rxDNcjWkMKfKGxuNdWnmOQxwGCDOPWnYm5obtq5U5bHIrPnlaS5Vc+XGBzjrVuNN0QYHkjrmqlwytc26DO7nOO/rSHck+225RlMiFVPADdaldz5W4Y5GRXnesfabbUXW2yY9537RnA9q660upXsImAJwMA46D0p2FctGXMIfcPNB4rCvL9UuGTzSGI37cHrWkNrPvaQc9AKxtcttuqWc6oWjCkPgUyGxDdSTOSZCqbcMM81jogvLzdECcOMt7DoKu3lq7RXHlZ3sp2iptAtWtrKJSMOgG/PUnNJiOY+J/nPJazSx7JY/lBHdexroPBmpHUNMjnLEOfkZfQrVzxpp/9reHp8x/voUaRW+gziuU+G12qJc2Z2jH74Z75qt0U9jsdKVraW5SU5ZWLIT/GDVpFYhpX5ZuG+lRyEThQvyyD5lJ6/Sm6ffGeOVZY9kiEqRWexJw15GIb2eMDhXOPpUJrR8QxeVqkh7SAMPes3IrJ7lIkgcpKpHrXVwtvgRu5Fchux0rpNMl32oyeRVRGW2JwTULKdx4709zwfpTWYbjz3qySmThef89ahc5NSMcg/wCfWoHPJrOZpEiu3KWkx/2SK19MUJFbKMA7Rnj2rGuFMkW3GcsB+Gef0roLQYeJdvRf/wBVZoo2kwoOSDishkWHdGp2upJ+oPP9f0q8seELsSOc4qpqyMUgmTb8hMbDucjINaIDaspAsKEnnZ0p0ykqrMcbunFZ2kX8N7YAoMvH8rE9qvsXeRE3DaBxVol7FzTmKoQehOAaxPGdpczIFhkKoR1AzzXQxJGsbICFxyajLJJbyROpYkdCe1UDM3w3aLbWO+eRmLYCqT1rUAlYYTIjPAFVIl8hI1cHao+Rf61NHM2CGbqPvU7ASoWy0e0Db3WrRZnCAYKHg571RgljjDbnzLjJXPOKniQsisrkd8GgCDUbeOaVHfAMP3cd/apEc7Y+Blyc5+lJcLJKwwg9iO9V3EnlnI4TrzTJNJD5aOSRg8DFZ1zM39ooixf6uMvu78kVU1XU/skNvF0diOScZz0qHT737Tf3Mqlm/cqh9ASc/wBDSC5rERXCqZEVyOcsv+FVYpo1LRxxpEgJYACnLMFUJG4Vu5PQVE+x5CTjHsOtMBIShdpAgAzhRmm3E2EJViT0YGoY13yMGBTB+Un1qSWMJCzSctnlvegkimTzApYMPlzxTS+1Cw5/hI9KHnbylYHLEY+lQgMOSMg8mpEW4UMw8p2Lo3y4zjOeK8u8OyHTPFogKfKJHgIPOck4r0u3dRIJAeh6V5r4zUWPi66lgI2nZOv4jP8ASqiUj0jeI3zt2kHGaYSBN5qjBf7x9feuft9TuLm9iZ0yhQHj3Fbly5AJ2jYFzgUSJZleLYwba1lA+ZSVJ9u1czn0rp9fIk0wkHlSDiuVJ4rGRSHA4Na2hzEOyE8HpWPnirWmy7bpAD1oiM6VjgH2qN872+tLITtNRs43HnvViK2eD/n1qFyBk08H+n9ajf2qZotD4CokLMQAqk/pWvp8yyOxUngDPNY0Z+WUBQSVwCfWtHTU8i1YSOdzLgFR7VMUUPXW4ZNV+xRtuHIYnkk47ValuVNvdw7CRFGXdh/e7Vz8emxWAjuZs/bLlisCDqv+2fYda6jRbUHSLyNyQSCrHH3j1J/GrsK5D4XtPs9mVf5TIxJz6DH+NbCOFnVmKhQ2AazoWZVTvtGeP1/lWX4g1I2jwQgORu8wlBk1RNztpghQsG+Y96jgAGWPzPjBIqjodybyyMsqkAnad3U1duHS2wkJ69TQIWRklHAJcDk0xCPskjMBleeafCY4wWBGT15okIRt4IIbgrTQHFPq0v8AbOUjk59uK7qJFkgjZiyM43Fc1kvoijUvPiAMZGcHqD7e1aILEBpAeu01TGiad/KdAN2FFRSOZEyVwoOeOpqYqssYwc44BqDy5EICODjtSEc/4p0yO8ZZgcgMCMkgCodPB0jUYRvVba9gKfMc/vF5H5gY/GulmXcArKCpByuOtYXi+ItpW8dLWRbjjgjBH9M0PcQi+ILFWVDFskztK574z/KtCadJowFQKWGQc4xXK3miG8uVvIZN+/50w2Rg+3rit+zffboky42Lj5uxqhEwkclAnIB2turGvtfW3u5ILuNN8bfKcnmr3mGKRFLZ3HJPaszVPD8d5dGcsSN2QTzihAbMUi3NvCyJsVhvzUGr3MlvaySR/wCsVd1MtFljtYYmfDRgqPcGnXVtuQxvvwVIJapaEV9PvBqFpBcLw8g5x3xXH/EWFP7TtZ9pAlh2H6jiu00ezjsYyIGJjEoGCOg71y/xHjLWsT45iZlB+ppLRjRoeFCJNIglbDMVKZ9CDW2ytkEDCsMVyvgeUDS5UJIRZSAfqM107TqqkEnA6ZqwkZ2uJnT5mU5wwFcpmuvvMNp7gDO/Jrjs8DPWsJhEdn1qW0IW4Q+9QZpYm2yKfepRZ1m7K/WoXPzt9aRG/dKfamPne31rVARKen+fWkamA/5/Onbhg5qWBNarlyvSryXEcErS3DKLcLhj/d4z/Ss+2J85lB+6uaraypl08hhjMkW4DgN84FOMQ5izaM1zLJfTdWG2FX6pHnp9T1P4V1uhlv7NuC0efm456DFcjNci2vkgO0rIMDPbHQV0dldCPS7kyOUJbbx3OKqStsFxQw8hthwx4xT7jThdQ+Z5YyMYB/ixUJQoU2MASM5P5H+dbNsjtGqMTnGc9qCGOsVEFlHCcJtHT1JpYyoDeYcKDjnvSywqgBkOfQ1BdT5iLkDZEh4/DrQMsSeUQhRfrxU/loCCQPm/SsLQNR+22zBSGcHPPUjNbTsZIwTw69qY7lpHxlQQNtIxUHk5/iqlgqv+03UU+MeYcsSFAwBQFyDU7oWUQk3AK7ADmp0ZXiV0bGBk+9cv40juHniigcKgZe2c1vWMUsGmRpIS0g6kjtQFy5DNsYBlzu6GmanGLi2uI2ADOhU+4IpWIMCnIyBUx2mISOvOM/lQDON8GzSNoxtNwM9s7RNnrjOc1ryEyRNGVwVGc+tYFtJ9h8dXdtEAq3yBs+h68VtXrrBF5Ss2c8mmiSvuZyBsAAHftV47YyS0nVeQKzln3oWJIQdc+lTRXSys6JIjsq5x3OKYhwdpJfkXKgcetSO7SALMTuUg/UVFFM5V2XCsRx2qFpJHILdQOuKGBckXdE5UHGc4rl/Hi77LEYykiFwD2IFdFFcBwEJO5W28HqSKyvFibtMmHH7tuPXGMGoBM5TwLKXjuYUYkkLIAPyNdJqcsrwIIzsPQ+9cJ4PvjYasADwwKEGvRxieOORgvHOK0Q2QoJI9PAkwTtOPyrkH4J9c12c0nmIcLjIwBXFzffc+5rGYR3AGkz8w+tMzSMcVBZ09s261U+1OZxuPPeq1i2bNKe+d7fWtUBEDz/n3pwJzxRRVWQiezbYxlA9iD3qPUGiklhRA4LOHbJ445/pRRVpCKOu2xlvrW5Vyu/gj8a37qNhpFvGXJzcouf8AgQoopgXDK7P5bnJLdfb/ACK3LNW8lWDtkHGKKKmwFm5O+EMOPUGs+7hBsplZjyuePzoopWATwrZx2+mCRAC7kknFaU7AFXA5oop2ASNj54YdWqzcny04AyeaKKVgKNzbi7jQvgFCHU+lWo3aaEnOG6UUU7AMQCWLGMEd6WViY427elFFKwzh/iSZNMm0rVLYqssUmDxyw61pXcglEmAcMQck8jODRRTsIr6igh0uUgt9w1z3hXzW1nBlPzK2D6UUU0FjqjGy7mdt+04FTSjzVRjxuIGBRRSCyOMgvJoPEBiQ4VZCc559K6DX3N1pk+Tj90zZxRRRYlLU8itJNl3C2Mnev88V6xZSMqRDr8vGaKKplk9wMRSzMfmVSQB06Vxdyf3j/X+YzRRXPIRBn5RSk9KKKko3dPObIfQ1OwO4896KKtCP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Signs of scoliosis include 1 shoulder that is higher than the other, a shoulder blade that sticks out, and a skin fold or crease at the waist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Susan Scherl.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_59_21439=[""].join("\n");
var outline_f20_59_21439=null;
